WO2003032916A2 - Organosulfur inhibitors of tyrosine phosphatases - Google Patents

Organosulfur inhibitors of tyrosine phosphatases Download PDF

Info

Publication number
WO2003032916A2
WO2003032916A2 PCT/US2002/033076 US0233076W WO03032916A2 WO 2003032916 A2 WO2003032916 A2 WO 2003032916A2 US 0233076 W US0233076 W US 0233076W WO 03032916 A2 WO03032916 A2 WO 03032916A2
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
substituted
unsubstituted
phenyl
cycloheteroalkyl
Prior art date
Application number
PCT/US2002/033076
Other languages
French (fr)
Other versions
WO2003032916A3 (en
Inventor
Jing Wang
Darryl Rideout
Kalyanaraman Ramnarayan
Chung-Ying Tsai
Venkatachalapathi V. Yalamoori
Feiyue Wu
Colin Loweth
Hassan Elabdellaoui
Leah Fung
Thomas P. Brady
Original Assignee
Structural Bioinformatics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Structural Bioinformatics Inc. filed Critical Structural Bioinformatics Inc.
Priority to JP2003535722A priority Critical patent/JP2005509616A/en
Priority to EP02784123A priority patent/EP1446110A2/en
Priority to CA002463724A priority patent/CA2463724A1/en
Priority to US10/493,113 priority patent/US20050065118A1/en
Publication of WO2003032916A2 publication Critical patent/WO2003032916A2/en
Publication of WO2003032916A3 publication Critical patent/WO2003032916A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • a common mechanism by which receptors regulate cell function is through an inducible tyrosine kinase activity which is either endogenous to the receptor or is imparted by other proteins that become associated with the receptor (Darnell et al, 1994, Science 264:1415-1421; Heldin, 1995, Cell 80:213-223; Pawson, 1995, Nature 373:573-580).
  • Protein tyrosine kinases comprise a large family of transmembrane receptor and intracellular enzymes with multiple functional domains (Taylor et al, 1992 Ann. Rev. Cell Biol. 8:429-62).
  • RPTKs receptor protein tyrosine kinase
  • EGFR epidermal growth factor receptor
  • PDGFR platelet-derived growth factor receptor
  • the protein tyrosine phosphatases comprise a family of transmembrane and cytoplasmic enzymes, possessing at least an approximately 230 amino acid catalytic domain containing a highly conserved active site with the consensus motif >I/V!HCXAGXXR>S/T!G.
  • the substrates of PTPs may be PTKs which possess phosphotyrosine residues or the substrates of PTKs (Hunter, 1989, Cell 58:1013-16; Fischer et al, 1991, Science 253:401-6; Saito & Streuli, 1991, Cell Growth and Differentiation 2:59-65; Pot and Dixon, 1992, Biochem. Biophys. Acta 1136:35-43).
  • PTPID also known as Syp or PTP2C
  • PTP2C has been shown to bind through SH2 domains to sites of phosphorylation in PDGFR, EGFR and insulin receptor substrate 1 (IRS-1). Reducing the activity of PTPID by microinjection of anti- PTP1D antibody has been shown to block insulin or EGF-induced mitogenesis (Xiao et al, 1994, JBiol Chem 269:21244-21248).
  • the present invention provides methods and compositions for the inhibition of tyrosine phosphatase activity. Such compositions and methods will find use in the freatment of diseases caused by dysfunctional signal transduction.
  • the compounds of the present invention are generally characterized as nitrogen- containing organosulfur compounds having the formula (I) and their pharmaceutically acceptable salts:
  • R5 is a phenylmethylthio group, optionally substituted with one or more halogens on the phenyl ring, or 2-oxo-2-(2- naphthylethylthio) optionally substituted with one or more alkyl groups (C1-C4).
  • R3 is as defined previously.
  • R2 be 2-phenyl-2-oxoethylthio, optionally substituted on phenyl with one or more of the following or their combinations: nitro, halogen, alkyl (C1-C4). It is preferred that that R14 be phenyl, optionally substituted with one or more alkyl groups (C1-C6).
  • alkylthio, alkenylthio, alkynylthio, alkylthio, hydroxy- alkylthio and phenyl-alkylthio mean the aforementioned alkyl, alkenyl, alkynyl, hydroxy-alkyl and phenyl-alkyl groups linked through a sulfur atom to group R.
  • the compounds of the present invention inhibit tyrosine phosphatases, including PTP-
  • Suitable antidiabetics comprise insulin, GLP-1 (glucagons like peptide-1) derivatives such as those disclosed in WO 98/08871, which is incorporated herein by reference, as well as orally active hypoglycemic agents.
  • the orally active hypoglycemic agents preferably comprise sulphonylureas, biguanides, meglitinides, oxadiazolidinediones, thizolidinediones, glucosidase inhibitors, glucagons antagonists such as those disclosed in WO 99/01423, GLP-1 agonists, potassium channel openers such as those disclosed in WO 98/26265 and WO 99/03861, insulin sensitizers, DPP-IV (dipeptidyl peptidase-IV) inhibitors, inhibitors of hepatic enzymes involved in stimulation of gluconeogensis and/or glycogenolysis, glucose uptake modulators, compounds modifying the lipid metabolism such as antihyperlipidemic agents
  • the present compounds are administered in combination with insulin.
  • the present compounds are administered in combination with a sulphonylurea e.g., tolbutamide, glibenclamide, glipizide or glicazide, a biguanide e.g.
  • metformin a meglitinide e.g., repaglinide, a thizolidinedione e.g., troglitazone, ciglitazone, pioglitazone, rosiglitazone or compounds disclosed in WO 97/41097 such as 5-[[4- [3-Methyl-4-oxo-3, 4-dihydro-2-quinazolinyl]methoxy]phenyl-methyl]thiazolidine-2, 4-dione or a pharmaceutically acceptable salt thereof, preferably the potassium salt.
  • the present compounds are administered in combination with an a-glucosidase inhibitor e.g. miglitol or acarbose, an agent acting on the ATP-dependent potassium channel of the B-cells e.g. tolbutamide, glibenclamide, glipizide, glicazide or repaglinide, nateglinide, an antihyperlipidemic agent or antilipidemic agent e.g., cholestyramine, colestipol, clofibrate, gemfibrozil, lovastatm, pravastatin, simvastatin, probucol or dexfrothyroxine,
  • an a-glucosidase inhibitor e.g. miglitol or acarbose
  • an agent acting on the ATP-dependent potassium channel of the B-cells e.g. tolbutamide, glibenclamide, glipizide, glicazide or repaglinide,
  • the present compounds are administered in combination with more than one of the above-mentioned compounds e.g., in combination with a sulphonylurea and metformin, a sulphonylurea and acarbose, repaglinide and metformin, insulin and a sulphonylurea, insulin and metformin, insulin, insulin and lovastatin, etc.
  • any suitable combination of the compounds according to the invention with one or more of the above-mentioned compounds and optionally one or more further pharmacologically active substances are considered to be within the scope of the present invention.
  • the therapeutically effective amounts of the present compounds will be a function of many variables, including the affinity of the inhibitor for the tyrosine phosphatase, any residual activity exhibited by competitive antagonists, the route of adminisfration, the clinical condition of the patient, and whether the inhibitor is to be used for the prophylaxis or for the treatment of acute episodes.
  • the therapeutic preparation will be administered to a patient in need of freatment at a therapeutically effective dosage level.
  • the lowest effective dosage levels can be determined experimentally by initiating treatment at higher dosage levels and reducing the dosage level until relief from reaction is no longer obtained.
  • therapeutic dosage levels will range from about 0.01-lOOOg/kg of host body weight.
  • the present invention contemplates combinations as simple mixtures as well as chemical hybrids.
  • One example of the latter is where the present compound is covalently linked to a pharmaceutical compound, or where two or more compounds are joined.
  • covalent binding of the distinct chemical moieties can be accomplished by any one of many commercially available cross-linking compounds.
  • the present compounds may be intravenously infused or introduced immediately upon the development of symptoms.
  • prophylaxis is suitably accomplished by intramuscular or subcutaneous administration.
  • the compositions are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid prior to injection may also be prepared.
  • These therapeutic preparations can be administered to mammals for veterinary use, such as with domestic animals, and clinical use in humans in a manner similar to other therapeutic agents.
  • the dosage required for therapeutic efficacy will vary according to the type of use and mode of administration, as well as the particularized requirements of individual hosts.
  • the compounds of the present invention are often mixed with diluents or excipients that are physiologically tolerable and compatible.
  • Suitable diluents and excipients are, for example, water, saline, dextrose, glycerol, or the like, and combinations thereof.
  • the compositions may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, stabilizing or pH buffering agents.
  • the reactants for the assay include 20mM Tris-HCl, pH 7.4, 2mM EDTA (ethylaminediamine tefraacetic acid) and 2mM DTT (dithiothreitol) as the assay buffer, and ImM pIRP in assay buffer (lmg in 0.59mL buffer) as the substrate stock.
  • the Malachite Green solution is prepared by adding 30 ⁇ L of 1% Tween 20 to ImL of Malachite Green Solution A. The stock of each compound to be tested is made up as lOmM in DMSO (dimethylsulfoxide).
  • a pNPP assay can be used to screen compounds for tyrosine phosphatase inhibitory activity as follows:
  • a 5X stock of pNPP (p-nifrophenol phosphate) substrate is prepared as 50mM pNPP in assay buffer prepared as described above.
  • Various tyrosine phosphatase solutions can be prepared as follows:
  • PTP-1B (SBI purified, lmg/mL) as a 1:250 dilution (to a final concentration of 4 ⁇ g/mL);
  • CD45 (Calbiochem, 20 ⁇ g, 400 units in lOO ⁇ L) as a 1:50 dilution (to a final concentration of 0.8U/10 ⁇ L (4 ⁇ g/mL));
  • the compound to be tested is prepared as 1:16.7 and 1:50 dilutions from stock in a total volume of lOO ⁇ M DMSO to give final concentrations of 626 and 200 ⁇ M.
  • the reaction mixtures are prepared in a 96-well microtiter plate (on ice) as 55 ⁇ L assay buffer, 5 ⁇ L of the diluted compound (to a final concentration of 31.3 and lO ⁇ M), 20 ⁇ L of the pNPP substrate solution (to a final concenfration of lOmM) and 20 ⁇ L PTPase in assay buffer.
  • the reactants are mixed well, the plate placed in a water bath at 30°C and incubated for 10 minutes.
  • the reaction is then terminated by adding lOO ⁇ L of 2M K 2 CO 3 per well, and the absorbance is measured at 405nm by conventional means.
  • a positive response is defined either as (i) a more than 25 percent reduction in blood glucose levels in the group receiving the compound of the invention compared to the group receiving the vehicle at any time point or (ii) statistically significant (i.e., p ⁇ 0.05) reduction in the area under the blood glucose curve during the whole period (i.e. 8 hrs) in the group treated with the compounds of the invention compared to controls.
  • Compounds that show positive response can be used as development candidates for freatment of human diseases such as diabetes and obesity.
  • Example 5 (3-Bromophenyl)-[5-(3-nitrophenyi)-l,3,4-thiadiazol-2-yl]-amine
  • 3-nifrophenacylamine hydrochloride 620mg; 2.8mmol
  • sodium bicarbonate 240mg; 2.8mmol
  • H 2 0 H 2 0
  • 3- bromophenylisothiocyanate 580mg; 2.7mmol
  • acetone 23mL
  • N- (3-nifrophenacyl)-N'-(3-bromophenyl)-thiourea 400mg; 38%).
  • the thiourea was suspended in acetic anhydride (lOmL) containing polyphosphoric acid (0.5mL). After stirring for 12 hours at RT, the mixture was poured over ice. The resulting solids were isolated via filtration and triturated with 4/1 ethyl acetate/hexanes to yield pure title compound as a yellow solid (150mg; 38%); mp 228-231°C, MS m/z 377.65 [MH+].
  • Trimethlsilyl diazomethane (15mL; 30mmol) was added to an ice cold solution of 3-(3- hydroxyphenyl)propanoic acid (3.32g; 20mmol). in acetonifrile (40mL). The mixture was stirred cold for 30 minutes and slowly brought to RT and continued to stir overnight. Acetic acid (ImL) was added to quench the excess trimethylsilyl diazomethane. The reaction mixture was diluted with methanol (lOmL) and IM hydrochloric acid (2mL), followed by rotoevaparation of the solvents. The residue was purified over silica gel column.
  • Methyl 3-[3-(3-formylphenoxy)phenyl]propanoate was prepared using Procedure B from methyl 3-(3-methoxyphenyl)propanoate (2.7g; 15mmol), 3-bromobenzaldehyde (1.75mL;
  • Methyl 3-(3- ⁇ 3-[(lE)-2-aza-2-( ⁇ [(3,4-dichlorophenyl)amino]thioxomethyl ⁇ amino) vinyl] phenoxy ⁇ phenyl)propanoate was prepared using the procedure in Example 2 from methyl 3-[3- (3-formylphenoxy)phenyl]propanoate (426mg; 1.5mmol) and the product from Procedure D (354mg; 1.5mmol) to obtain a white solid. Yield: 450mg (60%). Mass: M + : 502 (Calc); 502 (Obsd.).
  • Example 2 The reactions described in Example 2 were repeated, using aminohydrazinomethane-1- thione (1.82g; 20.0mmol) and 3-[3-(trifluoromethyl)phenoxy]benzaldehyde (5.32g; 20.0mmol) to yield [(l-aza-2- ⁇ 3-[3-(trifluoromethyl)phenoxy]phenyl ⁇ vinyl)amino]aminomethane-l-thione (6.43g; 95%) in the first step.
  • Example 29 (3,4-dichlorophenyl)[5-(3,5-dinitrophenyl)(l,3 . 4-thiadiazol-2-yl)]amine
  • the title compound was synthesized from 3,5-dinifrobenzoyl chloride (50mg; 0.25mmol) and the product from Procedure D (59mg; 0.25mmol) by the procedure of Example 3. mp 305-306.5°C (uncorrected) from ethanol. Yield: 61% (isolated)
  • Example 8 and purified using silica gel chromatography as the less polar of the two isomers.
  • Example 37 3-( ⁇ 5-[3,5-bis(phenylmethoxy)phenyl]-l,3,4-thiadiazol-2-yl ⁇ amino)benzoic acid 3-[(hydrazinothioxomethyl)amino]benzoic acid was prepared using Procedure F from 3- carboxyphenyl isothiocyanate (896mg; 5mmol) and hydrazine hydrate (485 ⁇ L; lOmmol) and was used for next reaction without further purification.
  • Tlie title compound was prepared using the procedure of Example 16 using 5-(3- nifrophenyl)-l,3,4-thiadiazole-2-ylamine (lllmg; 0.5mmol) and 3,4- (Trimethylenedioxy)phenacyl bromide (136mg; 0.5mmol). Yield: 75 mg (18%). mp 227-230°C. Mass: (MH) + : 395 (Calc); 395 (Obsd.).
  • 3-(4-Methoxy phenylmethylthio)phenylamine The title compound was prepared from 4- (chloromethyl)-l-methoxybenzene (4.7g; 30mmol) and 3-amino thiophenol (3.75g; 30mmol) using Procedure A. The solid was purified using a silica gel column and the title compound was eluted with 20% EtOAc/hexanes. Yield: 4.5g (61%).
  • 3-(3-Phenylpropylthio)phenylamine was prepared from 3-amino thiophenol (lOmmol, 1.06mL) and (3-bromopropyl)benzene (1.52mL; lOmmol) using Procedure A.
  • the yellow liquid was purified using a silica gel column and the title compound was eluted with 40% hexanes/ethylacetate. Yield: 1.7mL (74%).
  • Methyl 2- ⁇ 4-[3-( ⁇ 5-[3 , 5-bis(phenylmethoxy)phenyl] -1,3 ,4-thiadiazol-2-yl ⁇ amino) phenoxy]phenyl ⁇ acetate was prepared using the procedure as in Example 2 from methyl 2-[4-(3- ⁇ [( ⁇ (1 E)- 1 -aza-2- [3 ,5 -bis(phenylmethoxy)phenyl]vinyl ⁇ amino)thioxomethyl]amino ⁇ phenoxy)phenyl]acetate (379mg; 0.6mmol) and Iron chloride (486mg; 1.8mmol) in Ethanol. Yield: 146mg (37%). Mass (APCI): (MH) + : 630.
  • the title compound was prepared as described in Example 1 from 3- nifrobenzenecarbohydrazide (500mg) and 3-nifrobenzenisothiocyanate (500mg).
  • the title compound had the following physical properties: mp 325-330°C (decomposition).
  • the title compound was prepared as described in Example 1 from 2-chloro-5- nifrobenzenisothiocyanate (lOOmg) and 3-ethoxybenzenecarbohydrazide (90mg).
  • the title compound had the following physical properties: mp 128-130°C.
  • Example 56 [5-(3-methoxyphenyl)(l,3,4-thiadiazol-2-yl)](3-nitrophenyl)amine
  • the title compound was prepared as described in Example 1 from 3- nifrobenzenisothiocyanate (lOOmg) and 3-methoxybenzenecarbohydrazide (lOOmg).
  • the title compound had the following physical properties: mp 206-208°C.
  • Example 57 [5-(3-ethoxyphenyl)(l,3,4-thiadiazol-2-yl)](3-nitrophenyl)amine
  • the title compound was prepared as described in Example 1 from 3- nifrobenzenisothiocyanate (lOOmg) and 3-ethoxybenzenecarbohydrazide (lOOmg).
  • the title compound had the following physical properties: mp 155-157°C.
  • the title compound was prepared as described in Example 1 from 4-nifrobenzenisothiocyanate (220mg) and 3-nifrobenzenecarbohydrazide (200mg).
  • the title compound had the following physical properties: mp 327-329°C.
  • the title compound was prepared as described in Example 1 from 3-bromobenzenisothiocyanate (320mg) and 3-methoxybenzenecarbohydrazide (250mg).
  • the title compound had the following physical properties: LC-MS 364.6.
  • Example 64 (2,5-dibromophenyl)[5-(3-nitrophenyl)(l,3,4-thiadiazol-2-yl)]amine
  • the title compound was prepared as described in Example 1 from 2,5- dibromobenzenisothiocyanate (300mg) and 3-nifrobenzenecarbohydrazide (190mg).
  • the title compound had the following physical properties: LC-MS 457.4.
  • the title compound was prepared as described in Example 1 from 3-chloro-4- fluorobenzenisothiocyanate (570mg) and 3-nifrobenzenecarbohydrazide (500mg).
  • the title compound had the following physical properties : LC-MS 351.3.
  • the title compound was prepared as described in Example 1 from 4-bromo-3- chlorobenzenisothiocyanate (650mg) and 3-methoxybenzenecarbohydrazide (400mg).
  • the title compound had the following physical properties: mp 215-217°C; LC-MS 398.1.
  • the title compound was prepared as described in Example 1 from 3-chloro-4- fluorobenzenisothiocyanate (260mg) and 3-ethoxybenzenecarbohydrazide (250mg).
  • the title compound had the following physical properties: mp 170-172°C; LC-MS 350.5.
  • Example 72 (4-bromo-3-methylphenyl)[5-(3-methoxyphenyl)(l,3,4-thiadiazol-2-yl)]amine
  • the title compound was prepared as described in Example 1 from 4-bromo-3- methylbenzemsothiocyanate (690mg) and 3-nifrobenzenecarbohydrazide (500mg).
  • the title compound had the following physical properties: LC-MS 391.4.
  • Example 74 (3-bromophenyl)[5-(3-ethoxyphenyl)(l,3,4-thiadiazol-2-yl)]amine
  • the title compound was prepared as described in Example 1 from 3- bromobenzenisothiocyanate (650mg) and 3-ethoxybenzenecarbohydrazide (500mg).
  • the title compound had the following physical properties: mp 195-197°C; LC-MS 376.5.
  • the title compound was prepared as described in Example 1 from methyl 3- isothiocyanatobenzoate (500mg) and 3-nitoobenzenecarbohydrazide (500mg).
  • the title compound had the following physical properties: LC-MS 357.5.
  • Example 77 (3,4-dibromophenyl)[5-(3,5-dimethoxyphenyl)(l,3,4-thiadiazol-2-yl)]amine
  • the title compound was prepared as described in Example 1 from 3,4- dibromobenzenisothiocyanate (280mg) and 3,5-dimethoxybenzenecarbohydrazide (220mg).
  • the title compound had the following physical properties: mp 240-242°C; LC-MS 426.1.
  • Example 78 [5-(3-ethoxyphenyl)(l,3,4-thiadiazol-2-yl)](3-nitrophenyl)amine.
  • the title compound was prepared as described in Example 1 from 3- nifrobenzenisothiocyanate (4.0g) and 3-ethoxybenzenecarbohydrazide (4.1g).
  • the title compound had the following physical properties: mp 183-185°C.
  • Example 79 (5-benzo[3,4-c]l,2,5-oxadiazol-5-yl(l,3,4-thiadiazol-2-yl))(2,3-dichlorophenyl)amine
  • the title compound was prepared as described in Example 1 from 3-methyl-4- bromobenzenisothiocyanate (80mg) andbenzo[c]l,2,5-oxadiazole-5-carbohydrazide (53mg).
  • the title compound had the following physical properties: mp 229-231°C.
  • the title compound was prepared as described in Example 1 from 3- bromobenzenisothiocyanate (1.3g) and 3-nifrobenzenecarbohydrazide (l.Og).
  • the title compound had the following physical properties: mp 273-275°C; LC-MS 376.88.
  • Example 82 Following the procedure described in Example 1, the title compound was prepared from 4-bromo-3-chlorobenzenisothiocyanate (430mg) and 2- ⁇ 2-[(4,5-dichloroimidazolylthio)methyl] phenoxy ⁇ acetohydrazide (500mg). The title compound had the following physical properties: mp 183-185°C. Example 82:
  • Example 10 As described in Example 10 (with sulfonyl chloride in place of acyl chloride), the title compound was prepared from (4- ⁇ [5-(3-ethoxyphenyl)(l,3,4-thiadiazol-2-yl)]amino ⁇ phenyl) amine (lOOmg) and benzenesulfonyl chloride (lOOmg).
  • the title compound had the following physical properties: mp 216-218°C.
  • Example 2 The reactions described in Example 1 were repeated using 3-nifrobenzenecarbohydrazide (362mg; 2.0mmol) and 4-(piperidylsulfonyl) benzenisothiocyanate (565mg; 2.0mmol) to yield (3 -nitrophenyl)-N- [( ⁇ [4-(piperidylsulfonyl)phenyl] amino ⁇ thioxomethyl)amino] carboxamide (910mg, 98%) in the first step.
  • N-( ⁇ [(4-bromo-3- chlorophenyl)amino]thioxomethyl ⁇ amino)(3-nifrophenyl)carboxamide 750mg; 1.7mmol
  • sulfuric acid 2.0mL
  • the title compound (698mg; 97%) with the following physical properties: mp 330-331°C; Mass (M+l) + 413 (Calc); 413 (Obsd.).
  • Example 2 The reactions described in Example 1 were repeated using 3-nifrobenzenecarbohydrazide (362mg; 2.0mmol) and 2,3,4,5-tetrachlorobenzenisothiocyanate (546mg; 2.0mmol) to yield (3- nifrophenyl)-N-( ⁇ [(2,3,4,5-tefrachlorophenyl)amino] thioxomethyl ⁇ amino) carboxamide (690mg; 76%) in the first step.
  • 3-nifrobenzenecarbohydrazide (362mg; 2.0mmol)
  • 2,3,4,5-tetrachlorobenzenisothiocyanate 546mg; 2.0mmol
  • N-( ⁇ [(3-chloro-4-methylphenyl)amino]thioxomethyl ⁇ amino)(3-nifrophenyl)carboxamide (550mg; 1.5mmol) and sulfuric acid (2.0mL) were used to yield the title compound (486mg; 93%) with the following physical properties: mp 289-290°C; Mass (M) + 347 (Calc); 347 (Obsd.); Elemental analysis C 51.95, H 3.20, N 16.16, S 9.25 (Calc); C52.12, H 3.16, N 16.16, S 9.42 (Obsd.). (NuMega)
  • Example 88 (4-Methylthiophenyl)[5-(3-nitrophenyl)(l,3,4-thiadiazol-2-yl)amine
  • Example 1 The reactions described in Example 1 were repeated using 3-nifrobenzenecarbohydrazide (362mg; 2.0mmol) and 4-methylthiobenzenisothiocyanate (362mg; 2.0mmol) to yield N-( ⁇ [(4- methylthiophenyl)amino]thioxomethyl ⁇ amino)(3-nifrophenyl)carboxamide (710 mg; 98%) in the first step.
  • N-( ⁇ [(4-methylthiophenyl)amino]thioxomethyl ⁇ amino)(3- nifrophenyl)carboxamide 600mg; 1.7mmol
  • sulfuric acid 2.0mL
  • N-( ⁇ [(4-(methylethyl)phenyl)amino]thioxomethyl ⁇ amino)-(3-nifrophenyl)carboxamide 600mg; 1.7mmol
  • sulfuric acid 2.0mL
  • Example 2 The reactions described in Example 1 were repeated using 3-nifrobenzenecarbohydrazide (362mg; 2.0mmol) and 4-butylbenzenisothiocyanate (383mg; 2.0mmol) to yield N-( ⁇ [(4- butylphenyl)amino]thioxomethyl ⁇ amino)(3-niteophenyl)carboxamide (680mg; 92%) in the first step.
  • N-( ⁇ [(4-butylphenyl)amino]thioxomethyl ⁇ amino)(3- nifrophenyl)carboxamide 500mg; 1.3mmol
  • sulfuric acid 2.0mL
  • Example 91 (4-Decylphenyl)[5-(3-nitrophenyl)(l,3,4-thiadiazol-2-yl)amine
  • Example 2 The reactions described in Example 1 were repeated using 3-nifrobenzenecarbohydrazide (154mg; O. ⁇ mmol) and 4-decylbenzenisothiocyanate (237mg; 0.8 mmol) to yieldN-( ⁇ [(4- decylphenyl)amino]thioxomethyl ⁇ amino)-(3-nifrophenyl)carboxamide (340 mg; 81%) in the first step.
  • N-( ⁇ [(4-decylphenyl)ammo]thioxomethyl ⁇ amino)-(3- nifrophenyl)carboxamide 300mg; 0.7mmol
  • sulfuric acid 2.0mL
  • Example 2 The reactions described in Example 1 were repeated using 3-nifrobenzenecarbohydrazide (362mg; 2.0mmol) and 4-(4-nifrophenoxy)benzenisothiocyanate (545mg; 2.0mmol) to yield (3- nifrophenyl)-N-[( ⁇ [4-(4-nitrophenoxy) ⁇ henyl]amino ⁇ thioxomethyl)amino]carboxamide (890mg; 98%) in the first step.
  • Example 1 The reactions described in Example 1 were repeated using 3-nifrobenzenecarbohydrazide (300mg; 2.0mmol) and 4-(piperidylsulfonyl) benzenisothiocyanate (565mg; 2.0mmol) to yield (3-methylphenyl)-N-[( ⁇ [4-(piperidylsulfonyl)phenyl]amino ⁇ thioxomethyl)amino]carboxamide (757mg; 88%) in the first step.
  • Example 1 The reactions described in Example 1 were repeated using 3-nifrobenzenecarbohydrazide (362mg; 2.0mmol) and 5-chloro-2,4-dimethoxybenzenisothiocyanate (459mg; 2.0mmol) to yield N-( ⁇ [(5-chloro-2,4-dimethoxyphenyl)amino]thioxomethyl ⁇ amino)(3-nitrophenyl)carboxamide , (796mg; 97%) in the first step.
  • Example 2 The reactions described in Example 1 were repeated using l-phenoxybenzene-4- carbohydrazide (500mg; 2.2 mmol) and ethyl 4-isothiocyanatobenzoate (454mg; 2.2mmol) to yield ethyl 4-[( ⁇ [(4-phenoxyphenyl)carbonylamino]amino ⁇ thioxomethyl)amino]benzoate in the first step.
  • all the crude product and sulfuric acid (0.5mL) were used to yield the title compound (589mg; 64%) with the following physical properties: mp 206-207°C; MS (M+H) + : 418.
  • Example 7 The reaction described in Example 7 was repeated using methyl 2-[3-(3- ⁇ 5-[(3,4- dichlorophenyl)amino]-l,3,4-thiadiazol-2-yl ⁇ phenoxy)phenyl]acetate (140mg; 0.29mmol) and lithium hydroxide (20mL; 0.25 ) to yield the title compound (123mg; 91%) with the following physical properties: mp 183-184°C; MS (M) + : 471 , 473.
  • Example 2 The reactions described in Example 1 were repeated using l-phenoxybenzene-3- carbohydrazide (184mg; 0.80mmol) and 4-bromo-3-chlorobenzenisothiocyanate (200mg; 0.80mmol) to yield N-( ⁇ [(4-bromo-3-chlorophenyl)amino]thioxomethyl ⁇ amino)(3- phenoxyphenyl)carboxamide (365mg; 95%) of in the first step.
  • all the crude product and sulfuric acid (0.4mL) were used to yield the title compound (286mg; 81%) with the following physical properties: mp 216-217°C; MS (M) + : 457, 459, 461.
  • Example 2 The reactions described in Example 1 were repeated using l-methylbenzene-3- carbohydrazide (167mg; 0.80mmol) and 4-bromo-3-chlorobenzenisothiocyanate (121mg; 0.80mmol) to yield N-( ⁇ [(4-bromo-3-chlorophenyl)amino]thioxomethyl ⁇ amino)(3- methylphenyl)carboxamide (306mg; 93%) in the first step.
  • Example 2 The reactions described in Example 1 were repeated using l-nifrobenzene-3- carbohydrazide (245mg; 1.35mmol) and naphthylmethanisothiocyanate (270mg; 1.35mmol) to yield N-( ⁇ [(naphthylmethyl)amino]thioxomethyl ⁇ amino)(3-nifrophenyl)carboxamide (482mg; 94%) in the first step.
  • all the crude product and sulfuric acid (0.5mL) were used to yield the title compound (244mg; 53%) with the following physical properties: mp 150- 151°C;
  • Example 2 The reactions described in Example 1 were repeated using l-phenylbenzene-4- carbohydrazide (200mg; 0.94mmol) and 3,4-dichlorobenzenisothiocyana ⁇ e (192mg; 0.94mmol) to yield N-( ⁇ [(3,4-dichlorophenyl)amino]thioxomethyl ⁇ amino)(4-phenylphenyl)carboxamide (360mg; 92%) in the first step.
  • Example 140 (4- ⁇ 5-[(3,4-dichlorophenyl)amino](l,3,4-thiadiazol-2-yl) ⁇ phenyl)dimethylamine
  • the reactions described in Example 1 were repeated using 4-(dimethylamino) benzenecarbohydrazide (200mg; 1. lmmol) and 3,4-dichlorobenzenisothiocyanate (228mg; 1.1 mmol) to yield [4-(dimethylamino)phenyl]-N-( ⁇ [(3,4-dichlorophenyl)amino]thioxomethyl ⁇ amino)carboxamide (404mg; 94%) in the first step.
  • the second step all the crude product and sulfuric acid (0.4mL) were used to yield the title compound (368mg; 96%) with the following physical properties: mp 298.5-299.5°C;
  • Example 2 The reactions described in Example 1 were repeated using l-methylthiobenzene-4- carbohydrazide (200mg; 1.1 mmol) and 3,4-dichlorobenzenisothiocyanate (224mg; 1. lmmol) to yield N-( ⁇ [(3,4-dichlorophenyl)amino]thioxomethyl ⁇ amino)(4-methylthiophenyl)carboxamide (358mg; 84%) in the first step.
  • Example 142 methyl 3-( ⁇ 2- [aza(3,4-dichlor ophenyl)methylene] -5-(3-ethoxyphenyl)-l ,3,4-thiadiazolin-3- yl ⁇ methyI)benzoate
  • Example 143-144 methyl 3-( ⁇ 2-[aza(3,4-dichlorophenyl)methylene]-5-(3-ethoxyphenyl)-l,3,4-thiadiazolin-3- yl ⁇ methyl)benzoate and methyl 3-( ⁇ (3,4-dichlorophenyl) [5-(3-ethoxyphenyl)(l,3,4-thiadiazol-2- yl)]amino ⁇ methyl)benzoate
  • Example 8 The reaction described in Example 8 was repeated using (3,4-dichlorophenyl)[5-(3- ethoxyphenyl)(l,3,4-thiadiazol-2-yl)]amine (120mg; 0.33mmol), potassium tert-butoxide (33mL;
  • Example 146 l-( ⁇ 2-[aza(3,4-dichlorophenyl)methylene]-5-(3-ethoxyphenyl)(l,3,4-thiadiazolin-3- yl) ⁇ methyl)-3-methoxybenzene
  • Example 8 The reaction described in Example 8 was repeated using (3,4-dichlorophenyl)[5-(3- ethoxyphenyl)(l,3,4-thiadiazol-2-yl)]amine (120mg; 0.33mmol), potassium tert-butoxide (0.33mL; 0.33mmol) and 3 -(bromomethyl)-l -nitrobenzene (85mg; 0.39mmol) to yield 3- ⁇ 2- [aza(3,4-dichlorophenyl)methylene]-3-[(3-nifrophenyl)methyl](l,3,4-thiadiazolin-5-yl) ⁇ -l- ethoxybenzene (30mg; 18%) with the following physical properties: R f : 0.53 (hexanes / ethyl acetate, 2/1); mp 114-115°C; MS (M) + : 500, 502; and (3,4-dichlorophenyl)[5-(3- eth
  • Example 2 The reactions described in Example 2 were repeated using [3-(4-methylphenoxy)phenyl] formaldehyde (180mg; 0.85mmol) and the product from Procedure D (200mg; 0.85mmol) to yield ( ⁇ (lE)-l-aza-2-[3-(4-methylphenoxy)phenyl]vinyl ⁇ amino)[(3,4-dichlorophenyl)amino] methane- 1 -thione (322mg; 88%) in the first step.
  • Example 2 The reactions described in Example 2 were repeated using [3-(3,5-dichlorophenoxy) phenyl]formaldehyde (226mg; 0.85mmol) and the product from Procedure D (200mg; 0.85mmol) to yield ( ⁇ (lE)-l-aza-2-[3-(3,5-dichlorophenoxy)phenyl]vinyl ⁇ amino)[(3,4- dichlorophenyl)amino]methane-l -thione (366mg; 89%) in the first step.
  • Example 2 The reactions described in Example 2 were repeated using [3 -(3 ,4- dichlorophenoxy)phenyl]formaldehyde (226mg; 0.85mmol) and the product from Procedure D (200mg; 0.85mmol) to yield ( ⁇ (lE)-l-aza-2-[3-(3,4-dichlorophenoxy)phenyl]vinyl ⁇ amino)[(3,4- dichlorophenyl)amino]methane-l -thione (292mg; 71%) in the first step.
  • Example 7 the title compound was prepared from methyl 4- ⁇ [(3,4- dichlorophenyl)(5- ⁇ 3-[3-(trifluoromethyl)phenoxy]phenyl ⁇ (l,3,4-thiadiazol-2- yl))amino]methyl ⁇ benzoate (50mg) and sodium hydroxide (0.8mL; 2.5M).
  • the title compound had the following physical properties: mp 114-116°C (from 4/1 Hexanes/Ethyl Acetate), MS 615.93.
  • Example 158 (3,4-dichlorophenyl)(5- ⁇ 3-[3-(oxymethyl)phenoxy]phenyl ⁇ (l,3,4-thiadiazol-2-yl))amine
  • (4-aminophenyl)[5-(3-nifrophenyl)(l,3,4-thiadiazol-2- yl)]amine was prepared from (tert-butoxy)-N-(4-isothiocyanatophenyl)carboxamide (200mg) and N-amino(3-nifrophenyl)-carboxamide (130mg).
  • the Boc protecting group is lost during the cyclization reaction.
  • Example 160 (3,4-dichlorophenyl) ⁇ 5-[3,5-bis(phenylmethoxy)phenyl](l,3,4-thiadiazol-2-yl) ⁇ amine
  • the title compound was prepared from [3,5- bis(phenylmethoxy)phenyl]formaldehyde (400mg) and [(3,4-dichloro- phenyl)amino]hydrazinomethane-l -thione (290mg).
  • the title compound had the following physical properties: mp 212-214°C; LC-MS: 533.99.
  • the title compound was prepared from 3-carbonylbenzoic acid (70mg) and [(3 -bromophenyl)amino]hydrazinomethane-l -thione (lOOmg).
  • the title compound had the following physical properties: mp 270-272°C.
  • the title compound was prepared from 3,4- dichlorobenzenisothiocyanate (120mg) and N-aminobenzo[3,4-c]l,2,5-oxadiazol-5- ylcafboxamide (88mg).
  • the title compound had the following physical properties: mp 315- 317°C; LC-MS 364.1.

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Organosulfur modulators of tyrosine phosphatases and their use in the treatment of disease are disclosed.

Description

Description
Organosulfur Inhibitors of Tyrosine Phosphatases
Technical Field
The present invention is directed to inhibiting the activity of tyrosine phosphatases that regulate signal transduction, and, more particularly, to the use of organosulfur compositions as tyrosine phosphatase inhibitors for the treatment of diseases which respond to phosphatase inhibition.
Background of the Invention
Cellular signal transduction is a fundamental mechanism whereby external stimuli that regulate cellular processes are relayed to the interior of cells. The biochemical pathways through which signals are transmitted within cells comprise a circuitry of directly or functionally connected interactive proteins. One of the key biochemical mechanisms of signal transduction involves the reversible phosphorylation of tyrosine residues on proteins. The phosphorylation state of a protein may affect its conformation and/or enzymatic activity as well as its cellular location. The phosphorylation state of a protein is modified through the reciprocal actions of protein tyrosine kinases (PTKs) and protein tyrosine phosphatases (PTPs) at various specific tyrosine residues.
A common mechanism by which receptors regulate cell function is through an inducible tyrosine kinase activity which is either endogenous to the receptor or is imparted by other proteins that become associated with the receptor (Darnell et al, 1994, Science 264:1415-1421; Heldin, 1995, Cell 80:213-223; Pawson, 1995, Nature 373:573-580). Protein tyrosine kinases comprise a large family of transmembrane receptor and intracellular enzymes with multiple functional domains (Taylor et al, 1992 Ann. Rev. Cell Biol. 8:429-62). The binding of ligand allosterically transduces a signal across the cell membrane where the cytoplasmic portion of the PTKs initiates a cascade of molecular interactions that disseminate the signal throughout the cell and into the nucleus. Many receptor protein tyrosine kinase (RPTKs), such as epidermal growth factor receptor (EGFR) and platelet-derived growth factor receptor (PDGFR) undergo oligomerization upon ligand binding, and the receptors self- phosphorylate (via autophosphorylation or transphosphorylation) on specific tyrosine residues in the cytoplasmic portions of the receptor (Schlessinger and Ullrich, 1992, Neuron, 9:383-91, Heldin, 1995, Cell 80:213-223). Cytoplasmic protein tyrosine kinases (CPTKs), such as Janus kinases (e.g., JAK1, JAK2, TYK2) and Src kinases (e.g., src, lck, fyn), are associated with receptors for cytokines (e.g., IL-2, IL-3, IL-6, erythropoietin) and interferons, and antigen receptors. These receptors also undergo oligomerization and have tyrosine residues that become phosphorylated during activation, but the receptor polypeptides themselves do not possess kinase activity.
Like the PTKs, the protein tyrosine phosphatases (PTPs) comprise a family of transmembrane and cytoplasmic enzymes, possessing at least an approximately 230 amino acid catalytic domain containing a highly conserved active site with the consensus motif >I/V!HCXAGXXR>S/T!G. The substrates of PTPs may be PTKs which possess phosphotyrosine residues or the substrates of PTKs (Hunter, 1989, Cell 58:1013-16; Fischer et al, 1991, Science 253:401-6; Saito & Streuli, 1991, Cell Growth and Differentiation 2:59-65; Pot and Dixon, 1992, Biochem. Biophys. Acta 1136:35-43).
Transmembrane or receptor-like PTPs (RPTPs) possess an extracellular domain, a single transmembrane domain, and one or two catalytic domains followed by a short cytoplasmic tail. The extracellular domains of these RPTPs are highly divergent, with small glycosylated segments (e.g., RPTPα, RPTPε), tandem repeats of immunoglobulin-like and/or fϊbronectin type III domains (e.g., LAR) or carbonic anhydrase like domains (e.g., RPTPγ, RPTPβ). These extracellular features might suggest that these RPTPs function as a receptor on the cell surface, • and their enzymatic activity might be modulated by ligands. Intracellular or cytoplasmic PTPs (CPTPs), such as PTP1C, PTP1D, typically contain a single catalytic domain flanked by several types of modular conserved domains. For example, PTP1C, a hemopoietic cell CPTP is characterized by two Src-homology homology 2 (SH2) domains that recognize short peptide motifs bearing phosphotyrosine (pTyr). In general, these modular conserved domains influence the intracellular localization of the protein. SH2-containing proteins are able to bind pTyr sites in activated receptors and cytoplasmic phosphoproteins. Another conserved domain known as SH3 binds to proteins with proline-rich regions. A third type known as pleckstrin-homology (PH) domain has also been identified. These modular domains have been found in both CPTKs and CPTPs as well as in non-catalytic adapter molecules, such as Grbs (Growth factor Receptor Bound), which mediate protein-protein interactions between components of the signal transduction pathway (Skolnik et al, 1991, Cell 65:83-90; Pawson, 1995, Nature 373:573-580). Multiprotein signaling complexes comprising receptor subunits, kinases, phosphatases and adapter molecules are assembled in subcellular compartments through the specific and dynamic interactions between these domains with their binding motifs. Such signaling complexes integrate the extracellular signal from the ligand-bound receptor and relay the signal to other downstream signaling proteins or complexes in other locations inside the cell or in the nucleus (Koch et al, 1991, Science 252:668-674; Pawson, 1994, Nature 373:573-580; Mauro et al, 1994, Trends Biochem Sci 19:151-155; Cohen et al, 1995, Cell 80:237-248).
The levels of tyrosine phosphorylation required for normal cell growth and differentiation at any time are achieved through the coordinated action of PTKs and PTPS. Depending on the cellular context, these two types of enzymes may either antagonize or cooperate with each other during signal transduction. An imbalance between these enzymes may impair normal cell functions leading to metabolic disorders and cellular transformation.
For example, insulin binding to the insulin receptor, which is a PTK, triggers a variety of metabolic and growth promoting effects such as glucose transport, biosynthesis of glycogen and fats, DNA synthesis, cell division and differentiation. Diabetes mellitus, which is characterized by insufficient or a lack of insulin signal transduction, can be caused by any abnormality at any step along the insulin signaling pathway (Olefsky, 1988, in "Cecil Textbook of Medicine," 18th Ed., 2:1360-81).
It is also well known, for example, that the overexpression of PTKs, such as HER2, can play a decisive role in the development of cancer (Slamon et al, 1987, Science 235:77-82) and that antibodies capable of blocking the activity of this enzyme can abrogate tumor growth (Drebin et al, 1988, Oncogene 2:387-394). Blocking the signal transduction capability of tyrosine kinases such as Flk-1 and the PDGF receptor have been shown to block tumor growth in animal models (Millauer et al, 1994, Nature 367:577; Ueno et al, Science 252:844-848). Relatively less is known with respect to the direct role of tyrosine phosphatases in signal transduction; PTPs may play a role in human diseases. For example, ectopic expression of RPTPα produces a transformed phenotype in embryonic fibroblasts (Zheng et al, Nature 359:336-339), and overexpression of RPTPα in embryonal carcinoma cells causes the cells to differentiate into a cell type with neuronal phenotype (den Hertog et al, EMBO J 12:3789-3798). The gene for human RPTPγ has been localized to chromosome 3p21 which is a segment frequently altered in renal and small lung carcinoma. Mutations may occur in the extracellular segment of RPTPγ which result in RPTPs that no longer respond to external signals (LaForgia et al, Wary et al, 1993, Cancer Res 52:478-482). Mutations in the gene encoding PTP1C (also known as HCP, SHP) are the cause of the motheaten phenotype in mice which suffer severe immunodeficiency, and systemic autoimmune disease accompanied by hyperproliferation of macrophages (Schultz et al, 1993, Cell 73:1445-1454). PTPID (also known as Syp or PTP2C) has been shown to bind through SH2 domains to sites of phosphorylation in PDGFR, EGFR and insulin receptor substrate 1 (IRS-1). Reducing the activity of PTPID by microinjection of anti- PTP1D antibody has been shown to block insulin or EGF-induced mitogenesis (Xiao et al, 1994, JBiol Chem 269:21244-21248).
Disclosure of the Invention
The present invention provides methods and compositions for the modulation of tyrosine phosphatase activity. Such compositions and methods will find use in the freatment of diseases caused by dysfunctional signal transduction.
In one aspect the present invention provides a method for inhibiting protein tyrosine phosphatase activity which comprises administering to a mammal an effective amount of a compound having the formula:
R1 R2
(I) R3 or a pharmaceutically acceptable salt thereof, wherein:
Rl, R2, and R3 are each independently selected from H, hydroxyl, alkoxy, alkylthio, nitro, amino or amido (each optionally substituted with alkyl, amino, cycloheteroalkyl, cycloalkyl fluoro, aryl, heteroaryl, cycloheteroalkyl, alkylthio, arylthio, cyano, OR', OC=OR", C=O-OR"', or C=O-NR""R""); small alkyl (C1-C10) (optionally C1-C6) (optionally substituted with alkyl, amino, cycloheteroalkyl, cycloalkyl fluoro, aryl, heteroaryl, cycloheteroalkyl, alkylthio,
P=O(OR")2, CH2P=O(OR")2, CF2P=0(OR")2, NHCOCOOR", CH(COOR")2, arylthio, cyano, OR", OC=OR", C=O-OR'", or C=0-NR""R""); phenyl and mono and disubstituted (at positions 3 and 4) phenyl (wherein the phenyl ring is independently substituted with alkyl, trifluoromethyl, mono and di halogen atoms, alkylthio, alkoxy, nitro, cyano, morphilino, cyclohexyl, phenyl, phenolic, dioxymethylene, nitro, acetylamino, OR', P=0(OR")2, CH2P=O(OR")2, CF2P=O(OR")2, NHCOCOOR", CH(COOR")2 ); heteroaryl, cycloheteroalkyl and cycloheteroalkyl (each optionally substituted with alkyl, halogen, alkylthio, alkoxy, or nitro, OR', P=O(OR")2, CH2P=O(OR")2, CF2P=O(OR")2, NHCOCOOR", CH(COOR")2, ); cycloalkyl (C3-C10) (optionally substituted with alkyl, fluoro, aryl, heteroaryl, cycloheteroalkyl, cycloheteroalkyl alkylthio, arylthio, cyano, P=O(OR")2,
CH2P=0(OR")2, CF2P=O(OR")2, NHCOCOOR", CH(COOR")2, OR', OC=OR', C=0- OR", or C=0-NR'"R""); alkenyl (C1-C10) (optionally substituted with alkyl, fluoro, aryl, heteroaryl, cycloheteroalkyl, cycloheteroalkyl, alkylthio, arylthio, cyano, P=O(OR")2, CH2P=O(OR")2, CF2P=O(OR")2, NHCOCOOR", CH(COOR")2, OR', OC=OR', C=O- OR", or C=O-NR'"R""); alkadienyl (C1-C10) (optionally substituted with alkyl, fluoro, aryl, heteroaryl, cycloheteroalkyl, cycloheteroalkyl, alkylthio, arylthio, cyano, P=O(OR")2,
CH2P=O(OR")2, CF2P=O(OR")2, NHCOCOOR", CH(COOR")2, OR', -OC=OR5, - C=O-OR", C=0-NR"'R""); cycloalkenyl (C4-C10), optionally substituted with alkyl, fluoro, aryl, heteroaryl, cycloheteroalkyl, cycloheteroalkyl, alkylthio, arylthio, cyano, P=O(OR")2,
CH2P=O(OR")2, CF2P=O(OR")2, NHCOCOOR", CH(COOR")2, OR', -OC=OR', - C=O-OR", C=0-NR"'R""; bicycloalkyl (C5-C12), optionally substituted with alkyl, fluoro, aryl, heteroaryl, cycloheteroalkyl, cycloheteroalkyl, alkylthio, arylthio, cyano, P=O(OR")2,
CH2P=O(OR")2, CF2P=O(OR")2, NHCOCOOR", CH(COOR")2, OR', -OC=OR', - C=O-OR", C=0-NR'"R""; tricycloalkyl (C8-C14) , optionally substituted with alkyl, fluoro, aryl, heteroaryl, cycloheteroalkyl, cycloheteroalkyl, alkylthio, arylthio, cyano, P=O(OR")2,
CH2P=O(OR")2, CF2P=O(OR")2, NHCOCOOR", CH(COOR")2, OR', -OC=OR', - C=O-OR", C=0-NR"'R""; where Each R' is independently: hydrogen; alkyl (C1-C10), optionally substituted with alkyl, keto, fluoro, alkoxy, alkylthio, aryl, heteroaryl, cycloheteroalkyl, cycloheteroalkyl, cyano, aryloxy, cycloalkyl, COOR", P=0(OR")2, CH2P=0(OR")2, CF2P=O(OR")2, NHCOCOOR", CH(COOR")2; aryl, optionally substituted with alkyl, keto, fluoro, alkoxy, alkylthio, cyano, aryloxy, COOR", P=O(OR")2, CH2P=0(OR")2, CF2P=0(OR")2,
NHCOCOOR", CH(COOR")2; heteroaryl, cycloheteroalkyl, cycloheteroalkyl, optionally substituted with alkyl, keto, fluoro, alkoxy, alkylthio, cyano, aryloxy, COOR", P=O(OR")2, CH2P=0(OR")2, CF2P=0(OR")2, NHCOCOOR", CH(COOR")2; cycloalkyl, optionally substituted with alkyl, keto, fluoro, alkoxy, alkylthio, aryl, heteroaryl, cycloheteroalkyl, cycloheteroalkyl, cyano, COOR", P=O(OR")2, CH2P=O(OR")2, CF2P=0(OR")2, NHCOCOOR", CH(COOR")2; Each R" is independently hydrogen, alkyl (C1-C10), optionally substituted with alkyl, keto, fluoro, alkoxy, alkylthio, aryl, heteroaryl, cycloheteroalkyl, cycloheteroalkyl; aryl, optionally substituted with alkyl, keto, fluoro, alkoxy, alkylthio; heteroaryl, cycloheteroalkyl, optionally substituted with alkyl, keto, fluoro, alkoxy, alkylthio; cycloalkyl, optionally substituted with alkyl, keto, fluoro, alkoxy, alkylthio, aryl, heteroaryl, cycloheteroalkyl;
Each R'" is independently alkyl (C1-C10), optionally substituted with alkyl, keto, fluoro, alkoxy, alkylthio, aryl, heteroaryl, cycloheteroalkyl, COOR' ' , P=0(OR' ')2,
CH2P=O(OR")2, CF2P=O(OR")2, NHCOCOOR", CH(COOR")2; aryl, optionally substituted with alkyl, keto, fluoro, alkoxy, alkylthio; heteroaryl, cycloheteroalkyl, optionally substituted with alkyl, keto, fluoro, alkoxy, alkylthio, COOR", P=O(OR")2, CH2P=O(OR")2,
CF2P=O(OR")2, NHCOCOOR", CH(COOR")2; cycloalkyl, optionally substituted with alkyl, keto, fluoro, alkoxy, alkylthio, aryl, heteroaryl, cycloheteroalkyl, COOR", P=0(OR")2, CH2P=O(OR")2, CF2P=O(OR")2, NHCOCOOR", CH(COOR")2; and
Each R"" is independently alkyl (C1-C10), optionally substituted with alkyl, keto, fluoro, alkoxy, alkylthio, aryl, heteroaryl, cycloheteroalkyl, COOR", P=O(OR")2,
CH2P=O(OR")2, CF2P=O(OR")2, NHCOCOOR", CH(COOR")2; aryl, optionally substituted with alkyl, keto, fluoro, alkoxy, alkylthio, COOR", P=0(OR")2, CH2P=0(OR")2, CF2P=O(OR")2, NHCOCOOR", CH(COOR")2; heteroaryl, cycloheteroalkyl, optionally substituted with alkyl, keto, fluoro, alkoxy, alkylthio, COOR", P=0(OR")2, CH2P=0(OR")2, CF2P=O(OR")2, NHCOCOOR", CH(COOR")2; and cycloalkyl, optionally substituted with alkyl, keto, fluoro, alkoxy, alkylthio, aryl, heteroaryl, cycloheteroalky, COOR", P=O(OR")2, CH2P=0(OR")2, CF2P=O(OR") , NHCOCOOR", CH(COOR")2. And wherein each of Rl, R2 and R3 are linked to their respective core atoms through C, N, O or S of the substiuent group, provided that if R2 is to be linked through O or S, then the core atom S is oxidized.
Brief Description of the Drawings
Figure 1 depicts selected compounds of the invention, together with chemical names.
Detailed Description of the Invention
The present invention provides methods and compositions for the inhibition of tyrosine phosphatase activity. Such compositions and methods will find use in the freatment of diseases caused by dysfunctional signal transduction.
In one aspect the present invention provides a method for inhibiting protein tyrosine phosphatase activity which comprises administering to a mammal an effective amount of a compound having the formula:
R1 R2
R3 wherein Rl, R2 and R3 are as further defined below, together with a pharmaceutically acceptable salt thereof.
The compounds of the present invention inhibit tyrosine phosphatases, including PTP- 1B, and thus improve insulin sensitivity, among other benefits. The compounds therefore will find use in preventing or treating Type 1 and Type 2 diabetes [and associated complications such as hypertension, ischemic diseases of the large and small blood vessels, blindness, circulatory problems, kidney failure and atherosclerosis], syndrome X, metabolic syndrome, improving glucose tolerance, improving insulin sensitivity when there is insulin resistance, improving leptin sensitivity where there is leptin resistance, lowering body weight, and preventing or freating obesity. In addition, the compounds will be useful in preventing or freating cancer, neurodegenerative diseases, and the like.
The compounds of the present invention are generally characterized as nitrogen- containing organosulfur compounds having the formula (I) and their pharmaceutically acceptable salts:
Figure imgf000011_0001
wherein:
Rl, R2, and R3 are each independently selected from H, hydroxyl, alkoxy, alkylthio, nitro, amino or amido (each optionally substituted with alkyl, amino, cycloheteroalkyl, cycloalkyl fluoro, aryl, heteroaryl, cycloheteroalkyl, alkylthio, arylthio, cyano, OR', OC=OR", C=O-OR'", or C=O-NR""R""), small alkyl (C1-C10) (optionally C1-C6) (optionally substituted with alkyl, amino, cycloheteroalkyl, cycloalkyl fluoro, aryl, heteroaryl, cycloheteroalkyl, alkylthio,
P=O(OR")2, CH2P=O(OR")2, CF2P=0(OR")2, NHCOCOOR", CH(COOR")2, arylthio, cyano, OR", OC=OR", C=O-OR'", or C=O-NR""R""), phenyl and mono and disubstituted (at positions 3 and 4) phenyl (wherein the phenyl ring is independently substituted with alkyl, trifluoromethyl, mono and di halogen atoms, alkylthio, alkoxy, nitro, cyano, morphilino, cyclohexyl, phenyl, phenolic, dioxymethylene, nitro, acetylamino, OR', P=O(OR")2, CH2P=O(OR")2, CF2P=O(OR")2, NHCOCOOR", CH(COOR")2 ), heteroaryl, cycloheteroalkyl and cycloheteroalkyl (each optionally substituted with alkyl, halogen, alkylthio, alkoxy, or nitro, OR', P=O(OR")2, CH2P=0(OR")2, CF2P=0(OR")2, NHCOCOOR", CH(COOR")2, ), cycloalkyl (C3-C10) (optionally substituted with alkyl, fluoro, aryl, heteroaryl, cycloheteroalkyl, cycloheteroalkyl alkylthio, arylthio, cyano, P=0(OR")2,
CH2P=O(OR' ')2, CF2P=0(OR' ')2, NHCOCOOR", CH(COOR' ')2, OR', OC=OR', C=0-OR' ', or C=O-NR' "R" ' ') alkenyl (C1-C10) (optionally substituted with alkyl, fluoro, aryl, heteroaryl, cycloheteroalkyl, cycloheteroalkyl, alkylthio, arylthio, cyano, P=O(OR")2,
CH2P=O(OR")2, CF2P=O(OR")2, NHCOCOOR", CH(COOR")2, OR', OC=OR', COOR", or C=O-NR"'R"") alkadienyl (C1-C10) (optionally substituted with alkyl, fluoro, aryl, heteroaryl, cycloheteroalkyl, cycloheteroalkyl, alkylthio, arylthio, cyano, P=O(OR")2,
CH2P=O(OR")2, CF2P=0(OR")2, NHCOCOOR", CH(COOR")2, OR', -OCOR5, - C=0-OR", C=0-NR"'R"") cycloalkenyl (C4-C10), optionally substituted with alkyl, fluoro, aryl, heteroaryl, cycloheteroalkyl, cycloheteroalkyl, alkylthio, arylthio, cyano, P=O(OR")2, CH2P=0(OR")2, CF2P=O(OR")2, NHCOCOOR", CH(COOR")2, OR', -OC=OR', - CO-OR", G=O-NR"'R"" bicycloall yl (C5-C12), optionally substituted with alkyl, fluoro, aryl, heteroaryl, cycloheteroalkyl, cycloheteroalkyl, alkylthio, arylthio, cyano, P=O(OR")2, CH2P=0(OR")2, CF2P=O(OR")2, NHCOCOOR", CH(COOR")2, OR', -OC=OR', - C=0-OR", C=0-NR"'R"" tricycloalkyl (C8-C14) , optionally substituted with alkyl, fluoro, aryl, heteroaryl, cycloheteroalkyl, cycloheteroalkyl, alkylthio, arylthio, cyano, P=0(OR")2, CH2P=0(OR")2, CF2P=O(OR")2, NHCOCOOR", CH(COOR")2, OR', -OCOR', - C=O-OR", C=0-NR'"R"" where
Each R' is independently: hydrogen, alkyl (C1-C10), optionally substituted with alkyl, keto, fluoro, alkoxy, alkylthio, aryl, heteroaryl, cycloheteroalkyl, cycloheteroalkyl, cyano, aryloxy, cycloalkyl, COOR", P=O(OR")2, CH2P=O(OR")2, CF2P=O(OR")2, NHCOCOOR", CH(COOR")2; aryl, optionally substituted with alkyl, keto, fluoro, alkoxy, alkylthio, cyano, aryloxy, COOR", P=0(OR")2, CH2P=0(OR")2, CF2P=0(OR")2, NHCOCOOR", CH(COOR")2; heteroaryl, cycloheteroalkyl, cycloheteroalkyl, optionally substituted with alkyl, keto, fluoro, alkoxy, alkylthio, cyano, aryloxy, COOR", P=O(OR")2, CH2P=O(OR")2, CF2P=0(OR")2, NHCOCOOR", CH(COOR")2; cycloalkyl, optionally substituted with alkyl, keto, fluoro, alkoxy, alkylthio, aryl, heteroaryl, cycloheteroalkyl, cycloheteroalkyl, cyano, COOR",
P=0(OR")2, CH2P=O(OR")2, CF2P=0(OR")2, NHCOCOOR", CH(COOR")2;
Each R" is independently hydrogen, alkyl (C1-C10), optionally substituted with alkyl, keto, fluoro, alkoxy, alkylthio, aryl, heteroaryl, cycloheteroalkyl, cycloheteroalkyl; aryl, optionally substituted with alkyl, keto, fluoro, alkoxy, alkylthio; heteroaryl, cycloheteroalkyl, optionally substituted with alkyl, keto, fluoro, alkoxy, alkylthio; cycloalkyl, optionally substituted with alkyl, keto, fluoro, alkoxy, alkylthio, aryl, heteroaryl, cycloheteroalkyl;
Each R'" is independently alkyl (C1-C10), optionally substituted with alkyl, keto, fluoro, alkoxy, alkylthio, aryl, heteroaryl, cycloheteroalkyl, COOR", P=O(OR")2, CH2P=O(OR")2, CF2P=O(OR")2, NHCOCOOR", CH(COOR")2; aryl, optionally substituted with alkyl, keto, fluoro, alkoxy, alkylthio; heteroaryl, cycloheteroalkyl, optionally substituted with alkyl, keto, fluoro, alkoxy, alkylthio, COOR", P=0(OR")2, CH2PO(OR")2, CF2P=O(OR")2, NHCOCOOR", CH(COOR")2; cycloalkyl, optionally substituted with alkyl, keto, fluoro, alkoxy, alkylthio, aryl, heteroaryl, cycloheteroalkyl, COOR", P=O(OR")2, CH2P=O(OR")2, CF2P=O(OR")2, NHCOCOOR", CH(COOR")2; and Each R" " is independently alkyl (C1-C10), optionally substituted with alkyl, keto, fluoro, alkoxy, alkylthio, aryl, heteroaryl, cycloheteroalkyl, COOR", P=O(OR")2, CH2P=O(OR")2, CF2P=O(OR")2, NHCOCOOR", CH(COOR")2; aryl, optionally substituted with alkyl, keto, fluoro, alkoxy, alkylthio, COOR", P=0(OR")2, CH2P=0(OR")2, CF2P=O(OR")2, NHCOCOOR", CH(COOR")2; heteroaryl, cycloheteroalkyl, optionally substituted with alkyl, keto, fluoro, alkoxy, alkylthio, COOR", P=0(OR")2, CH2P=O(OR")2, CF2P=O(OR")2, NHCOCOOR", CH(COOR")2; and cycloalkyl, optionally substituted with alkyl, keto, fluoro, alkoxy, alkylthio, aryl, heteroaryl, cycloheteroalky, COOR' ' , P=O(OR' ')2,
CH2P=O(OR")2, CF2P=O(OR")2, NHCOCOOR", CH(COOR")2.
And wherein each of Rl, R2 and R3 are linked to their respective core atoms through C, N, O or S of the substituent group, provided that if R2 is to be linked through O or S, then the core atom S is oxidized.
In the compounds of formula (I), it is preferred that Rl be an aryl group optionally substituted with one or more halogen atoms; R2 be a phenylmethyl group optionally substituted at the 3 or 4 position with one or more aryl, perfluoroalkyl (C1-C4), or thiadiazolyl groups; and R3 be an benzoyl group optionally substituted with one or more perfluoroalkyl (C1-C4) substituents.
Specific examples of groups that may be represented by Rl include 3-bromophenyl and 3,4- dichlorophenyl. Specific examples of groups that may be represented by R2 include 4-phenyl phenylmethyl, 4-(l,2,3-thiadiazol-4-yl)-phenylmethyl, and 3-trifluoromethylphenylmethyl. A specific example of a group represented by R3 includes 3-frifluoromethylbenzoyl.
Alternatively, Rl and R2 can be taken together with the core unit to which they are attached (formula I) to form a heterocyclic group having formula (II) as follows:
Figure imgf000014_0001
Where R3 is as defined previously. Of the compounds of formula II, it is preferred that R3 is
(1) a phenyl group optionally substituted with one to three of the following and their combinations: halogen, hydroxy, aryloxy, nitro, carboxylic acid, CF2P=O(OH)2, NHCOCOOH, alkyl (C1-C10) or alkoxy (C1-C10) (optionally substituted with RlR2, COOH, cycloheteroalkyl), alkylthio (C1-C4), 2'-hydroxyethoxy, alkoxycarbonylmethoxy (C1-C4), dialkylamino (C1-C4 where the two alkyls optionally form a heteroalicyclic ring), 2- (dialkylamino)-2-oxoethoxy (C1-C7 where the two alkyls optionally form a heteroalicyclic ring), difluoromethoxy, perfluoroalkyl (C1-C4), perfluoroalkylthio (C1-C4), perfluoroalkoxy (C1-C4), 2-carboxyvinyl, alkanoyl (C1-C5), alkoxycarbonyl (C1-C4), alkanoylamino (C1-C8), benzoylamino (optionally substituted with one or more perfluoroalkyl group (Cl-C4)and/or CF2P=O(OH)2, NHCOCOOH,), aryl, aryloxy, arylcarbonyl, arylmethoxy, arylmethyl in which the methyl group is substituted with hydroxyl, 0(CH2)nCOOH (n=l-5), S(CH2)nCOOH (n=l-5), (4-carboxy)benzyloxy, (3-carboxybenzyloxy), or the group =N-0-CH2R in which R is carboxyl, alkoxycarbonyl (C1-C4), hydrogen, or phenyl (optionally substituted with one or more halogens), or the group =N-NHAr in which Ar is a phenyl (optionally substituted with one or more alkyl groups (C1-C4), and/or a carboxyl group, and/or CF2P=0(OH)2, NHCOCOOH), or the group-Y-(CH2)n-Z, where Y is O or S, n is 1, 2, or 3, and Z is hydrogen, methyl, branched alkyl (C3-C5), cycloalkyl (C3-C6), phenyl (optionally substituted with one or more of the following: halogen, trifluoroalkyl, carboxy, alkoxycarbonyl (C1-C4), CF2P=0(OH)2, NHCOCOOH, or carboxyl). It is also preferred that the aryl group in the aryl, aryloxy, arylcarbonyl, arylmethoxy and arylmethyl substituents within R3 will be phenyl or pyridyl (optionally substituted with one or more of the following and their combinations: amino, perfluoroalkyl (C1-C4), CF2P=0(OH)2, NHCOCOOH, CH=CH(CH2)nCOOH (n=l-5), 1- tefrazolo, 1-tefrazolo substituted at the 2 position with carboxyalkyl (n=l-5), N-(4- carboxyphenylamino)iminomethyl, perfluoroalkoxy (C1-C4), alkyl (C1-C10) or alkoxy (Cl- C10) (optionally substituted with NR1R2, COOH, cycloheteroalkyl), alkoxycarbonyl (C1-C4), carboxy, nifro, carboxyalkyl (C1-C7), carboxyalkenyl (C1-C7), formyl, hydroxyalkyl (C1-C4), halogen, hydroxy, cyano, tefrazole (optionally substituted with alkyl (C1-C4), carboxyalkyl (Cl- C4), or alkoxycarbonylmethyl (C1-C4)), CONHCH2(CHOCH2CH2O), or hydroxyalkyl (C1-C4); or
(2) a pyridylthio group optionally substituted with one or more halogen and/or one or more nitro groups, methylenedioxyphenyl, benzo[3,4-c]l,2,5-oxadiazol-5-yl, 4-oxo-3- hydroquinazolin-2-yl, or a group having fonnula (III) as follows:
Figure imgf000015_0001
in which the imidazole ring is optionally substituted with one or more halogens, and where R5 is as defined for Rl, R2 and R3 above.
Of these, it is preferred that R5 is an amino group with two substituents, where one substituent is arylcarbonyl, arylmethylcarbonyl, arylsulfonyl, aryldimethyloxycarbonyl, or aryloxymethylcarbonyl, [where the aryl group is phenyl, benzox[c]l,2,5-oxadiazol-5-yl, 1-furyl, 2-furyl 1 -naphthyl or 2-naphthyl, optionally substituted with one or more of the following or their combinations: perfluoroalkyl (C1-C4), alkyl (C1-C4), nifro, alkoxycarbonyl (C1-C4), carboxyl, carboxyalkyl(Cl-C4), CF2P=0(OH)2, NHCOCOOH, phenoxy (optionally substituted with alkoxy (C1-C4), CF2P=0(OH)2, NHCOCOOH, COOH, and/or halogen), or phenylalkoxy (C1-C4)], hydrogen, CF2P=0(OH)2, NHCOCOOH, or a phenyl group [optionally with one or more of the following substituents or combinations: hydroxy, halogen, nitro, CF2P=O(OH)2, NHCOCOOH, carboxy, carboxyalkyl(Cl-C4), carboxyalkylthio (C1-C6), phenyl, alkyl (Cl- C10) or alkoxy (C1-C10) (optionally substituted with NR1R2, COOH, cycloheteroalkyl), perfluoroalkyl (C1-C4), alkoxycarbonyl (C1-C4), alkylthio (C1-C4), phenylalkoxy (C1-C4), phenylsulfonylamino (each optionally substituted on phenyl with alkyl (C1-C4)), phenoxy (optionally substituted on phenyl with nifro, perfluoroalkyl (C1-C4), carboxymethyl, carboxy, CF2P=0(OH)2, NHCOCOOH, alkoxycarbonylmethyl (C1-C4)), carboxyalkyl(Cl-C4), phenylalkylthio (C1-C4, optionally substituted on phenyl with alkoxy (C1-C4), and/or phenyl), aminosulfonyl, alkylaminosulfonyl (C1-C4), dialkylaminosulfonyl (C1-C4 where the two alkyls optionally form a heteroalicyclic ring).] The second substituent on the amino group forming R5 is hydrogen, alkyl (C1-C10) or alkoxy (C1-C10) (each optionally substituted with NR1R2, COOH, CF2P=O(OH)2, NHCOCOOH, cycloheteroalkyl), naphthylalkyl (C1-C4), phenylalkyl (C1-C4, with the phenyl group optionally substituted with phenyl, alkyl (C1-C4), halo, amino, amido, keto, CF2P=0(OH)2, NHCOCOOH, alkyl (C1-C10) or alkoxy (C1-C10) (optionally substituted with NR1R2, COOH, cycloheteroalkyl), nifro, carboxy, perfluoroalkylthio (C1-C4), halogen, CF2P=0(OH)2, NHCOCOOH, 1,2,3-thiadiazolyl, and/or alkoxy carbonyl (C1-C4)), alkyl (C1-C10), cycloalkyl (C4-C8, optionally substituted with alkyl (C1-C4)), or indanyl (optionally substituted with alkyl (C1-C4)). It is also preferred that R5 is a phenylmethylthio group, optionally substituted with one or more halogens on the phenyl ring, or 2-oxo-2-(2- naphthylethylthio) optionally substituted with one or more alkyl groups (C1-C4).
Specific examples of groups that may be represented by R3 include: 3-nifrophenyl, 3,5- dinifrophenyl, 3,4-dihydroxyphenyl, 2-chlorophenyl, 2-trifluoromethylphenyl, 3-carboxyphenyl, 3-methylphenyl, 3-methoxyphenyl, 3-ethoxyphenyl, 3-trifluoromethoxyphenyl, 4- carboxyphenylmethyl, 3 -(3 -(N-(4-carboxyphenylamino)iminomethyl)phenoxy)phenyl, 3 -(3 -(6- carboxy-hex-l-enyl)phenoxy)phenyl, 3-(3-carboxyphenylmethoxy)-5-(phenylmethoxy)phenyl, 3 -(3 -carboxyphenoxy)phenyl, 3 , 5-bis(phenylmethoxy)phenyl, 3 , 5-bis(3 - methoxyphenylmethoxy)phenyl, 3 , 5-bis(3 -trifluoromethylphenylmetlιoxy)phenyl, 3 -(3 -((2- carboxybutyl)-l-tefrazolo))phenoxy)phenyl, 3-((4-carboxyphenylamino)imino)(3- trifluoromethylphenyl)methyl)phenyl,- 3-((carboxymethylthio)(3- trifluoromethylphenyl)methyl)phenyl, 3-(3-(l-hydroxy, 2,2 difluoro, 2-
(dihydroxyphosphono)ethyl)phenoxy)phenyl, 3-trifluoromethylthiophenyl, 3 -(4- methylpentanoylamino)phenyl), 4-dimethylaminophenyl, 4-ethoxyphenyl, 4-methylthiophenyl, 4-difluoromethoxyphenyl, 4-(2-carboxyvinyl)phenyl, 3,4-dimethoxyphenyl, 3-chloro-4- bromophenyl, 3-bromo-4-chlorophenyl, 3-nifro-4-morpholinophenyl, 3-phenylmethoxyphenyl, 3-[2-(4-methylpiperidyl)-2-oxoethoxy]phenoxy, 3-(l-naphthylsulfonylamino)phenyl, 4- phenylphenyl, 3,5-dimethoxyphenyl, 3,4-methylenedioxyphenyl, 3-phenylmethoxy-4- methoxyphenyl, benzo[3,4-c]l,2,5-oxadiazol-5-yl, 4-oxo-3-hydroquinazolin-2-yl, 3- (2'- hydroxyethoxy)phenyl, 3-(ethoxycarbonylmethoxy)phenyl, 3-n-butoxyphenyl, 4- ethylaminophenyl, 4-phenoxyphenyl, 3-(3'trifluoromethylphenoxy)phenyl, 3- (3'aminophenoxy)phenyl, 3,5-bis(3'trifluoromethylphenoxy)phenyl, 6- (3 'trifluoromethylphenoxy)-2-pyridyl, 3-(3 'methoxycarbonylphenoxy)phenyl, 3- (3'trifluoromethylphenoxy)-5-hydroxyphenyl, 3-(3'-hydroxyphenoxy)phenyl, 3-(3'-(l- ethoxycarbonylmethyl-l,2,3,4-tetrazol-5-yl)phenoxy)phenyl, 3-(4'-t-butylphenoxy)phenyl, 3- (3'carboxyphenoxy)phenyl, 3-(3'nitrophenoxy)phenyl, -(3'carboxymethylphenoxy)phenyl, 3- (4'methoxyphenoxy)phenyl, 3- (4'methylphenoxy)phenyl, 3-(3', 5'-dichlorophenoxy)phenyl, 3- (3', 4'-dichlorophenoxy)phenyl, 3-(4'hydroxyphenoxy)phenyl, 3-(3'cyanophenoxy)phenyl, -3- (3 ' (tetrazole- 1 -yl)phenoxy)phenyl, 3 -(3 ' -(N-( 1 ,3 -dioxolan-2- ylmethyl)carbamoyl)phenoxy)phenyl, 3-(3 '-hydroxymethylphenoxy)phenyl, 3-(3 '(2"- carboxyethyl)phenoxy)phenyl, 3 -(4 '-t-butylphenylmethoxy)phenyl, 4-(3 ' , 5 ' - bis(trifluoromethyl)benzoylamino)phenyl, 3 -(3 '-trifluoromethoxyphenylmethoxy)phenyl, 3-(3 '- trifluorophenylmethoxy)phenyl, 3-(3 '-trifluoromethylbenzoyl)phenyl, 3-((3 '- trifluoromethylphenyl)hydroxymethyl)phenyl, 3-[3'-[2-aza-2- (ethoxycarbonylmethoxy)vinyl]phenoxy]phenyl, 3-[3 '-[2-aza-2- (carboxymethoxy)vinyl]phenoxy]phenyl, 3-[3'-[2-aza-2-(4"- carboxyphenylamino)vinyl]phenoxy]phenyl, 3-{ethoxy [3- (trifluoromethyl)phenyl]methyl}phenyl, 3-{(carboxymethoxy)[3- (trifluoromethyl)phenyl]methyl}phenyl, 3-{(ethoxylcarbonylmethoxy)[3- (trifluoromethyl)phenyl]methyl}phenyl, 3-{(ethoxylcarbonylmethyl)[3- (trifluoromethyl)phenyl]methyl}phenyl, 3-{(carboxymethyl)[3- (trifluoromethyl)phenyl]methyl}phenyl, 3 - {(2 ' ,4 ' -dichlorophenylmethylthio) [3 - (trifluoromethyl)phenyl]methyl}phenyl, 3-(l-(3'-trifluoromethylphenyl)-2-aza-2-(4"- carboxyphenylamino)vinyl)phenoxy, 3-(3'-(6-carboxyhex-l-enyl)phenoxy)phenyl, 3-{(3- ethyl- 1 -butylthio) [3 -(trifluoromethyl)phenyl]methyl}phenyl, 3 - {(2-carboxyethylthio) [3 - (trifluoromethyl)phenyl]methyl}phenyl, 3-{(ethoxycarbonylmethoxy)[3- (trifluoromethyl)phenyl]methyl}phenyl, 3,5-bis(phenylmethoxy)phenyl, (4,5- dichloroimidazolyl)methyl]phenoxy}methyl), 2-nifro-4-bromo-(2-pyridylthio).
Specific examples of groups that may be represented by R5 include 3- bromophenylamino, 4-bromophenylamino, 4-fluorophenylamino, 3-nifrophenylamino, 4- nifrophenylamino, 3-fluorophenylamino, 4-aminosulfonylρhenylamino, 3-methylphenylamino, 3-hydroxyphenylamino, 3-carboxyphenylamino, 4-ethoxycarbonylphenylamino, 3- methoxyphenylamino, 3-methoxycarbonylphenylamino, 4-carboxyphenylamino, 3- trifluoromethylphenylamino, 4-acetylphenylamino, 4-ethylphenylamino, 4- isopropylphenylamino, 3,5-dinifrophenylamino, 4-(n-butyl)-phenylamino, 4-(n-decyl)amino, 4- ethoxycarbonylphenylamino, 4-methoxycarbonylphenylamino, 3,(4- carboxymethylphenoxy)phenylamino, 4-piperidinosulfonylphenylamino, 4-(4- nitrophenoxy)phenylamino, 3 -(4-phenylphenylmethylthio)phenylamino, 3 -(2- phenylphenylmethylthio)phenylamino, 3-carboxymethylphenylamino, 3-(2- carboxyethyl)phenylamino, 3-(3-trifluoromethylphenoxy)phenylamino, naphthalene- 1 - sulfonylamino, naphthalene-2-sulfonylamino, 3-(4-methoxylphenylmethylthio)phenylamino, 3- (3-phenylpropylthio)phenylamino, 2,5-dibromophenylamino, 3-chloro-4-fluorophenylamino, 2,3-dichlorophenylamino, 3,4-dichlorophenylamino, 3,4-dibromophenylamino, 2-chloro-5- nitrophenylamino, 2,4-dimethoxy-5-chlorophenylamino, 3-chloro-4-methylphenylamino, 3- chloro-4-bromophenylamino, 3-methyl-4-bromophenylamino, 4-(phenylsulfonylamino)- phenylamino, 4-(4'-methylphenylsulfonylamino)-phenylamino, (3-chloro-4-bromophenyl)(2- phenylmethyl)amino, (3-chloro-4-bromophenyl)(2-trifluoromethylthiophenylmethyl)amino, (3- chloro-4-bromophenyl)(4-t-butylphenylmethyl)amino, (2,3,4,5-tefrachlorophenyl)(4-t- butylphenylmethyl)amino, (3 ,4-dichlorophenyl)(3 -methoxycarbonylphenyl)methyl)amino, (3 ,4- dichlorophenyl)(4-methoxycarbonylphenyl)methyl)amino, (3,4-dichlorophenyl)(3- carboxyphenyl)methyl)amino, 3-phenylmethoxyphenylamino, 3-chloro-4-methylphenylamino, 2,3,4,5-tefrachlorophenylamino, (3,4-dichlorophenyl)[(4-carboxyphenyl)methyl]amino, (3,4- dichlorophenyl)[(4-methoxycarbonylphenyl)methyl]amino, (phenylmethyl)(3-chloro-4- bromophenyl)amino, (phenylmethyl)(3-bromophenyl)amino, (3,4-dichlorophenyl)[(4- phenylphenyl)methyl]amino, (3,4-dichlorophenyl)[4-(t-butylphenyl)methyl]amino, (3,4- dichlorophenyl)[(3-nifrophenyl)methyl]amino, (3,4-dichlorophenyl)[2-naphthylmethyl]amino, (methyl)(3,4-dichlorophenyl)amino, 3-trifluoromethylbenzoylamino, 3,5- bistrifluoromethylbenzoylamino, 3-methoxycarbonylbenzoylamino, 3-nifrobenzoylamino, 4-t- butylphenoxyacetylamino, 2-(4-chlorophenoxy)-2-methylpropanoylamino, benzo[c] 1 ,2,5- oxadiazol-5-yl-amino, 2-(4-methoxyphenoxy)-5-niteobenzoylamino, 5-(3,5-dichlorophenoxy)-2- furoylamino, 2-methyl-3-chlorobenzoyl, 4-(phenylmethoxy)ρhenylacetylamino, 1- naphthoylamino, 2-(4-methylphenyl)ethylamino, 1-napthylmethylamino, 2-indanylamino, 3,3,5- trimethylcyclohexylamino, 2-heptylamino, 3,4-dichlorophenylmethylthio, 2,6- dichlorophenylmethylthio, and 2-oxo-2-(2-naphthyl)ethylthio.
Alternatively, Rl and R2 can be taken together with the core unit to which they are attached (formula I) to form a heterocyclic group having formula (IV) as follows:
R7 R6 R7 R6 =
R1-R2= H> (Le- ϊζS )
R3 Wherein R3 is as defined previously.
Of these, it is preferred that that R3 be an arylamino group in which the aryl group is phenyl or pyridyl (optionally substituted with one or more of the following groups: phenyl, halogen, or hydroxy), or a phenylamino group (optionally substituted on the phenyl with one or more of the following: halogen, phenoxy, perfluoroalkyl (C1-C4), alkyl (C1-C4), or nitro), or a phenyl group optionally substituted with one or more nitro groups.
Specific examples of groups that may be represented by R3 include 2-hydroxy-5- chlorobenzoylamino, 2-hydroxy-5-bromobenzoylamino, 3-pyridinecarboxylamino, 4- bromobenzoylamino, 2-nifro-5-chlorobenzoylamino, 2,6-dimethoxy-3,5-dichlorobenzoylamino, 3-bromophenylamino, 4-phenoxyphenylamino, 3,4-dichlorophenylamino, 2,4,5- trichlorophenylamino, 3,5-dichlorophenylamino, bis(trifluoromethyl)phenylamino, and 3- nifrophenyl.
Wherein R6 is as defined above for Rl, R2 and R3.
Of these, it is preferred that that R6 be hydrogen, naphthyl, or phenyl [optionally substituted with one or more of the following: phenyl, alkoxy (C1-C4), alkyl (C1-C4), nifro, cyano, halogen, dialkylamino (C1-C4, with the two alkyl groups optionally joined to form a heterocycle), alkoxycarbonyl (C1-C4), benzoyloxy]. Specific examples of groups that may be represented by R6 include hydrogen, 4- phenylphenyl, 3-methoxyphenyl, 4-methylphenyl, 4-nitrophenyl, 4-cyanophenyl, 3-chloro-4- methylphenyl, 3,4-dichlorophenyl, 3-methyl-4-chlorophenyl, 4-diethylaminophenyl, 4-N- pyrrolidinophenyl, 2-(ethoxycarbonyl)phenyl, 3- benzoyloxyphenyl, 4- benzoyloxyphenyl, 2- naphthyl.
Wherein R7 is as defined above for Rl, R2 and R3.
Of these, it is preferred that that R7 be hydrogen, alkyl (C1-C4), benzoyl (optionally substituted with one or more of the following or their combinations: halogen, nifro, alkoxy (Cl- C4)), phenyl (optionally substituted with one or more halogen or nitro group), phenylamino (optionally substituted with one or more halogens), or 2H,3H,4H-benzo[3,4-b]l,4-dioxepan-7-yl (optionally substituted with one or more alkyl(Cl-C4)).
Specific examples of groups that may be represented by R7 include hydrogen, methyl, benzoyl, 4-bromobenzoyl, 3,4-dichlorobenzoyl, 2-nitrophenyl, 3-nifrophenyl, 4-chlorophenyl, 2H,3H,4H-benzo[3,4-b]l,4-dioxepan-7-yl, and 3-bromophenylamino.
Alternatively, Rl and R2 are linked through an aromatic ring, and taken together with the N=CR3-S unit to which they are attached, form a tricyclic heterocyclic group having formula (V) as follows:
Figure imgf000020_0001
/ Where R3 is as defined above for Rl, R2 and R3. Where R9 is as defined above for Rl, R2 and R3. Where R10 is as defined above for Rl, R2 and R3. Where Rl 1 is as defined above for Rl , R2 and R3.
Of these, it is preferred that that R3 be phenylamino (optionally substituted on phenyl with one or more of the following: halogen, alkyl(Cl-C4), perfluoroalkyl(Cl-C4)). It is preferred that that R9 be hydrogen or alkyl(Cl-C4). It is preferred that that R10 and Rl 1, independently, be H, alkyl (C1-C4), or halogen. In a specific example, R3 is 2,4,5- trichlorophenylamino, and R9, RIO, and Rl 1 are hydrogen.
Alternatively, Rl and R2, taken together with the N=CR3-S unit to which they are attached, form a heterocyclic group having formula (VI) as follows:
Figure imgf000022_0001
Where R3 is as defined above for Rl, R2 and R3.
Where R12 is as defined above for Rl, R2 and R3.
Where R13 is as defined above for Rl, R2 and R3.
Of these, it is preferred that that R3 be phenyl, optionally substituted with one or more of the following: Halogen, nitro, alkyl (C 1 -C 10), CF2P=O(OH)2, or alkoxy (C 1 -C 10) (optionally substituted with NR1R2, COOH, cycloheteroalkyl), phenoxy (optionally substituted with perfluoroalkyl(Cl-C4), carboxy, carboxymethyl, N-(4-carboxyphenylamino)iminomethylene, CF2P=0(OH) , alkyl (C1-C10) or alkoxy (C1-C10) (optionally substituted withNRlR2, COOH, cycloheteroalkyl), and/or halogen). It is preferred that that R12 be alkyl (C1-C10, optionally substituted with carboxyl or
Figure imgf000022_0002
or alkoxy (C 1 -C 10) (optionally substituted with NR1R2, COOH, cycloheteroalkyl), naphthylalkyl(Cl-C4), orphenylalkyl(Cl-C4, optionally substituted on phenyl with carboxyalkyl, carboxy, CF2P=O(OH)2> phenyl, alkyl (C1-C10) or alkoxy (C 1 -C 10) (optionally substituted with NR1 R2, COOH, cycloheteroalkyl), or alkoxycarbonylalkyl(Cl-C4)). It is preferred that that R13 be branched alkyl (C1-C5), alkyl (Cl -C5), cycloalkyl (C3-C7), phenyl (optionally substituted with one or more of the following or their combinations: halogen, alkoxycarbonyl(Cl-C4), alkyl (C1-C10), piperidinosulfonyl, or alkoxy (C1-C10) (optionally substituted with NR1R2, COOH, cycloheteroalkyl)), cycloalkyl, alkyl (C1-C10) or alkoxy (C1-C10) (optionally substituted withNRlR2, COOH, cycloheteroalkyl), heteroaryl, and cycloheteroaryl. Specific examples of R3 are 3-nifrophenyl, 3-ethoxyphenyl, 3-phenoxyphenyl, 3-(3-carboxyphenoxy)phenyl, 4-carboxyphenyl, 3-(3-(N-(4- carboxyphenylamino)iminomethyl)phenoxy)phenyl, 3 -(4-
(dihydroxyphosphonodifluoromethyl)phenoxy)phenyl, and 3-(3-trifluoromethylphenoxy)phenyl. Specific examples of R12 include methyl, phenylmethyl, 3-methoxyphenylmethyl, 3- (methoxycarbonyl)phenylmethyl, 2-trifluoromethylphenylmethyl, 4-carboxyphenylmethyl, 4- (carboxymethyl)phenylmethyl, carboxylmethyl, -4-(dihydroxyphosphonodifluoromethyl)-butyl, -4-(dihydroxyphosphonodifluoromethyl)phenylmethyl, 4-(l,2,3-thiadiazole-4-yl)phenylmethyl, 4-t-butylphenylmethyl, 3-methoxycarbonylphenyl, 4-methoxycarbonylphenyl, 2-naphthylmethyl, and 4-phenylphenylmethyl. Specific examples of R13 include 3-bromophenyl, 3,4- dichlorophenyl, 3-chloro-4-bromophenyl, isopropyl, 4-(piperidinosulfonyl)phenyl, 3-(3- trifluoromethylphenoxy)phenyl, and 3-methoxycarbonylphenyl.
Alternatively, Rl and R3, taken together with the N=C-SR2 unit to which they are attached, form a heterocyclic group having formula (VII) as follows:
Figure imgf000024_0001
Where R2 is as defined above for Rl, R2 and R3.
Where R14 is as defined above for Rl, R2 and R3.
Where R15 is as defined above for Rl, R2 and R3.
Of these, it is preferred that that R2 be 2-phenyl-2-oxoethylthio, optionally substituted on phenyl with one or more of the following or their combinations: nitro, halogen, alkyl (C1-C4). It is preferred that that R14 be phenyl, optionally substituted with one or more alkyl groups (C1-C6).
It is preferred that that R15 be hydrogen or alkyl(Cl-C4). A specific example of R2 is 2-(4- nifrophenyl)-2-oxoethylthio. A specific example of R14 is 4-n-pentylphenyl. A specific example of R15 is hydrogen.
Alternatively, Rl and R3, taken together with the N=C-SR2 unit to which they are attached, form a bicylic heterocyclic group having formula (VIII) as follows:
Figure imgf000025_0001
Where R2 is as defined above for Rl, R2 and R3.
Where R18 is as defined above for Rl, R2 and R3.
Where R19 is as defined above for Rl, R2 and R3.
Of these, it is preferred that that R2 be 2-phenyl-2-oxyethyl, optionally substituted on phenyl with one or more of the following or their combinations: halogen, alkyl (C1-C4). It is preferred that that R18 be amino, optionally substituted with one or two alkyl groups (C1-C4). It is preferred that that R19 be benzoyl, optionally substituted with one or more of the following or their combinations: halogen, alkyl (C1-C4).
Alternatively, Rl, R2 and R3, taken together with the N=C-S unit to which they are attached, form a bicyclic heterocyclic group having formula (IX) as follows:
R1 , R2, R3= R20
Figure imgf000026_0001
Where R20 is as defined above for Rl, R2 and R3. Where R21 is as defined above for Rl, R2 and R3. Where R22 is as defined above for Rl, R2 and R3. Of these, it is preferred that that R20 be phenyl, optionally substituted with one or more of the following or their combinations: halogen, alkyl (C1-C4). It is preferred that that R21 be hydrogen, alkyl (C1-C4), or phenyl, optionally substituted with one or more of the following or their combinations: hydroxy, alkyl (C1-C4). It is preferred that that R22 be hydrogen, phenylthioacyl (optionally substituted with one or more halogens), phenylaminoacylamino (optionally substituted on phenyl with one or more halogens), phenylhydrazinoacylamino (optionally substituted on phenyl with one or more halogens).
A specific examples of R20 is 4-chlorophenyl. Specific examples of R21 are methyl or 2,4- dihydroxyphenyl. Specific examples of R22 are hydrogen, 2,4-difluorophenylthioacyl, phenylaminocarbonylamino, 2,4-dichlorophenylaminocarbonylamino, and 2,4- dichlorophenylhydrozinocarbonylamino.
Alternatively, Rl, R2 and R3, taken together with the N=C-S unit to which they are attached, form a bicyclic heterocyclic group having formula (X) as follows:
Figure imgf000027_0001
Where R23 is as defined above for Rl, R2 and R3.
Where R24 is as defined above for Rl, R2 and R3.
Of these, it is preferred that that Y be nitrogen or carbon substituted with an aromatic group which consists of phenyl (optionally substituted with one or more of the following or their combinations: halogen, phenyl, alkoxy (C1-C4)), phenyhsoxazolyl, optionally substituted with one or more halogens, or 2H,3H,4H-benzo[3,4-b]l,4-dioxepan-7-yl, optionally substituted with one or more alkyl groups (C1-C4). It is preferred that that R23 be hydrogen, alkyl (C1-C4), or phenyl, optionally substituted with one or more halogens. It is preferred that that R24 be phenyl, optionally substituted with one or more of the following: halogen, nitro, alkoxy (C1-C4), or alkyl (C1-C4).
Specific examples of Y include nitrogen and carbon substituted with 4-bromophenyl, 4-chlorophenyl, 4-phenylphenyl, 3-(2,4-dichlorophenyl)isoxazol-5-yl], and 2H,3H,4H- benzo[3,4-b]l,4-dioxepan-7-yl. Specific examples of R23 include hydrogen, 4-chlorophenyl, or in whichRl and R2, together with the N=CR3-S unit to which they are attached, form a bicyclic heterocyclic group as follows:
Figure imgf000027_0002
Where R25 is as defined above for Rl, R2 and R3. Where R26 is as defined above for Rl, R2 and R3. Of these, it is preferred that that R3 be benzoylamino, optionally substituted on the phenyl ring with one or more of the following or their combinations: halogen, alkyl (C1-C4), and optionally substituted on nitrogen with alkyl (C1-C4). It is preferred that that R25 be phenyl, optionally substituted with one or more of the following or their combinations: halogen, alkyl (C1-C4). It is preferred that that R26 be perfluoroalkyl (C1-C4).
A specific example of R3 is 4-chlorobenzoylamino. A specific example of R25 is phenyl. A specific example of R26 is trifluoromethyl.
The compounds of the present invention generally contain one or more asymmetric centers and thus give rise to optical isomers and diastereomers. The scope of the present invention includes all possible isomers and diastereomers, as well as their racemic and resolved, enantiomerically pure forms.
Certain of the present compounds contain olefinic double bonds and, unless specified to the contrary, the compounds of the present invention include both the E and Z geometric isomeric forms.
Pro-Drug Compounds of the Invention
Alternatively, the compounds of the present invention can be further modified to act as prodrugs. It is a well-known phenomenon in drug discovery that compounds such as enzyme inhibitors can display potency and selectivity in in vitro assays, yet not readily manifest the same activity in vivo. This lack of "bioavailability" may be due to a number of factors, such as poor absorption in the gut, first-pass metabolism in the liver, and poor uptake in the cells. Although the factors determining bioavailability are not completely understood, there are many techniques known by those skilled in the art to modify compounds, which are potent and selective in biochemical assays but show low or no activity in vivo, into drugs that are biologically and therapeutically active. It is considered to be within the scope of the invention to modify any of the compounds of the invention (termed the Original compound') by attaching chemical groups that will improve the bioavailability of the original compound. Examples of said modifications include changing of one or more carboxy groups to esters (for instance methyl esters, ethyl esters, acetoxymethyl esters or other acyloxy-methyl esters). Compounds of the invention so modified by attaching chemical groups are termed 'modified compounds.'
Other examples of modified compounds are compounds that have been cyclized at specific positions ('cyclic compounds') which upon uptake in cells or mammals become hydrolyzed at the same specific position(s) in the molecule to yield the compounds of the invention, the original compounds, which are then said to be 'non-cyclic'. For the avoidance of doubt, it is understood that the latter original compounds in most cases will contain other cyclic or heterocyclic structures that will not be hydrolyzed after uptake in cells or mammals. Generally, said modified compounds will not show a behavior in biochemical assays similar to that of the original compound, i.e., the corresponding compounds of the invention without the attached chemical groups or said modifications. Said modified compounds may even be inactive in biochemical assays. However, after uptake in cells or mammals these attached chemical groups of the modified compounds may in turn be removed spontaneously or by endogenous enzymes or enzyme systems to yield compounds of the invention, original compounds. 'Uptake' is defined as any process that will lead to a substantial concentration of the compound inside cells or in mammals. After uptake in cells or mammals and after removal of said attached chemical group or hydrolysis of said cyclic compound, the compounds may have the same structure as the original compounds and thereby regain their activity and hence become active in cells and/or in vivo after uptake.
A number of techniques well known to those skilled in the art may be used to verify that the attached chemical groups have been removed or that the cyclic compound has been hydrolyzed after uptake in cells or mammals. One example of such techniques is as follows: A mammalian cell line, which can be obtained from the American Type Culture Collection (ATCC) or other similar governmental or commercial sources, is incubated with a modified compound. After incubation under appropriate conditions, the cells are washed, lysed and the lysate is isolated. A number of different procedures, well known to those skilled in the art, may in turn be used to extract and purify the modified compound (or a metabolite thereof) (the 'purified compound') from the lysate. The modified compound may or may not retain the attached chemical group or the cyclic compound may or may not have been hydrolyzed. Similarly, a number of different procedures may be used to structurally and chemically characterize the purified compound. Since the purified compound has been isolated from said cell lysate and hence has been taken up by said cell line, a comparison of the structurally and chemically characterized compound with that of the original compound (i.e. without the attached chemical group or other modification) will provide information on whether the attached chemical group as been removed in the cell or if the cyclic compound has been hydrolyzed. As a further analysis, the purified compound may be subjected to enzyme kinetic analysis as described in detail in the present description. If the kinetic profile is similar to that of the original compound without the attached chemical group, but different from the modified compound, this result confirms that the chemical group has been removed or the cyclic compounds has been hydrolyzed. Similar techniques may be used to analyze compounds of the invention in whole animals and mammals.
A preferred form of prodrug is acetoxymethyl esters of the compounds of the present invention, which may be prepared by the following general procedure (C. Schultz et al, J. Biol. Chem. 1993, 268:6316-6322):
A carboxylic acid (leq) is suspended in dry acetonifrile (2mL/0.1mmol). Diisopropyl amine (3.0eq) is added followed by bromomethyl acetate (1.5eq). The mixture is stirred under nitrogen overnight at room temperature. Acetonifrile is removed under reduced pressure to yield an oil, which is diluted in ethylacetate and washed with water (3 x). The organic layer is dried over anhydrous magnesium sulfate. Filtration, followed by solvent removal under reduced pressure, affords a crude oil. The product is purified by column chromatography on silica gel, using an appropriate solvent system.
As used herein, the term "attached" (or "-" or "bound") signifies a stable covalent bond. As used herein, the term "alkyl" includes a straight or branched chain saturated hydrocarbon group having from 1 to 20 carbons such as methyl, ethyl, isopropyl, n-butyl, s- butyl, t-butyl, n-amyl, isoamyl, n-hexyl, n-octyl and n-decyl, and includes such cyclic and alkyl- substituted cyclic alkyls that are possible within the given carbon number limitations.
As used herein, the terms "alkenyl" and "alkynyl" include straight or branched chain hydrocarbon groups having from 2 to 10 carbons and unsaturated by a double or triple bond respectively, such as vinyl, allyl, propargyl, 1-methylvinyl, but-1-enyl, but-2-enyl, but-2-ynyl, l-methylbut-2-enyl, pent-1-enyl, pent-3-enyl, 3-methylbut-l-ynyl, 1,1-dimethylallyl, hex-2-enyl and 1 -methyl- 1-ethylallyl.
As used herein, the term "phenylalkyl" includes the aforementioned alkyl groups substituted by a phenyl group such as benzyl, phenethyl, phenopropyl, 1 -benzylethyl, phenobutyl and 2-benzylpropyl. As used herein, the term "aryl" includes a monocyclic or bicyclic rings, wherein at least one ring is aromatic including aromatic hydrocarbons or hetero-aromatic hydrocarbons.
As used herein, the term "hydroxy-alkyl" includes the aforementioned alkyl groups substituted by a single hydroxyl group such as 2-hydroxybutyl, 2-hydroxypropyl, 3- hydroxypropyl, 4-hydroxybutyl, 1-hydroxybutyl and 6-hydroxyhexyl.
As used herein, the terms "alkylthio, alkenylthio, alkynylthio, alkylthio, hydroxy- alkylthio and phenyl-alkylthio" mean the aforementioned alkyl, alkenyl, alkynyl, hydroxy-alkyl and phenyl-alkyl groups linked through a sulfur atom to group R.
As used herein, the term "substituted" means that the group in question, e.g., alkyl group, aryl group, etc., may bear one or more substituents including but not limited to halogen, hydroxy, cyano, amino, nifro, mercapto, carboxy and other substituents known to those skilled in the art.
As used herein, the term "saturated" means an organic compound with neither double nor triple bonds, and the term "unsaturated" means an organic compound containing either double or triple bonds.
Procedures for the Synthesis of Compounds and Intermediates
Procedure A
(3-[(2-Phenylphenyl) methylthio] phenylamine): 2-phenyl benzylbromide (2.47g; lOmmol) is added slowly to a stirred solution of 3-aminotiophenol (1.25g; lOmmol) in the mixture of ethanol (20mL) and 1M NaOH (lOmL). The mixture is stirred for 30 minutes, the solvent evaporated and the residue is purified using a Biotage column. The product is eluted with EtoAc/Hexanes (4/1). Yield: 1.8 g (62%). lR NMR: (300 MHz, CDC13) 7.39δ(7H, m); 7.315 (3H, m); 7.00 δ (IH, t); 6.49δ (IH, s); 6.48δ(lH, d); 4.07δ (2H, s).
Procedure B
A mixture of 3-bromobenzaldehyde (l.OOOg; 5.4mmol), methyl 3-hydroxybenzoate (987mg; 6.5mmol) and potassium carbonate (1.494g; 10.8mmol) in dry pyridine (8mL) is stirred under argon at RT. Copper (II) oxide (86Qmg; 10.8mmol) is added and the reaction mixture is refluxed for 12 hours. After cooling to RT, CH2C12 (50mL) is added and the mixture is filtered through celite. The filter cake is washed with fresh CH2CI2 (50mL). The combined organics are concentrated in vacuo. The residue is purified by flash chromatography (ethyl acetate / hexanes, 1 : 10 to 1 :4) to yield methyl 3-(3-carbonylphenoxy)benzoate (776mg; 56%) as a yellow oil. 1H NMR (300 MHz, CDC13): δ 9.97 (IH, s), 7.85 (IH, d, J= 6.9Hz), 7.69-7.24 (7H, m), 3.91 (3H, s).
Procedure C
3-[(2-phenylphenyl) methylthio] benzeneisothiocyanate: Thiophosgene (1.37g; 12mmol) is slowly added to a solution of 3-[(2-Phenylphenyl) methylthio] phenyl amine in a mixture of water (60mL) and Methylenechloride (45mL). The mixture is stirred under nitrogen at RT for two hours. The aqueous layer is separated, and the methylenechloride is washed with water.
The organic layers are dried over anhydrous sodium sulfate and rotovaped to provide a brown oil. Yield: 2.2g (70%). Procedure D
The hydrazine hydrate (7.12mL; 147mmol) is dissolved in 220mL of ethanol. This solution is stirred at 0°C and 3,4-dichlorobenzenisothiocyanate (20.00g; 98mmol) is added dropwise, and the reaction mixture is warmed to RT and stirred for two hours. After being cooled to 0°C, the mixture is filtered and the solid washed by cold ethanol (40mL). The solid is crystallized from ethanol to yield ([(3,4-dichlorophenyl)amino]hydrazinomethane-l-thione) (12.702g; 55%) as a white solid.
1H NMR (300 MHz, d6-DMSO): δ 9.40 (IH, s), 8.19 (IH, s), 7.69 (IH, d), 7.53 (IH, d), 5.30 (3H, br s).
Procedure E
(3 -( 1 ,3 -Dioxolan-2-yl)phenyl) [3 -(trifluoromethyl)phenyl]methan- 1 -ol ) A l.OmL aliquot of 2-(3-bromophenyl)-l,3-dioxolane is added into magnesium (610mg; 25mmol) and THF (5mL) under Argon. After the reaction is started, the residue of 2-(3- bromophenyl)-l,3-dioxolane (total: 5.73g; 25mmol) in THF (20mL) is added dropwise into the reaction mixture. The resulting solution is stirred at room temp for six hours, and then at 50- 60°C for 20 hours. After the mixture is cooled, a solution of 3-(trifluoromethyl)-benzaldehyde (4.35g; 25mmol) in THF (20mL) is added dropwise and the reaction is stirred at room temp for 24 hours. The NH4C1 saturated solution (50mL) is added and stirred for 30 minutes. The organic layer is separated and the aqueous layer is exfracted with ethyl acetate (2 x lOOmL). The organic layers are combined and dried over anhydrous Na2S04. The solvent is removed and the residue is purified by column chromatography on silica gel. Eluting with ethyl acetate/hexanes (20:80) provide a colorless oil (3.23 g; 40%) as (3-(l,3-dioxolan-2-yl)phenyl)[3- (trifluoromethyl)phenyl]-methan-l-ol: MS 307.0 (M-17).
Procedure F
(Methyl-4- [(hydrazinylthioxomethyl) amino] benzoate: A mixture of methyl 4- isothiocyanato benzoate (193mg; lmmol) and hydrazine (lOOmg; 2mmol) are stirred in toluene (7.5mL) at RT for two hours. The solid is filtered, washed with a small volume of ethanol and hexanes and dried in vacuum. Yield: 192mg (85%).
1H NMR: (300 MHz, DMSO-d6) 9.66δ (IH, s); 7.86δ (5H, m); 3.83δ (3H, s). Procedure G
N-(3-bromophenyl)-2-[(3-nifrophenyl)carbonylamino]acetamide 3-nifrohippuric acid (250mg; 1.116mmol) is dissolved in methylene chloride (5mL) containing a catalytic amount of DMAP, l-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (640mg; 3.34mmol) and 3-bromoaniline (290mg; 1.685mmol). The solution is stirred for 18 hours at 25°C, diluted with enough methylene chloride to dissolve the resulting precipitate, and washed three times with 2N hydrochloric acid (aqueous) and saturated aqueous sodium chloride. The organic layer is dried with sodium sulfate, filtered, and stripped of solvent in vacuo. The resulting yellow solid is washed with 1:1 acetone/methylene chloride, then with 1:1 acetone/methanol to yield the title compound as a gray solid.
Procedure H
Iron powder (5.03g; 56mmol), water (5mL) and hydrochloric acid (O.lmL; 36mmol) are added consecutively to a solution of methyl 2-[4-(3-nifrophenoxy)phenyl] acetate (1.3g; 4.5mmol) in ethanol (20mL). After stirring at 95°C for four hours, the solid is filtered while still hot and the filtrate is stripped of solvent in vacuo to yield methyl 2-[4-(3- aminophenoxy)phenyl]acetate as an oil. Yield: l.lg (95%).
'H NMR: (300 MHz, DMSO-d6) 7.24δ (2H, d); 6.96δ (3H, m); 6.315. (IH, d); 6.135 (IH, s); 6.105 (IH, d); 5.23δ (2H, d); 3.65δ (2H, s); 3.625 (3H, s).
Prophylaxis and Treatment of Disease
The compounds of the present invention inhibit tyrosine phosphatases, including PTP-
1B, and thus improve insulin sensitivity, among other benefits. The compounds therefore will find use in preventing or freating Type 1 and Type 2 diabetes, improving glucose tolerance, improving insulin sensitivity when there is insulin resistance, lowering body weight, and preventing or freating obesity. In addition, the compounds will be useful in preventing or treating cancer, neurodegenerative diseases, and the like.
The present compounds may also be administered in combination with one or more further pharmacologically active substances e.g., selected from antiobesity agents, antidiabetics, antihypertensive agents, agents for the freatment and/or prevention of complications resulting from or associated with diabetes and agents for the freatment and/or prevention of complications and disorders resulting from or associated with obesity. In a further aspect of the invention the present compounds may be administered in combination with one or more antiobesity agents or appetite regulating agents. Such agents may be selected from the group consisting of CART (cocaine amphetamine regulated transcript) agonists, NPY (neuropeptide Y) antagonists, MC4 (melanocortin 4) agonists, orexin antagonists, TNF (tumor necrosis factor) agonists, CRF (corticofropin releasing factor) agonists, CRF BP (corticofropin releasing factor binding protein) antagonists, urocortin agonists, B3 agonists, MSH (melanocyte-stimulating hormone) agonists, MCH (melanocyte-concentrating hormone) antagonists, CCK (cholecystokinin) agonists, serotonin re-uptake inhibitors, serotonin and noradrenaline re-uptake inhibitors, mixed serotonin and noradrenergic compounds, 5HT (serotonin) agonists, bombesin agonists, galanin antagonists, growth hormone, growth hormone releasing compounds, TRH (thyreofropin releasing hormone) agonists, UCP 2 or 3 (uncoupling protein 2 or 3) modulators, leptin agonists, DA agonists (bromocriptin, doprexin), lipase/amylase inhibitors, PPAR (peroxisome proliferator activated receptor) modulators, RXR (retinoid X receptor) modulators or TR B agonists. In one embodiment of the invention the antiobesity agent is leptin. In other embodiments, the antiobesity agent is dexamphetamine or amphetamine, fenfluramine or dexfenfluramine, sibuframine, orlistat, mazindol or phentermine.
Suitable antidiabetics comprise insulin, GLP-1 (glucagons like peptide-1) derivatives such as those disclosed in WO 98/08871, which is incorporated herein by reference, as well as orally active hypoglycemic agents. The orally active hypoglycemic agents preferably comprise sulphonylureas, biguanides, meglitinides, oxadiazolidinediones, thizolidinediones, glucosidase inhibitors, glucagons antagonists such as those disclosed in WO 99/01423, GLP-1 agonists, potassium channel openers such as those disclosed in WO 98/26265 and WO 99/03861, insulin sensitizers, DPP-IV (dipeptidyl peptidase-IV) inhibitors, inhibitors of hepatic enzymes involved in stimulation of gluconeogensis and/or glycogenolysis, glucose uptake modulators, compounds modifying the lipid metabolism such as antihyperlipidemic agents and antilipedimic agents as HMG CoA inhibitors (statins), compounds lowering food intake, PPAR and RXR agonists and agents acting on the ATP- dependent potassium channel of the B-cells.
In one embodiment of the invention the present compounds are administered in combination with insulin. In further embodiments, the present compounds are administered in combination with a sulphonylurea e.g., tolbutamide, glibenclamide, glipizide or glicazide, a biguanide e.g. metformin, a meglitinide e.g., repaglinide, a thizolidinedione e.g., troglitazone, ciglitazone, pioglitazone, rosiglitazone or compounds disclosed in WO 97/41097 such as 5-[[4- [3-Methyl-4-oxo-3, 4-dihydro-2-quinazolinyl]methoxy]phenyl-methyl]thiazolidine-2, 4-dione or a pharmaceutically acceptable salt thereof, preferably the potassium salt.
Furthermore, the present compounds may be administered in combination with the insulin sensitizers disclosed in WO 99/19313 such as (-) 3-[4-[2-Phenoxazin-10- yl)ethoxy]phenyl]-2-ethoxypropanoic acid or a pharmaceutically acceptable salts thereof, preferably the arginine salt.
In further embodiments, the present compounds are administered in combination with an a-glucosidase inhibitor e.g. miglitol or acarbose, an agent acting on the ATP-dependent potassium channel of the B-cells e.g. tolbutamide, glibenclamide, glipizide, glicazide or repaglinide, nateglinide, an antihyperlipidemic agent or antilipidemic agent e.g., cholestyramine, colestipol, clofibrate, gemfibrozil, lovastatm, pravastatin, simvastatin, probucol or dexfrothyroxine,
In still further embodiments, the present compounds are administered in combination with more than one of the above-mentioned compounds e.g., in combination with a sulphonylurea and metformin, a sulphonylurea and acarbose, repaglinide and metformin, insulin and a sulphonylurea, insulin and metformin, insulin, insulin and lovastatin, etc.
Furthermore, the present compounds may be administered in combination with one or more antihypertensive agents. Examples of antihypertensive agents are B-blockers such as alprenolol, atenolol, timolot, pindolol, propranolol and metoprolol, ACE (angiotensin converting enzyme) inhibitors such as benazepril, captopril, analapril, fosinopril, lisinopril, quinapril and ramipril, calcium channel blockers such as nifedipine, felodipine, nicardipine, isradipine, nimodipine, diltiazem and verapamil, and α-blockers such as doxazosin, urapidil, prazosin and terazosin. Further reference can be made to Remington: The Science and Practice of Pharmacy, 19th Edition, Gennaro, Ed., Mack Publishing Co., Easton, PA, 1995.
It should be understood that any suitable combination of the compounds according to the invention with one or more of the above-mentioned compounds and optionally one or more further pharmacologically active substances are considered to be within the scope of the present invention. The therapeutically effective amounts of the present compounds will be a function of many variables, including the affinity of the inhibitor for the tyrosine phosphatase, any residual activity exhibited by competitive antagonists, the route of adminisfration, the clinical condition of the patient, and whether the inhibitor is to be used for the prophylaxis or for the treatment of acute episodes.
In practicing the method of the present invention, the therapeutic preparation will be administered to a patient in need of freatment at a therapeutically effective dosage level. The lowest effective dosage levels can be determined experimentally by initiating treatment at higher dosage levels and reducing the dosage level until relief from reaction is no longer obtained. Generally, therapeutic dosage levels will range from about 0.01-lOOOg/kg of host body weight.
As discussed above, the present compounds can also administered in conjunction with other agents used in or proposed for the freatment of individual conditions as appropriate. However, when employed together with the present compounds, these agents may be employed in lesser dosages than when used alone.
Where combinations are contemplated, it is not intended that the present invention be limited by the particular nature of the combination. The present invention contemplates combinations as simple mixtures as well as chemical hybrids. One example of the latter is where the present compound is covalently linked to a pharmaceutical compound, or where two or more compounds are joined. For example, covalent binding of the distinct chemical moieties can be accomplished by any one of many commercially available cross-linking compounds.
In view of the therapeutic urgency attendant acute episodes, the present compounds may be intravenously infused or introduced immediately upon the development of symptoms. However, prophylaxis is suitably accomplished by intramuscular or subcutaneous administration. In this regard, the compositions are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid prior to injection may also be prepared. These therapeutic preparations can be administered to mammals for veterinary use, such as with domestic animals, and clinical use in humans in a manner similar to other therapeutic agents. In general, the dosage required for therapeutic efficacy will vary according to the type of use and mode of administration, as well as the particularized requirements of individual hosts.
It is not intended that the present invention be limited by the particular nature of the therapeutic preparation. For example, such compositions can be provided together with physiologically tolerable liquid, gel or solid carriers, diluents, adjuvants and excipients. Such compositions are typically prepared as sprays (e.g. intranasal aerosols) for topical use. However, they may also be prepared either as liquid solutions or suspensions, or in solid forms including respirable and nonrespirable dry powders. Oral formulations (e.g. for gastrointestinal administration) usually include such normally employed additives such as binders, fillers, carriers, preservatives, stabilizing agents, emulsifiers, buffers and excipients as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, cellulose, magnesium carbonate, and the like. These compositions take the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations, or powders, and typically contain l%-95% of active ingredient, preferably 2%-70%.
The compounds of the present invention are often mixed with diluents or excipients that are physiologically tolerable and compatible. Suitable diluents and excipients are, for example, water, saline, dextrose, glycerol, or the like, and combinations thereof. In addition, if desired the compositions may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, stabilizing or pH buffering agents.
Additional formulations which are suitable for other modes of adminisfration, such as topical administration, include salves, tinctures, creams, lotions, and, in some cases, suppositories. For salves and creams, fraditional binders, carriers and excipients may include, for example, polyalkylene glycols or triglycerides.
Determination of Activity
The compounds of the present invention are evaluated for biological activity as inhibitors of PTP-1B using, for example, a Malachite Green assay with pIRP as a subsfrate. The pIRP subsfrate includes a phosphotyrosine residue, and PTP-1B cleaves the phosphate group from the tyrosine, yielding the peptide and phosphate. The rate of the enzymatic reaction is determined by measuring the phosphate released during the reaction.
The reactants for the assay include 20mM Tris-HCl, pH 7.4, 2mM EDTA (ethylaminediamine tefraacetic acid) and 2mM DTT (dithiothreitol) as the assay buffer, and ImM pIRP in assay buffer (lmg in 0.59mL buffer) as the substrate stock. The Malachite Green solution is prepared by adding 30μL of 1% Tween 20 to ImL of Malachite Green Solution A. The stock of each compound to be tested is made up as lOmM in DMSO (dimethylsulfoxide).
The compound to be tested is prepared as 1 :5, 1 : 15.8, 1 :50 and 1 : 158 dilutions from stock in a total volume of lOOμM DMSO. The reaction mixtures are prepared in a 96-well microtiter plate as 27.5μL assay buffer, 3.5μL of the diluted compound (to a final concenfration of 100, 32, 10 and 3.2μM), lOμL of the pIRP subsfrate solution (to a final concenfration of 200μM) and lOμL PTPase in assay buffer. The reactants are mixed well, the plate placed in a water bath at 30°C and incubated for 3 minutes. The reaction is then terminated by adding lOOμL of Malachite Green solution per well, color is allowed to develop for 15 minutes, and the A6so is measured by conventional means. Unless otherwise indicated, this assay was used to determine activity for the selected compounds whose activity is recorded in the Table.
Alternatively, a pNPP assay can be used to screen compounds for tyrosine phosphatase inhibitory activity as follows: A 5X stock of pNPP (p-nifrophenol phosphate) substrate is prepared as 50mM pNPP in assay buffer prepared as described above. Various tyrosine phosphatase solutions can be prepared as follows:
PTP-1B (SBI purified, lmg/mL) as a 1:250 dilution (to a final concentration of 4μg/mL);
) TC-PTP (NEB, lOOOunits in lOOμL) as a 1:50 dilution (to a final concenfration of
2U/10μL (4μg/mL));
CD45 (Calbiochem, 20μg, 400 units in lOOμL) as a 1:50 dilution (to a final concentration of 0.8U/10μL (4μg/mL));
LAR (NEB, lOOOunits in 200μL) as a 1:75 dilution (to a final concentration of
0.7U/10μL (4μg/mL)); and
PTP-β (UBI, #14-350, 10,000 units, 40μg/571μL) as a 1:17.5 dilution (to a final concenfration of lOU/lOμL (4μg/mL));
The compound to be tested is prepared as 1:16.7 and 1:50 dilutions from stock in a total volume of lOOμM DMSO to give final concentrations of 626 and 200μM. The reaction mixtures are prepared in a 96-well microtiter plate (on ice) as 55μL assay buffer, 5μL of the diluted compound (to a final concentration of 31.3 and lOμM), 20μL of the pNPP substrate solution (to a final concenfration of lOmM) and 20μL PTPase in assay buffer. The reactants are mixed well, the plate placed in a water bath at 30°C and incubated for 10 minutes. The reaction is then terminated by adding lOOμL of 2M K2CO3 per well, and the absorbance is measured at 405nm by conventional means.
Compounds which demonsfrate inhibitory activity against tyrosine phosphatases can have application in the treatment of various diseases. For example, compounds which demonsfrate inhibitory activity against PTP-1B can find use in the freatment of diabetes. Compounds which demonsfrate such activity against CD45 can find use in the freatment of autoimmune diseases, inflammation, transplantation rejection reactions, and other diseases including arthritis, systemic lupus, Crohn's disease, inflammatory bowel disease, and other autoimmune disorders known to those skilled in the art. Compounds which demonstrate such activity against TC-PTP can find use in the freatment of cancer, typically as antiangiogenic agents. In the case of compounds which demonsfrate inhibitory activity against PTP-1B, one can test the compounds for blood glucose lowering effects in diabetic obese female db/db mice as follows: The mice will be of similar age and body weights and randomized into groups often mice. They have free access to food and water during the experiment. The compounds are administered by either gavage, subcutaneous, intravenous or intraperitoneal injections. Examples of typical dose ranges for such evaluations are 0.1, 0.3, 1.0, 3.0, 10, 30, lOOmg per kg body weight. The blood glucose levels are measured twice before administration of the compounds of the invention. After administration of the compound, the blood glucose levels are measured at the following time points: 1, 2, 4, 6, and 8 hours. A positive response is defined either as (i) a more than 25 percent reduction in blood glucose levels in the group receiving the compound of the invention compared to the group receiving the vehicle at any time point or (ii) statistically significant (i.e., p<0.05) reduction in the area under the blood glucose curve during the whole period (i.e. 8 hrs) in the group treated with the compounds of the invention compared to controls. Compounds that show positive response can be used as development candidates for freatment of human diseases such as diabetes and obesity.
The invention now being generally described, the same will be better understood by reference to the following detailed examples, which are provided for illustration and are not to be considered as limiting the invention unless so specified. The structures of various of the disclosed compounds will he found depicted in Figure 1.
Experimental
In the experimental disclosure which follows, all weights are given in grams (g), milligrams (mg), micrograms (μg), nanograms (ng), or picograms (pg), all amounts are given in moles (mol), millimoles (mmol), micromoles (μmol), nanomoles (nmol), picomoles (pmol), or femtomoles (finol), all concentrations are given as percent by volume (%), proportion by volume (v:v), molar (M), millimolar (mM), micromolar (μM), nanomolar (nM), picomolar (pM), femtomolar (fM), or normal (N), all volumes are given in liters (L), milliliters (mL), or microliters (μL), and linear measurements are given in millimeters (mm), micrometers (μm), or nanometers (nm) and mp is melting point, unless otherwise indicated.
Example 1: N2-(3-bromophenyl)-5-(3-nitrophenyl)-l,3,4-thiadiazol-2-amine
To a solution of 3-bromophenyl isothiocyanate (6.5g; 30.4mmol) in toluene (150mL) is added 3-nifrobenzhydrazide (5.0g; 27.6mmol) under argon. The reaction mixture is heated at reflux for two hours. The mixture is filtered while the toluene still is warm. The solid is washed with warm toluene (3 x 50mL) and dried to yield Nl-(3-bromophenyl)-2-(3-nitrobenzoyl) hydrazine- 1-carbothioamide (10.7g; 98%) (mp. 163 - 165°C). The product is used for the next step without further purification.
To a slurry mixture of the above carbothioamide (5.0g; 12.7mmol) in toluene (50mL) at 0°C is dropped con. H2SO4 (2.5mL). The reaction mixture is stirred at room temperature (RT) for three hours. The toluene is removed and ice-H20 (50mL) is added. The mixture is neutralized with NH3 ' H2O until pH 8 and filtered. The solid product is recrystallized with DMSO/MeOH/H2O (3:5:10) to yield N2-(3-bromophenyl)-5-(3-nifrophenyl)-l,3,4-thiadiazol-2- amine (4.5g; 94%). mp. 273 - 275°C. mass spec obsd M+ 376.88, M+ - NO2 330.93, calcd exact mass 377.22 (C14H9BrN4O2S).
!H NMR (DMSO-de) 5 7.23 ( d, IH), 7.34 (t, IH), 7.52 (d, IH), 7.82 (t, IH), 8.10 (s, IH), 8.32 (t, 2H), 8.62 (s, IH).
13C NMR (DMSO-d6) δ 116.5, 119.9, 120.7, 122.0, 124.6, 124.8, 131.0, 131.5, 133.1, 141.7, 148.3, 156.1. Example 2: Methyl (3-(3-{5-[(3,4-dichlorophenyl)amino]-l,3,4-thiadiazol-2-yl}phenoxy)benzoate
A solution of the product from Procedure B (methyl 3-(3-carbonylphenoxy)benzoate) (750mg; 2.9mmol) and (aminoamino)[(3,4-dichlorophenyl)amino]methane-l-thione (692mg; 2.9mmol) in dry ethanol (8mL) under argon is refluxed for two hours. After cooling to RT, the mixture was filtered and the solid washed by ethanol. The solid was suspension in dry ethanol (5mL) and iron (III) chloride hexahydrate (1.546g; 5.7mmol) was added. The reaction mixture was refluxed for two hours, then cooled to RT. The solid was collected by filter and washed by ethanol, then crystallized from ethyl acetate / hexanes to yield the title compound (348mg; 25%) of as a yellow solid.
XH NMR (300 MHz, d6-DMSO): 5 10.92 (IH, s), 8.13 (IH, d, J = 2.1Hz), 7.79 (IH, d, J= 7.5Hz), 7.68-7.55 (5H, m), 7.49 (IH, dd, J= 8.7, 2.1Hz), 7.43 (IH, dd, J= 8.1, 2.4Hz), 7.21 (IH, d, J= 8.1Hz), 3.84 (3H, s).
Example 3:
(3,4-dichlorophenyl)[5-(3,5-dinitrophenyl)(l,3,4-thiadiazol-2-yl)]amine
To the product from Procedure D (59mg; 0.25mmol) was added 3,5dinitrobenzoyl chloride (50mg; 0.25mmol) in dichloromethane (~ ImL) at 0°C (under argon). The reaction was allowed to rise to ambient temperature (~25°C) and stirred for one hour. The solvent was removed by vacuum and the residue was subjected to silica gel flash chromatography (3% methanol in dichloromethane). The resulting intermediate was dissolved in toluene (~ 1.5mL) with con. H2S04 (~ leq) and refluxed for two hours. Water and ammonium hydroxide were added (to neutralize) and the precipitate was collected by vacuum filtration. Recrystallization (ethanol/water) yielded the title compound (61% yield), mp 305-306.5°C
Example 4: (4-{2[(3,4-dichlorophenyl)amino](l,3-thiazol-4-yl)}phenyl)diethylamine
To 3,4 dichlorobenzeneisothiocyanate (lg; 4.8mmol) in dry dioxane (15mL) at RT was added ammonium hydroxide (0.8mL; 0.023mmol) and ammonium acetate (1.5g; 19.5mmol). The reaction mixture was refluxed for one hour. The solvent was removed under reduced pressure which afforded amino[(3,4-dichlorophenyl)amino]methane-l-thione (1.04g; 98%) as white solid. !H MR (CDC13) 9.88 (s, IH); 7.91(s, IH); 7.56 (d, IH); 7.39 (d, IH).
To a solution of amino[(3,4-dichlorophenyl)amino]methane-l-thione (lOOmg; 4.32mmol) in dioxane (3mL) at RT was added alpha -bromo-4-(diethylamino)acetophenone (121mg;
4.5mmol). The reaction mixture was stirred at RT for one hour and pyridine (0.4mL; 4.66mmol) was added. After refluxing for five hours, the reaction mixture was concentrated under reduced pressure, quenched with water, and the resulting mixture was exfracted with ethyl acetate. The organic layer was washed with water, then with brine, and dried over anhydrous sodium sulfate. Concentration under reduced pressure afforded a crude product which was purified by flash chromatography (50/50 Ethyl acetate/Hexane) to yield the title compound (128mg; 75%) as a purple solid. The product had a HPLC retention time of 3.27 min (Column: C18, 5μm, 50x3mm); Solvent A = (H2O, 10 % AcOH); solvent B = (Acetonifrile, 10% AcOH) and LC/SM M+ = 393. !H NMR ( CDC13) 7.70-7.67(m, 2H); 7.37-7.26(m, 3H); 6.72-6.62(m, 3H); 3.42-3.35(m, 4H); 1.21-1.16(m, 3H)
Example 5 (3-Bromophenyl)-[5-(3-nitrophenyi)-l,3,4-thiadiazol-2-yl]-amine A mixture of 3-nifrophenacylamine hydrochloride (620mg; 2.8mmol) and sodium bicarbonate (240mg; 2.8mmol) in H20 (lOmL) was added to a solution of 3- bromophenylisothiocyanate (580mg; 2.7mmol) in acetone (23mL). The resulting homogeneous solution was stirred at RT for 30 minutes, after which it was partitioned between ethyl acetate and water. The ethyl acetate layer was dried over Na2SO4 and evaporated to dryness to yield N- (3-nifrophenacyl)-N'-(3-bromophenyl)-thiourea (400mg; 38%). The thiourea was suspended in acetic anhydride (lOmL) containing polyphosphoric acid (0.5mL). After stirring for 12 hours at RT, the mixture was poured over ice. The resulting solids were isolated via filtration and triturated with 4/1 ethyl acetate/hexanes to yield pure title compound as a yellow solid (150mg; 38%); mp 228-231°C, MS m/z 377.65 [MH+].
!H NMR (300 MHz, DMSO-. ) δ 7.17 (d, J= 7.8Hz, 1 H), 7.30 (t, J= 8.1Hz, 1 H), 7.52 (d, J= 7.8Hz, 1 H), 7.69 (t, J= 7.8Hz, 1 H), 7.99 (d, j= 8.4Hz , 2H), 8.09 (d, J= 6.0Hz, 2 H), 8.31 (s, 1 H), 10.72 (br s, 1 H).
Example 6:
(3-bromophenyl) [2-(3-nitrophenyl)(l,3-thiazol-5-yl)] amine
Without further purification, the intermediate from Procedure G (20mg; 0.053mmol) was combined with 2,4-bis(4-methoxyphenyl)-l,3,2,4-dithiadiphosphetane-2,4-dithione (Lawesson's reagent, lOOmg; O.lmmol) in pyridine (3mL) and heated to reflux for three hours. The reaction mixture was diluted with ethyl acetate, exfracted 3x with 2N HCl, lx with saturated aqueous potassium carbonate, and lx with saturated aqueous sodium chloride. The organic layer was dried with sodium sulfate, filtered, and stripped of solvent in vacuo. The resulting solid was purified using silica chromatography using methylene chloride and 97:3 methylene chloride/methanol as solvents, yielding the title compound as an orange solid (12mg; 60% yield). Mass Spectrum (elecfrospray, positive ion): calculated for MH+ 377, found 377; calculated for MNa+ 400, found 400.
Example 7:
(3-(3-{5-[(3,4-dichlorophenyl)amino]-l,3,4-thiadiazol-2-yl}phenoxy)benzoic acid)
The product from Example 2 (methyl 3-(3-{5-[3,4-dichlorophenyl)amino]-l,3,4- thiadiazol-2-yl}phenoxy)benzoate (228mg; 0.48mmol) and LiOH (32mg; 1.3mmol) were suspension in THF / MeOH / H2O (2 / 3 / 9) (30mL). The mixture was stirred overnight at RT and concentrated in vacuo. The residue was washed by ethyl acetate, then 15% HCl aqueous solution was added until the pH was < 7. The solid was collected by filter and washed by water, then crystallized from ethanol/ethyl acetate/hexanes yields 3-(3-{5-[(3,4-dichlorophenyl)amino]- l,3,4-thiadiazol-2-yl}phenoxy)benzoic acid (195mg; 89%) as a white solid, mp 258-259°C; MS (M+H)+ 458.2. lΕ NMR (300 MHz, d6-DMSO): δ 13.21 (IH, br s), 10.94 (IH, s), 8.13 (IH, d, J = 2.4Hz), 7.70 (IH, d, J= 8.4Hz), 7.68-7.49 (7H, m), 7.40 (IH, dd, J= 7.8, 2.1Hz), 7.21 (IH, dd, J= 8.1, 1.5Hz). Example 8:
(3,4-dichlorophenyl){[4-(tert-butyl)phenyl]methyl}[5-(3-ethoxyphenyl)(l,3,4-thiadiazol-2- yl)] amine and
(l-(2-[aza(3,4-dichlorophenyl)methylene]-3-{[4-(tert-butyl)phenyl]methyI}(l,3,4- thiadiazolin-5-yl))-3-ethoxybenzene)
To a solution of (3,4-dichlorophenyl)[5-(3-ethoxyphenyl)(l,3,4-thiadiazol-2-yl)]amine
(120mg; 0.33mmol) in dry DMF (5mL) was added a solution of potassium tert-butoxide (0.33mL; IM; 0.33mmol) in THF at RT under an argon atmosphere. After five minutes, 4-(tert- butyl)benzyl bromide (89mg; 0.39mmol) was injected, and the solution was stirred overnight.
The DMF was evaporated (rotavap) under vacuum. The crude residue was purified by flash chromatography (ethyl acetate / hexanes, 100% hexanes to 1:4) to the isolation of the less polar isomer (l-(2-[aza(3,4-dichlorophenyl)methylene]-3-{[4-(tert-butyl)phenyl]methyl}(l,3,4- thiadiazolin-5-yl))-3-ethoxybenzene) (20mg) in 12% yield Rf = 0.60 (ethyl acetate/hexanes, 1:2).
1H NMR (300 MHz, dι-CDCl3): δ 7.42-6.92 (11H, m), 5.29 (2H, s), 4.05 (2H, q), 1.42 (3H, t),
1.32 (9H, s).
The other, more polar isomer, (3,4-dichlorophenyl){[4-(tert-butyl)phenyl]methyl}[5-(3- ethoxyphenyl)(l,3,4-thiadazol-2-yl)]amine (122mg; 72%) was also isolated. Rf = 0.48 (ethyl acetate/hexanes, 1:2);
1H NMR (300 MHz, dι-CDCl3): δ 7.49-6.92 (11H, m), 5.18 (2H, s), 4.07 (2H, q), 1.43 (3H, t),
1.30 (9H, s).
Example 9: 3-[3-(3-{5-[(3,4-Dichlorophenyl)amino]-l,3,4-thiadiazol-2-yl}phenoxy)phenyl] propanoic acid
Trimethlsilyl diazomethane (15mL; 30mmol) was added to an ice cold solution of 3-(3- hydroxyphenyl)propanoic acid (3.32g; 20mmol). in acetonifrile (40mL). The mixture was stirred cold for 30 minutes and slowly brought to RT and continued to stir overnight. Acetic acid (ImL) was added to quench the excess trimethylsilyl diazomethane. The reaction mixture was diluted with methanol (lOmL) and IM hydrochloric acid (2mL), followed by rotoevaparation of the solvents. The residue was purified over silica gel column. The compound was eluted with EtOAC/Hexanes (1/1) to yield methyl 3-(3-hydroxyphenyl)propanoate as an oil. Yield: 3.2g (90%). TLC (silica gel): Rf=0.8 (EtOAc/Hexane=l/l).
Methyl 3-[3-(3-formylphenoxy)phenyl]propanoate was prepared using Procedure B from methyl 3-(3-methoxyphenyl)propanoate (2.7g; 15mmol), 3-bromobenzaldehyde (1.75mL;
15mmol), copper oxide (2.4g; 30mmol) and potassium carbonate (4.14g; 30mmol) in pyridine as an oil. Yield: 1.7g (40%).
'HNMR: (300 MHz, CDC13) 9.965. (IH, s); 7.605. (IH, d); 7.505. (IH, t); 7.45δ (IH, s); 7.25δ (2H, t); 7.015 (IH, d) 6.885. (IH, s); 6.865 (IH, d); 3.665 (3H, s); 2.955. (2H, t); 2.635 (2H, t).
Methyl 3-(3-{3-[(lE)-2-aza-2-({[(3,4-dichlorophenyl)amino]thioxomethyl}amino) vinyl] phenoxy}phenyl)propanoate was prepared using the procedure in Example 2 from methyl 3-[3- (3-formylphenoxy)phenyl]propanoate (426mg; 1.5mmol) and the product from Procedure D (354mg; 1.5mmol) to obtain a white solid. Yield: 450mg (60%). Mass: M+: 502 (Calc); 502 (Obsd.).
Ethyl 3-[3-(3-{5-[(3,4-dichlorophenyl)amino]-l,3,4-thiadiazol-2-yl}phenoxy) phenyl] propanoate was prepared using the procedure in Example 2 from methyl 3-(3-{3-[(lE)-2-aza-2- ({[(3,4-dichlorophenyl)amino] thioxomethyl} amino)vinyl] phenoxy}phenyl)propanoate (400mg; 0.8mmol) and iron(III) chloride hexahydrate (432mg; 1.6mmol). This product was used in the next reaction without further purification. Yield: 250mg (61%). Mass: M"1": 514 (Calc); 514 (Obsd).
3-[3-(3-{5-[(3,4-Dichlorophenyl)amino]-l,3,4-thiadiazol-2-yl}phenoxy) phenyl] propanoic acid: The title compound was prepared using the procedure for Example 7 from ethyl 3-[3-(3- {5-[(3,4-dichlorophenyl)amino] -1 ,3,4-thiadiazol-2-yl}phenoxy)phenyl] propanoate (150mg; 0.29mmol) and lithium hydroxide (24mg; lmmol). Yield: 130mg (91%). mp 194- 196°C. Mass: M+: 486 (Calc); 486 (Obsd.).
Example 10:
2-[4-(Phenylmethoxy)phenyl]-N-(5-{3-[3-(trifluoromethyl)phenoxy]phenyl}(l,3,4- thiadiazol-2-yl))acetamide
A mixture of the product from Example 23 (202mg; 0.6mmol) and 2-[4- (phenylmethoxy)phenyl]acetyl chloride (313mg; 1.2mmol), and dimethyl-4-pyridylamine (244mg; 2.0mmol) in CH2Cl2 (3 mL) was stirred at RT for 20 hours, then IN HCl aqueous (lOmL) was added and stirred at RT for one hour. The aqueous layer was removed and the CH2C12 was concentrated. Water was added and filtration provided the title compound (107mg; 32%), which was washed with water and then ethyl acetate: mp 194-195°C; Mass (M) 562 (Calc); 562 (Obsd.).
Example 11:
(3-bromophenyl)[5-(3-{[3-(trifluoromethyl)phenyl]methoxy}phenyl)(l,3.4-thiadiazol-2- yl)] amine A mixture of 3-{5-[(3-bromophenyl)amino]-l ,3,4-thiadiazol-2-yl}phenol (lOOmg;
0.29mmol) and 3-(bromomethyl)-l-(trifluoromethyl)benzene (82mg; 0.34mmol) in dry DMF (5mL) were stirred under argon at RT. Cesium carbonate (56mg; 0.17mmol) was added and this mixture stirred overnight. The reaction mixture was heated at 50°C for one hour. The DMF was evaporated (rotovap) under vacuum. The crude residue was purified by flash chromatography (ethyl acetate / hexanes, 1 : 10 to 1 :2) to yield the title compound ((3-bromophenyl)[5-(3-{[3- (trifluoromethyl)phenyl]methoxy}phenyl)(l,3,4-thiadiazol-2-yl)]amine) (92mg; 63%) as white solid, mp 186-187°C. NMR: GE 300, QE+, LCMS: Finnigan, SSQ 7000 Mass Spectrometer
Example 12: 3-[(3-{5-[(3,4-Dichlorophenyl)amino] (l,3,4-thiadiazol-2-yl)}phenyl) [3- (trifluoromethyl)phenyl]methylthio]propanoic acid
A mixture of 3-[(3-{5-[(3,4-dichlorophenyl)amino](l,3,4-thiadiazol-2-yl)}phenyl)[3- (frifluoromethyl)phenyl]methan-l-ol (248mg; 0.5mmol) and 3-mercaptopropionic acid (531mg; 5.0mmol) in trifluoroacetic acid (ImL) was stirred at RT for 20 hours. The solvent and excess 3- mercaptopropionic acid was removed by rotovapor. The residue was purified by column chromatography on silica. Eluting with ethyl acetate provided the title compound as a slightly brown solid (40mg; 16%): mp 140-141°C; MS 583.9 (M). Example 13:
(3,4-dichlorophenyl)[5-(3-{ethoxy[3-(trifluoromethyl)phenyl]methyl}phenyl)(l,3,4- tridiazole-2-ylO] amine Phosphorus tribromide (0.300mL; 6.66mmol) was added dropwise to a solution of ((3-
(l,3-dioxan-2-yl)phenyl)[3-trifluoromethyl)phenyl]methan-l-ol) (2.15g; 6.66mmol) in ether (20mL) while stirring under nitrogen at 0°C. After stirring for 2.5 hours at RT, the reaction was quenched by slow addition of the reaction mixture onto ice (lOOg). Following separation of layers, the aqueous layer was exfracted with ether (3 x 75mL). The organic layer was dried with magnesium sulfate, and evaporated under reduced pressure. The crude was purified using flash chromatography to yield (3-{bromo[trifluoromethyl)phenyl]methyl}phenyl)formaldehyde (1.42g; 4.15mmol; 63%) as a colorless oil. XH NMR: 300 MHz; CDC13; 10.02 (s, IH); 8.14-7.26(m, 8H); 6.32(s, IH).
A solution of this aldehyde (290mg; 0.85mmol) and the product from Procedure D (200mg; 0.85mmol), in ethanol (4mL) was refluxed for 1.5 hours, cooled to RT, and Iron (III) chloride hexahydrate was added to the reaction mixture. The reaction mixture was heated under reflux for two hours and then was cooled to RT. The solid was filtered and dried to yield the title compound (150mg; 0.29mmol). mp 200-205°C; mass spectrum M+ = 525. IH NMR: 300 MHz; CDC13; 7.93-7.26 (m, 12H); 5.46(s, IH); 3.58-3.55(m, 2H); 1.33-1.28(m, 3H).
Example 14:
{5-[3-(3-(lH-l,2,3,4-tetraazol-5-yl)phenoxy)phenyl](l,3.4-thiadiazol-2-yl)}(3,4- dichlorophenyl)amine To the product from Example 19 (120mg; 0.28mmol) in DMF (1.5mL), under argon, was added ammonium chloride (42mg; 0.82mmol) and sodium azide (53mg; 0.82mmol). The reaction was then heated at 115°C for 96 hours. TLC analysis revealed that a new product had formed in addition to unreacted starting material. The mixture was cooled to RT, diluted with water, exfracted with dichloromethane, and dried over magnesium sulfate. The crude oil was subjected to silica chromatography (100% dichloromethane; 5% methanol in dichloromethane) to yield pure tefrazole (45mg), compound 2. Isolated yield 31%, uncorrected mp 227 to 229°C (with decomposition). Example 15:
Ethyl 2-[(3-{5-[(3,4-Dichlorophenyl)amino](l,3,4-thiadiazol-2-yl)}phenyl)[3-
(trifluorόmethyl)phenyl] methoxyl] acetate A solution of (3 -( 1 ,3 -dioxolan-2-yl)phenyl) [3 -(trifluoromethyl)phenyl]methan- 1 -ol
(3.23g; lOmmol) and sodium hydrade (260mg; 1 lmmol) in THF (20mL) was stirred under Argon at room temp for 1 hours. A solution of tert-butyl bromoacetate (1.95g; lOmmol) in THF (lOmL) was added and the resulting solution was refluxed for 24 hours. Water (lOmL) was added to quench the reaction. The organic layer was separated and the aqueous layer was exfracted with ethyl acetate (2xl00mL). The organic layers were combined and dried over anhydrous a2S04. The solvent was removed and the residue was purified by column chromatography on silica gel. Eluting with ethyl acetate/hexanes (20:80) provide a colorless sticky oil (2.4g) as a mixture of tert-butyl 2-{(3-(l,3-dioxolan-2-yl)phenyl)[3- (trifluoromethyl)phenyl]methoxy} acetate and (3-(l ,3-dioxolan-2-yl)phenyl)[3- (trifluoromethyl)phenyl]methan-l -ol.
A sample of the product from the preceding paragraph (2.45g) was combined, without further purification, with pyridinium tosylate (500mg; 2.0mmol) in acetone/water (4:1; 2mL). The resulting solution was refluxed for two days. The solvent was removed and the residue was exfracted with ethyl acetate (3 x 30mL). The organic layers were combined and dried over anhydrous Na2S04. The solvent was removed and the residue was purified by flash column chromatography on silica gel. Eluting with ethyl acetate/hexanes (20:80) provided a sticky oil (1.53g) as a mixture of tert-butyl 2-{(3-carbonylphenyl)[3-(trifluromethyl)phenyl]methoxy} acetate and (3-{hydroxy[3-(trifluromethyl)phenyl]methyl}phenyl)formaldehyde.
A sample of the product from the preceding paragraph (1.52g) was combined, without furtlier purification, with the product from Procedure D (1.28g; 5.4mmol) in ethanol (20mL). The resulting solution was refluxed for five hours. After cooling, the solution was concentrated and the residue was purified by flash column chromatography on silica gel. Eluting with ethyl acetate provided a brown solid (2.51g) as a mixture of tert-butyl 2-({3-[2-aza-2-({[(3,4- dichlorophenyl)amino]thioxomethyl} -amino)vinyl]phenyl} [3 -(trifluoromethyl)phenyl] methoxy)acetate and {3-[2-aza-2-({[(3,4-dichlorophenyl)amino]-thioxomethyl}amino)vinyl] phenyl} [3-(trifluoromethyl)phenyl]methan-l-ol. A sample of the product from the preceding paragraph (2.49g) was combined, without further purification, with iron (III) chloride hexahydrate (4.05g; 15mmol) in ethanol (20mL). The resulting solution was refluxed for five hours. After cooling, the solution was concentrated and water (20mL) was added. A brown sticky solid was filtered. This crude product was purified by flash column chromatography on silica gel. Eluting with ethyl acetate/hexanes (1 : 1) provided a brown solid (1.95g), which is a mixture of 3-[(3-{5-[(3,4-dichlorophenyl)amino] (l,3,4-thiadiazol-2-yl)}ρhenyl)[3-(trifluoromethyl)-phenyl]methan-l-ol and ethyl 2-[(3-{5-[(3,4- dichlorophenyl)amino](l,3,4-thiadiazol-2-yl)}phenyl)[3-(trifluoromethyl)phenyl]methoxyl] acetate. This mixture (800mg) was separated further by column chromatography on silica gel. Eluting with ethyl acetate/hexanes (20:80) provided ethyl 2-[(3-{5-[(3,4-dichlorophenyl)amino] (l,3,4-thiadiazol-2-yl)}phenyl)[3-(trifluoromethyl)phenyl]methoxyl]acetate (200mg): mp 135- 136°C; MS 582.0 (M); and also provided 3-[(3-{5-[(3,4-dichlorophenyl) amino]-(l,3,4- thiadiazol-2-yl)}phenyl)[3-(trifluoromethyl)phenyl]methan-l-ol (250mg): mp 191-192°C; MS 495.8 (M).
Example 16: (3-methoxy-l-(6-(4-phenylphenyl)imidazolo(2,l-b)l,3,4-thiadiazolin-2-yl)benzene)
A mixture of anisic acid (9.88g; 65mmol), thiosemicarbozide (5.92g; 65mmol) and phosphorous oxychloride (32.08g; 210mmol) was refluxed gently for 30 minutes. After cooling in an ice bath, a mixture of ice and water (60mL) was added with stirring. The mixture was slowly warmed and refluxed for four hours. The reaction was cooled, neutralized with 5M potassium hydroxide solution and the solid was filtered. The solid was washed with water, then ether and dried to obtain 5-(3-methoxyphenyl)-l,3,4-thiadiazole-2-ylamine. Yield: 8.10g (60%). *H NMR: (300 MHz, DMSO-d6) 8.37δ (2H, b), 7.41δ (IH, t), 7.39δ (2H, m), 7.075 (IH, d), 3.825 (3H, s).
A solution of 5-(3-methoxyphenyl)-l,3,4-thiadiazole-2-ylamine (1.8g; 8.7mmol) and 2- bromo-4' -phenyl acetophenone (2.4g; 8.7mmol) were refluxed for about 36 hours. The solid was filtered, washed with ethanol and hexane and dried to yield the title compound. Yield: 2.3g (69%). lR NMR: (300 MHz, DMSO-d6) 8.845 (IH, s), 7.99δ (2H, d), 7.74δ (4H, m), 7.51δ (5H, m), 7.395 (IH, d), 7.22δ (IH, m), 3.88δ (3H, s). Mass: MH+: 384 (Calc); 384 (Obsd.). Example 17:
N-{(lE)-2-aza-2-(3-bromophenyl)-l-[(4-phenylphenyl)methylthio]vinyl}[3- (trifluoromethyl)phenylcarboxamide
A solution of amino[(3-Bromophenyl)amino]methane-l-thione (lOOmg; 0.43mmol) and 4-(bromomethyl-l-phenylbenzene (106mg; 0.43mmol) in dioxane (4mL) was refluxed for four hours. Most of the solvent was evaporated under vacuum, and the residue was washed with ether (3x20mL) to provide {[(3Bromophenyl)amino][(4-phenylphenyl)methylthio] methyleneamine hydrobromide (160mg; 78%) as a yellow solid. The intermediate was 95% pure by LC-MS (SSQ 7000) (retention time = 3.26 min.; M+ = 398 free base. Column: Betasil C18 5μm 50x3 mm.; Solvent A = water-0.1% AcOH; B = Acetonifrile -0.1% AcOH).
To a solution of {[(3Bromophenyl)amino][(4-phenylphenyl)methylthio]methyleneamine hydrobromide (lOOmg; 0.2mmol) in dry pyridine (5mL) was added 3-(trifluoromethyl)benzoyl chloride at ambient temperature. The resulting solution was refluxed for 15 minutes. The cold reaction mixture is poured into the water (lOmL). After filtration, the residue was washed with water and recrystallized from ethanol to yield the title compound. The product was 95% pure by LC-MS (SSQ 7000) ( retention time = 4.33 min.; M+ = 570 free base. Column: Betasil C18 5μm 50x3 mm.; Solvent A = water-0.1% AcOH; B = Acetonifrile -0.1% AcOH). mp 220- 225°C from ethanol.
Example 18:
[3-(3-{5-[(3,4-dichlorophenyl)amino](l,3,4-thiadiazol-2-yl)}phenoxy)phenyl]-N-(l,3- dioxolan-2-ylmethyl)carboxamide
To 3-(3-{5-[(3,4-dichlorophenyl)amino]-l,3,4-thiadiazol-2-yl}phenoxy)benzoic acid (50mg; O.llmmol) in DMF (1.5mL) was added l,3-dioxolan-2-ylmethylamine (lOμL; 0.1 lmmol). The mixture was warmed to dissolve the reactants and HATU (45mg; 0.12mmol) followed by triethylamine (49μL) were added and the mixture was stirred for four hours. The solution was diluted with 0.5N aqueous HCl and extracted with dichloromethane (3 x 3mL). The solvent was removed by high vacuum and the resulting residue was purified by silica gel chromatography (9/1 Hex/EtOAc; 7/3 Hex/Oac). Yield: 27%, 15mg., mp 200-203°C Example 19: 3-(3-{5-[3,4-dichlorophenylamino]-l,3,4-thiadiazol-2-yl}phenoxy)benzenecarbonitrile
3-hydroxybenzaldehyde and 3-bromobenzenecarbonitrile were combined as in Procedure B to yield 3-(3-carbonylphenoxy)benzenecarbonitrile. Yield: 12% (isolated) !H NMR (300 MHz, CDC13): 5 10.00 (IH , s); 5 7.71 (IH, d, J=7.5Hz); δ 7.58 (IH , t, J=7.8Hz); 5 7.50-7.42 (3H, m); δ 7.33-7.26 (3H, m).
3-(3-Formyl-phenoxy)-benzonitrile, 67mmol, and [(3,4-dichloropheny)amino] hydrazinomethane-1-thione, 67mmol, were combined in ethanol and heated to reflux for two hours. The solution was cooled to room temperature and the precipitate was collected by filfration, and then washed with hexane (3x). The white solid was slurried in ethanol and 3eq of Fe(III)Cl3 was added. The slurry was refluxed for two hours, cooled and the crude product was collected by filfration. The crude product was washed (3x) with water followed by hexane. The product was recrystallized from hot ethanol to give 1.4g of the title compound. Yield 47%. mp 237-239°C. MS m/z 437.5 [M-H].
Example 20: 3-{5-[(3,4-dichlorophenyl)amino](l,3,4-thiazol-2-yl)}3-(trifluoromethyl)phenyl]methan-l-ol
The product from Procedure E was refluxed for 18 hours with pyridinium p-toluenesulfonate in 4: 1 acetone/water. After removal of acetone in vacuo, water and ethyl acetate were added. The organic layer was washed 3 times with water, then with saturated sodium chloride, dried over sodium sulfate, filtered and stripped of solvent in vacuo to yield (3- {hydroxy[3-(trifluoromethyl)phenyl]methyl}phenyl)formaldehyde.
A solution of [(3,4-dichlorophenyl)amino]hydrzinomethane-l-thione (200mg; 0.85mmol), and (3-{hydroxy[3-(trifluoromethyl)phenyl]methyl}phenyl)formaldehyde (290mg; 0.85mmol) in ethanol (4mL) was refluxed for 1.5 hours, cooled to RT, and Iron (III) chloride hexahydrate was added to the reaction mixture. And the reaction mixture was heated under reflux for two hours. The reaction was cooled to RT, and the ethanol was removed under reduced pressure. The crude was purified by flash chromatography to yield the title compound (25mg; 0.05mmol, 16 %) Example 21:
(2E)-3-{4-[5-({3-[(2-Phenylphenyl)methylthio]phenyl}amino)(l,3,4-thiadiazol-2- yl)] phenyl} prop-2-enoic acid
(2E)-3-[4-((lE)-2-Aza-2-{[({3-[(2-Phenylphenyl)methylthio]phenyl}amino) thioxomethyl] ammo}vinyl)phenyl]prop-2-enoic acid was prepared using the procedure for Example 2 from hydrazino({3-[(2-phenylphenyl)methylthio] phenyl} amino)methane-l-thione (183 mg; 0.5 mmol) and 4-formylcinnamic acid (88mg; 0.5mmol) to obtain a yellow solid. Yield: 197mg (75%). TLC (silica gel): Rf=0.43.
Ethyl (2E)-3-{4-[5-({3-[(2-phenylphenyl)methylthio]ρhenyl}amino)(l,3,4-thiadiazol-2- yl)]phenyl}prop-2-enoate was prepared using the procedure for Example 2 from (2E)-3-[4-((lE)- 2-aza-2- {[( {3-[(2-phenylphenyl)methylthio]phenyl} amino)thioxomethyl]amino}vinyl)phenyl] prop-2-enoic acid (130.9mg; 0.25mmol) and iron(III) chloride hexahydrate (203 mg; 0.75 mmol) to obtain a yellow solid. Yield: 88mg ( 64%). TLC (silica gel): Rf=0.56.
The title compound was prepared using the procedure for Example 7 from ethyl (2E)-3- {4-[5-({3-[(2-phenylphenyl)methylthio]phenyl}amino) (l,3,4-thiadiazol-2-yl)]phenyl}prop-2- enoate (70mg; 0.13mmol) and lithium hydroxide (24mg; lmmol). Yield: 56mg ( 84%). mp 255-257°C. Mass (APCI): (MH)+: 522 (Calc); 522 (Obsd.).
Example 22: [4-(3,4-dichlorophenyl)(l,3-thiazol-2-yl)](3-bromophenyl)amine
To a solution of ammo[(3-bromophenyl)amino]methane-l-thione (lOOmg; 4.32mmol) in dioxane (3mL) at RT was added l-(3,4-dichlorophenyl)-2-bromoethan-l-one (120mg; 4.5mmol). The reaction mixture stirred at RT for one hour and pyridine (0.4 mL; 4.66mmole) was added. After refluxing for five hours, the reaction mixture was concentrated under reduced pressure, quenched with water, and the resulting mixture was exfracted with ethyl acetate. The organic layer was washed with water, with brine, and dried over anhydrous sodium sulfate. Concenfration under reduced pressure afforded a crude product that was purified by flash chromatography (50/50 Ethyl acetate/Hexane) to yield the title compound (135mg; 78%) as a liquid. The product had a HPLC retention time of 3.90 minutes (Column: C 18, 5μm, 50x3 mm); Solvent A = (H20, 10 % AcOH); solvent B = ( Acetonifrile , 10 % AcOH) and LC/SM (SSQ- 7000) M+ = 400. Example 23: 5-{3-[3-(trifluoromethyl)phenoxy]phenyl}-l,3,4-thiadiazole-2-ylamine
The reactions described in Example 2 were repeated, using aminohydrazinomethane-1- thione (1.82g; 20.0mmol) and 3-[3-(trifluoromethyl)phenoxy]benzaldehyde (5.32g; 20.0mmol) to yield [(l-aza-2-{3-[3-(trifluoromethyl)phenoxy]phenyl}vinyl)amino]aminomethane-l-thione (6.43g; 95%) in the first step.
In the second step, [(l-aza-2-{3-[3-(trifluoromethyl)phenoxy]phenyl}vinyl)amino] aminomethane-1-thione (6.35g; 18.7mmol) and iron (III) chloride hexahydrate (12.16g; 45.0mmol) were used to yield the title compound (2.42g; 38%). mp 214-215°C; Mass (M)+ 337 (Calc); 337 (Obsd.).
Example 24: 4-{2-[(3-bromophenyl)amino]-l,3-thiazol-4-yl}phenyl benzoate
To a solution of amino[(3-bromophenyl)amino]methane-l-thione (lOOmg; 4.32mmol) in dioxane (3mL) at RT was added 4-(2-bromoacetyl)phenyl benzoate (143mg; 4.5mmol). The reaction mixture stirred at RT for one hour and pyridine (0.4 mL; 4.66mmole) was added. After refluxing for five hours the reaction mixture was concentrated under reduced pressure, quenched with water, and the resulting mixture was exfracted with ethyl acetate. The organic layer was washed with water, with brine, and dried over anhydrous sodium sulfate. Concenfration under reduced pressure afforded a crude product that was purified by flash chromatography (50/50
Ethyl acetate/Hexane) to yield the title compound (146mg; 75%) as a white solid, mp from ethyl acetate: 168-170°C. The product had a HPLC retention time of 3.57 min (Column: C18, 5μm, 50x3mm); Solvent A = (H2O, 10 % AcOH); solvent B = ( Acetonifrile , 10 % AcOH) and LC/SM (SSQ-7000) M+ = 452.
Example 25:
3-{5-[(3,4-dichlorophenyl)amino](l,3,4-thiadiazol-3-yl)}phenyl 3-(trifluorometUyl)phenyl ketone
To the product from Procedure E (500mg; 1.5mmol) and celite (l.Og) in dichloromethane (4mL) was add pyridinium chlorochromate (970mg; 4.5mmol). The mixture was stirred for two hours, filtered, and the filter cake was rinsed with additional dichloromethane and the filtrate concentrated in vacuo to an oily residue. The residue was subjected to silica gel chromatography (1/9 ethyl acetate/hexane) to yield 3-(l,3-dioxolan-2- yl)phenyl 3-(trifluoromethyl)phenyl ketone (442mg; 91%).
This intermediate was hydrolyzed to the 3-{[3-(teifluoromethyl)phenyl]carbonyl} benzaldehyde by stirring in IN HCl /Dioxane (1/1) for two hours at 25°C. The aldehyde (154mg, 0.56mmol) and the product from Procedure D (132mg; 0.56mmol) were then combined as in Example 2 and recrystallized from ethanol to yield the title compound. Yield 175 mg (63%). mp (uncorrected): 216-217°C.
Example 26: N-{(lZ)-2-aza-2-(3,4-dichlorophenyl)-l-[(4-(l,2,3-thiadiazol-4-yl)phenyl)methylthio] vinyl} [3-(trifluoromethyl)phenyl] carboxamide
A solution of amino[(3,4-dichlorophenyl)amino]methane-l-thione (145mg; 0.65mmol) and 4-[4-(bromomethyl)phenyl]-l,2,3-thiadiazole in dioxane (4mL) was refluxed for four hours.
Most of the solvent was evaporated under vacuum, and the residue was washed with ether (3x20mL) to provide the HBr salt of {amino[(4-(l ,2,3-thiadiazol-4-yl)phenyl)methylthio] methyl} (3 ,4-dichlorophenyl)amine (248mg; 80%) as a yellow solid.
1HNMR (300 MHz, CDC13); 11.31(s, IH); 8.69(s, IH); 8.08-8.05(d, J= 9Hz, IH); 7.59-7.20 (m,
7H); 4.68 (s, 2H).
To a solution of this salt (116mg; 0.23mmol) in dry pyridine (5mL) was added 3- (trifluoromethyl)benzoyl chloride at RT. The resulting solution was refluxed for 15 minutes.
The cold reaction mixture is poured into the water (lOmL). The precipitate is filtered, washed with water, and recrystallized from ethanol to yield the title compound as a white solid. Mass spec (APCI): M+ = 566 : mp 150-155°C
Example 27: l-(4-{[5-(3-nitrophenyl)-l,3,4-thiadiazol-2-yl]amino}phenyl)ethan-l-one
The title compound was synthesized from 3-nifro-benzenecarbohyrazide (181mg; lmmol) and 4-acetylbenzenisothiocyanate (197mg; l.lmmol) by the procedure of Example 1. recrystallized from ethanol/water. Yield: 38% (isolated) Mass spec: (MH+): 341.1 (NuMega) Example 28: Ethyl 2-(3-{5-[(3-bromophenyl)amino]-l,3,4-thiadiazol-2-yl}phenoxy)acetate
The title compound was synthesized from [(3-bromophenyl)amino]hydrazinomethane-l- thione (80mg; 0.47mmol) and 2-(3-carbonylphenoxy) acetic acid (lOOmg; 0.43mmol) by the procedure of Example 2. Yield: 62% (isolated) mp 175°C (uncorrected) from ethyl acetate/hexane.
Example 29: (3,4-dichlorophenyl)[5-(3,5-dinitrophenyl)(l,3.4-thiadiazol-2-yl)]amine The title compound was synthesized from 3,5-dinifrobenzoyl chloride (50mg; 0.25mmol) and the product from Procedure D (59mg; 0.25mmol) by the procedure of Example 3. mp 305-306.5°C (uncorrected) from ethanol. Yield: 61% (isolated)
Example 30: [5-(4-nitrophenyl)(l ,3-thiazol-2-yl)] (4-phenoxyphenyl)amine
The title compound was synthesized from amino[(4-phenoxyhenyl)amino] methane- 1- thione (228mg; 0.9mmol) and 2-bromo-l-(4-nifrophenyl)ethan-l-one (240mg; 1.2mmol) by the procedure of Example 4. Yield: 45% (isolated) mp 191-196°C (uncorrected) from ethyl acetate/hexane
Example 31:
Methyl 3-(aza{5-(3-ethoxyphenyl)-3-[4-phenylphenyl)methyl](l,3,4-thiadiazolin-2- ylidene)}methyl)benzoate
The title compound was synthesized from methyl-3 {[5-(3-ethoxyphenyl)-l,3,4- thiadiazol-2-yl]amino}benzoate and 4-(bromomethyl)-l-phenylbenzene by the procedure in
Example 8 and purified using silica gel chromatography as the less polar of the two isomers.
Mass: (MH+)+ 552.07 SBI APCI + Qlms
Example 32:
Ethyl 2-[(lZ & lE)-l-aza-2-(3-{5-[(3,4-dichlorophenyl)amino](l,354-thiadiazol-3- yl)}phenyl)-2-[3-(trifluoromethyl)phenyl]vinyloxy]acetate
To the product from Example 25 (168mg; 0.34mmol) was added carboxymethoxylamine hydrochloride (43mg; 0.34mmol) in ethanol. The reaction mixture was refluxed for six hours, then allowed to cool to 0°C. The precipitate was collected and recrystallized from ethanol to yield the product (75mg; a mixture of cis and trans). Yield 37% (isolated), mp 170-179°C.
Example 33: l-(4-{[5-(3-nitrophenyl)-l,3,4-thiadiazol-2-yl]amino}phenyl)ethan-l-one
The title compound was synthesized from 4-acetylphenyl isothiocyanate and 3- nifrobenzoylhydrazide using the procedure in Example 1. Yield: 38% (isolated) Mass: (MH+)+ 341.1
Example 34:
[5-(4-nitrophenyl)(l,3-thiazoI-2-yl)](4-phenoxyphenyl)amine
4-phenoxybenzenisothiocyanate (l.Og; 4.4mmol) and 0.5M ammonia (30mL; 15mmol) in dioxane were combined as in Example 4 to yield (amino[(4-phenoxyphenyl)amino]methane-l- thione) in 83% yield. Without purification, this intermediate was combined with 4-nifrophenyl- 2'-bromoacetophenone as in Example 4 to yield the title compound in 45% yield, mp 191-196°C (uncorrected); Yield: 45% (isolated).
Example 35:
3-{2-[Aza(3,4-dichlorophenyl)methylene]-3-methyl(l,3,4-thiadiazoIin-5-yl)}-l-[3- (trifluoromethyl)phenoxy]benzene and
(3,4-Dichlorophenyl)methyl(5-{3-[3-(trifluoromethyl)phenoxy]phenyl}(l,3,4-thiadiazol-2- yl))amine
The reactions described in Example 8 were repeated, but using (3,4-dichlorophenyl)(5- {3-[3-(trifluoromethyl)phenoxy]phenyl}(l,3,4-thiadiazol-2-yl))amine (241mg; 0.5mmol), potassium t-butoxide (0.55mL; 0.55mmol; IM in THF) and of iodomethane (0.12mL; 2mmol) to yield 3-{2-[Aza(3,4-dichlorophenyl)methylene]-3-methyl(l,3,4-thiadiazolin-5-yl)}-l-[3- (trifluoromethyl)phenoxy]benzene (41mg; 17%, the less polar of the two isomers) with the following physical properties: mp 78-79°C; MS m/z 496 (M+) (LC/MS SSQ.7000).
The more polar isomer, (3,4-Dichlorophenyl)methyl(5-{3-[3- (trifluoromethyl)phenoxy]phenyl}(l,3,4-thiadiazol-2-yl))amine, was isolated in a yield of 20mg (8%), with the following physical properties: MS m/z 496 (M*) (LC/MS SSQ.7000);
!H MR (300MHz, CDC13) 3.63 (s, 3H), 7.07 (d, J = 8.7Hz, IH), 7.19 (d, J = 8.1Hz, IH), 7.26- 7.53 (m, 9H).
Example 36: (3-Bromophenyl) {5- [(2-nitrophenoxy)methyl] (l,3,4-thiadiazol-2-yl)} amine
2-(2-niteophenoxy)acetohydrazide (211mg; lmmol) and 3 -bromophenyl isothiocyanate (235mg; 1. lmmol) were combined as in Example 1 to form the title compound (193mg; 81% yield): mp 184-185°C;
*H NMR (300MHz, DMSO-d6) δ 5.64 (s, 2H), 7.19 (d, J= 6.0Hz, 2H), 7.31 (t, J = 6.9Hz, IH), 7.47 (d, J = 8.4Hz, IH), 7.55 (d, J = 9.0Hz, IH), 7.70 (t, J = 6.6Hz, IH), 7.92 (d, J = 6.9Hz, IH), 8.05 (s, IH), 10.67 (s, IH); MS m/z 407 (M+); Rf 0.65 (EtOAc, silica).
Example 37: 3-({5-[3,5-bis(phenylmethoxy)phenyl]-l,3,4-thiadiazol-2-yl}amino)benzoic acid 3-[(hydrazinothioxomethyl)amino]benzoic acid was prepared using Procedure F from 3- carboxyphenyl isothiocyanate (896mg; 5mmol) and hydrazine hydrate (485μL; lOmmol) and was used for next reaction without further purification.
1HNMR: (300 MHz, DMSO-d6) 9.11 5 (IH, b); 8.07 5 (IH, s); 7.73 δ (IH, d); 6.23 δ (IH, d); 7.23 δ (IH, t); 7.00 δ (2H, b); 4.84 δ (IH, b). The title compound was prepared using the procedure for Example 2 from 3-
[(hydrazinothioxomethyl)amino]benzoic acid (845mg; 4mmol) and 3,5-dibenzyloxy benzaldehyde (1.27g; 4mmol). Yield: 152mg (10%). Mass: (MH)+: 510 Example 38: l-{6-[3-(2,4-Dichlorophenyl)isoxazol-5-yl]imidazolo[2,l-b]l,3,4-thiadiazolin-2-yl}-3- methoxybenzene
The title compound was prepared as in Example 16 from 5-(3-methoxy phenyl)-l,3,4- thiadiazole-2-ylamine (103mg; 0.5mmol) and 5-(bromoacetyl)-3-(2,4-dichlorophenyl)isoxazole (168 mg; 0.5 mmol). Yield: 75 mg (34%). mp 195-198° C. Mass: (M)+: 443 (Calc); 443 (Obsd.).
Example 39: 2-(3-Nitrophenyl)-6-(4-phenylphenyl)imidazolo [2,1-b] 1,3,4-thiadiazoline
5-(3-Nifrophenyl)-l,3,4-thiadiazole-2-ylamine was prepared using the procedure for Example 16 from 3-nifro benzoic acid (5.01g; 30mmol) and thiosemicarbozide (2.73g; 30mmol) and phosphorous oxychloride (9mL). Yield: 3.29g (50%). mp 205-206°C. Mass: (M+2H)+: 224 (Calc), 224 (Obsd.). 2-(3-Nifrophenyl)-6-(4-phenylphenyl)imidazolo[2,l-b]l,3,4-thiadiazoline: The title compound was prepared using the procedure of Example 16 using 5-(3-nifrophenyl)-l,3,4- thiadiazole-2-ylamine (111 mg; 0.5mmol) and 2-bromo-4' -phenyl acetophenone (138mg; 0.5mmol). Yield: 75 mg (19%). mp 263-265°C. Mass: (MH)+: 399 (Calc); 399 (Obsd.).
Example 40:
6-(2H,3H,4H-Benzo [b] l,4-dioxepan-7-yl)-2-(3-nitrophenyl)imidazolo [2,1-b] 1,3,4- thiadiazoline
Tlie title compound was prepared using the procedure of Example 16 using 5-(3- nifrophenyl)-l,3,4-thiadiazole-2-ylamine (lllmg; 0.5mmol) and 3,4- (Trimethylenedioxy)phenacyl bromide (136mg; 0.5mmol). Yield: 75 mg (18%). mp 227-230°C. Mass: (MH)+: 395 (Calc); 395 (Obsd.).
Example 41: {3- [(4-Methoxyphenyl)methylthio] phenyl} [5-(3-nitrophenyl)(l,3,4-thiadiazol-2-yl)] amine
3-(4-Methoxy phenylmethylthio)phenylamine: The title compound was prepared from 4- (chloromethyl)-l-methoxybenzene (4.7g; 30mmol) and 3-amino thiophenol (3.75g; 30mmol) using Procedure A. The solid was purified using a silica gel column and the title compound was eluted with 20% EtOAc/hexanes. Yield: 4.5g (61%).
3-[(4-Methoxyphenyl)methylthio] benzenisothiocyanate was prepared using Procedure C from 3-(4-methoxy phenylmethylthio)phenylamine (1.84g; 7.5mmol) and thiophosgene (1.14mL; 15mmol) to obtain slightly purple solid. Yield: 2.0 g (93%). Hydrazino({3-[(4-methoxyphenyl)methylthio]phenyl}amino)methane-l-thione was prepared from 3-(phenylmethylthio) benzenisothiocyanate (290mg; lmmol) and hydrazine hydrate (0. ImL; 2mmol) using Procedure D. Yield: 275mg (86%).
[( 1 E)- 1 -Aza-2-(3 -nitrophenyl)vinyl]amino } ( {3 -[(4-methoxyphenyl)methylthio]phenyl} amino)methane-l -thione was prepared from hydrazino({3-[(4-methoxyphenyl) methylthio]phenyl}amino)methane-l -thione (240mg; 0.75mmol) and 3-nifrobenzaldehyde (113mg; 0.75mmol) as in Example 2. Yield: 275mg (81%). TLC (silica gel): Rp0.9 (EtOAc/Hexane=l/l).
The title compound was prepared as in Example 2 from {[(lE)-l-aza-2-(3- nifrophenyl)vinyl]amino} ({3-[(4-methoxyphenyl)methylthio]phenyl} amino)methane-l -thione (226mg; 0.5mmol) and iron (III) chloride hexahydrate (405mg; 1.5mmol). Yield: 176mg, (78%). mp 208-209°C. Mass spectrum (elecfrospray): (MH)+: 451 (Calc); 451 (Obsd.).
Example 42:
[5-(3-Ethoxyphenyl)(l,3,4-thiadiazol-2-yl)] {3-[(4-phenylphenyl)methylthio] phenyl} amine 3-[(4-Phenylρhenyl)methylthio]phenylamine: The title compound was prepared using
Procedure A from 3-aminothiophenol (0.4mL; 3.5mmol) and l-(chloromethyl)-4-phenylbenzene (750mg; 3.5mmol) as a white solid. Yield: 970mg(95%). TLC (silica gel):
Figure imgf000061_0001
(EtOAc/Hexane=l/4).
3-[(4-Phenylphenyl)methylthio]benzenisothiocyanate was prepared using Procedure C from 3-[(4-phenylphenyl)methylthio]phenylamine (950mg; 3.25mmol) and thiophosgene (0.49mL; 6.5mmol). Yield: 910mg (84%). TLC (silica gel): Rf=0.9 (EtOAc/Hexane=l/4). Hydrazino({3-[(4-phenylphenyl)methylthio]phenyl}amino)methane-l-thione was prepared using Procedure D from 3-[(4-phenylphenyl)methylthio] benzenisothiocyanate (900mg; 2.7mmol) and hydrazine hydrate (0.27mg; 5.4mmol) as a white solid. Yield: 750mg (76%).
{[(lE)-l-Aza-2-(3-ethoxyphenyl)vinyl]amino}({3-[(4-phenylphenyl)methylthio]phenyl} amino)methane-l -thione: The title compound was prepared as in Example 2 from hydrazino({3- [(4-phenylphenyl)methylthio]phenyl}amino)methane-l -thione (274mg; 0.75mmol) and 3- ethoxybenzaldehyde (113mg; 0.75mmol) to obtain a white solid. Yield: 320mg (85%).
The title compound was prepared using the procedure for Example 2 from {[(lE)-l-aza- 2-(3-methoxyphenyl)vinyl]amino}({3-[(4-phenylphenyl)methylthio] phenyl} amino) methane-1- thione (242mg; 0.5mmol) and iron(III) chloride hexahydrate (405mg, 1.5mmol). Yield: 172mg (69%). mp 215-217°C. Mass: (MH)+: 496 (Calc); 496 (Obsd.). AA
Example 43:
[5-(3-Nitrophenyl)(l,3,4-thiadiazol-2-yl)] {3-[(4-phenylphenyl)methylthio] phenyl} amine {[(lE)-l-Aza-2-(3-nifrophenyl) vinyl]amino}({3-[(4-phenylphenyl)methylthio] phenyl} amino)methane-l -thione was prepared using the procedure in Example 2 from hydrazino({3-[(4- phenylphenyl)methylthio]phenyl}amino)methane-l -thione (183mg; 0.5mmol) and 3- nifrobenzaldehyde (76mg; 0.5mmol) as a white solid. Yield: 210mg (84%).
The title compound was prepared as in Example 2 from {[(lE)-l-aza-2-(3-nifrophenyl) vinyl]amino} ({3-[(4-phenylphenyl)methylthio] phenyl}amiήo) methane- 1 -thione (200mg;
0.4mmol) and iron(III) chloride hexahydrate (324mg; 1.2mmol). Yield: 90mg (45%). mp 229- 231°C. Mass: (MH)+: 497 (Calc); 497 (Obsd.).
Example 44: [5-(3-Methylphenyl)(l,3,4-thiadiazol-2-yl)](2,4,5-trichlorophenyl)amine
(3-Methylphenyl)-N-({thioxo[(2,4,5-trichlorophenyl)amino]methyl}amino)carboxamide:
The title compound was prepared using the procedure for Example 1 from 3-toluic hydrazide
(lOOmg; 0.67mmol) and 2,4,5-trichlorophenyl isothiocyanate (160mg; 0.67mmol). Yield: 39.2 mg (15%). TLC (silica gel):
Figure imgf000062_0001
The title compound was prepared using the procedure for Example 1 from (3- methylphenyl)-N-({thioxo[(2,4,5-trichlorophenyl)amino]methyl}amino)carboxamide (79mg; 0.2mmol) and sulfuric acid (6 drops). Yield: 16mg (21.5%). mp 229-231°C. Mass (electeospray): (MH)+: 497 (Calc); 497 (Obsd.).
Example 45: {5-[3,5-Bis(phenylmethoxy)phenyl](l,3,4-thiadiazol-2-yl)}[3-(3-phenylpropylthio) phenyl] amine
3-(3-Phenylpropylthio)phenylamine was prepared from 3-amino thiophenol (lOmmol, 1.06mL) and (3-bromopropyl)benzene (1.52mL; lOmmol) using Procedure A. The yellow liquid was purified using a silica gel column and the title compound was eluted with 40% hexanes/ethylacetate. Yield: 1.7mL (74%).
3-(3-Phenylpropylthio)benzenisothiocyanate was prepared using Procedure C from 3-(3- phenylpropylthio)phenylamine (1.8g; 7.4mmol) and thiophosgene (1.12mL; 14.8mmol) to obtain a brown liquid. Yield: 2.3g (100%).
Hydrazino{[3-(3-phenylpropylthio)phenyl]amino}methane-l-thione: The title compound was prepared using Procedure F from 3-(3-phenylpropylthio)benzenisothiocyanate (2.3g;
8mmol) and hydrazine hydrate (0.4mL; 16mmol) to obtain a white solid. Yield: 2.1 lg (83%). TLC (silica gel): Rf=0.25.
( {( 1 E)- 1 -Aza-2-[3 ,5 -bis(phenylmethoxy)phenyl] vinyl} amino) { [3 -(3 -phenylpropylthio) phenyl]amino}methane-l -thione was prepared using the procedure for Example 2 from hydrazino{[3-(3-phenylpropylthio)phenyl]amino}methane-l-thione (159mg; 0.5mmol) and 3,5- dibenzyloxybenzaldehyde (159mg; 0.5mmol). Yield: 290mg (94%). TLC (silica gel): Rf=0.84.
5-[3,5-bis(phenylmethoxy)phenyl](l,3,4-thiadiazol-2-yl)}[3-(3-phenylpropylthio) phenyl]amine: The title compound was prepared as in Example 2 from ({(lE)-l-aza-2-[3,5- bis(phenylmethoxy)phenyl]vinyl} amino) {[3-(3-phenylpropylthio) phehyl]amino} methane-1- thione (154mg; 0.25mmol) and iron(III) chloride hexahydrate (202mg; 0.75mmol). Yield: 124mg ( 81%). mp l60-162°C. Mass: (MH)+: 616 (Calc); 616 (Obsd.). AA
Example 46:
{5-[3,5-Bis(phenylmethoxy)phenyl](l,3,4-thiadiazol-2-yl)}{3-[(2-phenylphenyI) methylthio] phenyl} amine
3-[(2-Phenylphenyl)methylthio]phenylamine was prepared from 3-amino thiophenol (lOmmol, 1.06mL) and 2-phenylbenzyl bromide (1.83mL; lOmmol) using Procedure A. The yellow liquid was purified using a silica gel column and the title compound was eluted with 40% hexanes/ethylacetate. Yield: 1.8mL (62%). TLC (silica gel): Rf=0.72
3-[(2-Phenylphenyl)methylthio]benzenisothiocyanate was prepared using Procedure C from 3-[(2-phenylphenyl)methylthio]phenylamine (1.8g; 6mmol) and thiophosgene (0.91mL; 12mmol) to obtain a brown liquid. Yield: 2.2g (90%). TLC (silica gel): RpO.69.
Hydrazino({3-[(2-Phenylphenyl)methylthio]phenyl}amino)methane-l-thione was prepared using Procedure F from 3-[(2-phenylphenyl)methylthio]benzenisothiocyanate (2.2g, 6.6mmol) and hydrazine hydrate (0.33mL; 13.2mmol) to obtain a white solid. Yield: 1.91g (79%). TLC (silica gel): Rf=0.28. ({(lE)-l-Aza-2-[3,5-bis(phenylmethoxy)phenyl]vinyl}amino)({3-[(2-phenylphenyl) methylthio]phenyl}amino)methane-l-thione: The title compound was prepared using the procedure for Example 2 from hydrazino({3-[(2-phenylphenyl)methylthio]phenyl} amino)methane-l -thione (183mg; 0.5mmol) and 3,5-dibenzyloxybenzaldehyde (159mg; 0.5mmol) to obtain a white solid. Yield: 132mg (40%). TLC (silica gel): Rf=0.84 The title compound was prepared using the procedure for Example 2 from ({(lE)-l-aza-
2-[3,5-bis(phenylmethoxy)phenyl]vinyl}amino)({3-[(2-phenylphenyl) methylthio]phenyl} amino)methane-l -thione (120mg; 0.18mmol) and iron(III) chloride hexahydrate (146mg; 0.54mmol). Yield: 85mg ( 71%). mp 128-130°C. Mass (elecfrospray):
(MH)+: 664 (Calc); 664 (Obsd.)4
Example 47:
{3-[(2-Phenylphenyl)methylthio]phenyl}{5-[2-(trifluoromethyl)phenyl](l,3,4-thiadiazol-2- yl)} amine
({(lE)-l-Aza-2-[2-(trifluoromethyl)phenyl]vinyl}amino)({3-[(2-phenylphenyl) . methylthio]phenyl}amino)methane-l-thione was prepared using the procedure for Example 2 from hydrazino({3-[(2-phenylphenyl)methylthio]phenyl}amino)methane-l-thione (183mg; 0.5mmol) and 2-(trifluoromethyl) benzaldehyde (0.7mL; 0.5mmol) to obtain a white solid. Yield: 104mg (40%). TLC (silica gel): Rf= 0.84.
{3-[(2-Phenylphenyl)methylthio]phenyl} {5-[2-(trifluoromethyl)phenyl](l,3,4-thiadiazol- 2-yl)}amine was prepared using the procedure for Example 2 from ({(lE)-l-aza-2-[2- (trifluoromethyl)phenyl]vinyl} amino)( {3-[(2-phenylphenyl)methylthio]phenyl} amino) methane- 1 -thione (94mg; 0.18mmol) and iron(III) chloride hexahydrate (146mg; 0.54mmol). Yield: 50mg (53%). mp 73-75°C. Mass (elecfrospray): (MH)+: 520.
Example 48: [5-(3-Nitrophenyl)(l,3,4-thiadiazol-2-yl)][3-(3-phenylpropylthio)phenyl]amine
The intermediate {[(lE)-l-Aza-2-(3-nifrophenyl)vinyl] amino} {[3-(3-phenylpropylthio) phenyl]amino}methane-l -thione was prepared using the procedure for Example 2 using hydrazino{[3-(3-phenylpropylthio)phenyl]amino}methane-l-thione (159mg; 0.5mmol) and 3- nifrobenzaldehyde (76mg; 0.5mmol) as a yellow solid. Yield: 194 mg (86%). TLC (silica gel): Rf= 0.78.
The title compound was prepared using the procedure for Example 2 from {[(lE)-l-aza- 2-(3-nifrophenyl)vinyl]amino}{[3-(3-phenylpropylthio)phenyl]amino}methane-l-thione (112.6mg; 0.25mmol) and iron(III) chloride hexahydrate (203mg; 0.75mmol). Yield: 945 mg (85%). mp l69-171°C. Mass: (MH)+: 449 (Calc); 449 (Obsd.). AA
Example 49: 4-({5-[3,5-bis(phenylmethoxy)phenyl]-l,3,4-thiadiazol-2-yl}amino)benzoic acid
Methyl 4-[(hydrazinothioxomethyl)ammo]benzoate was prepared using Procedure F from 4-methoxycarbonylphenyl isothiocyanate (193mg; lmmol) and hydrazine hydrate (O.lmL; 2mmol) as a white solid. Yield: 192mg (85%).
Methyl 4-{[({(lE)-l-aza-2-[3,5-bis(phenylmethoxy)phenyl]vinyl}amino)thioxomethyl] amino}benzoate was prepared using the procedure for Example 2 from methyl 4- [(hydrazinothioxomethyl) amino]benzoate (180mg; 0.8mmol) and 3,5-dibenzyloxybenzaldehyde (255mg; 0.8mmol) as a white solid. Yield: 302mg (72%). Methyl 4-({5-[3,5-bis(phenylmethoxy)phenyl]-l ,3,4-thiadiazol-2-yl}amino)benzoate was prepared using the procedure for Example 2 from methyl 4-{[({(lE)-l-aza-2-[3,5- bis(phenylmethoxy)phenyl]vinyl}amino) thioxomethyl]amino} benzoate (289mg; 0.55mmol) and iron(III) chloride hexahydrate (446mg; 1.65mmol). Yield: 226mg (78%). TLC (silica gel): Rf = 0.69.
The title compound was prepared as in Example 7 using methyl 4-({5-[3,5- bis(phenylmethoxy)phenyl]-l,3,4-thiadiazol-2-yl}amino)benzoate (lOOmg; 0.19mmol) and- lithium hydroxide (30mg; 1.25mmol). Yield: 94 mg (97%). mp 297-299°C. Mass (APCI): (MH)+: 510 (Calc); 510 (Obsd.).
Example 50:
Ammonium (2E)-3-{4-[5-({3-[(2-phenylphenyl)methylthio] phenyl}amino) (1,3,4-thiadiazol- 2-yl)] phenyl}prop-2-enoate
The product from Example 21 (20.5mg; 0.04mmol) was dissolved in ammonium hydroxide (5mL) and water (5mL). The mixture was stirred until all solid was in solution. The solvents were removed in vacuo to obtain the title compound as a yellow solid. Yield: 18.5mg
(87%). Mass: (MH)+: 522 (Calc); 522 (Obsd.).
Example 51:
{5-[3,5-bis(phenylmethoxy)phenyl](l,3,4-thiadiazol-2-yl)}{4-[3-(trifluoromethyl) phenoxy] phenyl} amine
4-[3-(trifluoromethyl)phenoxy]benzenisothiocyanate was prepared using Procedure C from 4-[3-(trifluoromethyl)phenoxy]phenylamine (883mg; 3.5mmol) and thiophosgene
(0.53mL; 7mmol) as a brown liquid. Yield: 900mg (87%).
Hydrazino({4-[3-(trifluoromethyl)phenoxy]phenyl}amino)methane-l-thione was prepared using Procedure F from 4-[3-(trifluoromethyl) phenoxy] benzenisothiocyanate (800mg;
2.7mmol) and hydrazine hydrate (0.26mL; 5.4mmol) as a white solid. Yield: 737mg (83%). ({(lE)-l-Aza-2-[3,5-bis(phenylmethoxy)phenyl]vinyl}amino)({4-[3-(trifluoromethyl) phenoxy]phenyl}ammo)methane-l -thione was prepared by the procedure for Example 2 using hydrazino({4-[3-(trifluoromethyl)phenoxy] phenyl} amino) methane- 1 -thione (327mg; lmmol) and 3,5-dibenzyloxybenzaldehyde (318mg; lmmol) as a white solid. Yield: 534mg (85%).
The title compound was prepared by the procedure for Example 2 from ({(lE)-l-aza-2- [3,5 -bis(phenylmethoxy)phenyl]vinyl} amino)( {4-[3 -(trifluoromethyl)phenoxy]phenyl} amino) methane- 1 -thione (377mg; 0.6mmol) and iron(III) chloride hexahydrate (486mg; l.δmmol).
Yield: 201mg (53%). mp 181-183°C. Mass (APCI): (MH)+: 626 (Calc); 626 (Obsd.). Example 52:
2-{4-[3-({5-[3,5-bis(phenylmethoxy)phenyI]-l,3,4-thiadiazol-2-yl}amino)phenoxy] phenyl} acetic acid Methyl 2-[4-(3-nifrophenoxy)phenyl]acetate was prepared using Procedure B from methyl-4-hydroxy phenylacetate (3.32g; 20mmol) and 3-bromo nitrobenzene (4.04g; 20mmol), Copper oxide (3.19g; 40mmol) and potassium carbonate (5.54g; 40mmol) inpyridine (20mL). Yield: 1.4g (25%).
Methyl 2-[4-(3-isothiocyanatophenoxy)phenyl]acetate was prepared as in Procedure C from the product of Procedure H (1.16g; 4.5mmol) and thiophosgene (0.69mL; 9mmol) in methylene chloride. Yield: 1.3 g (97%). TLC (silica gel): Rf=0.9 (EtOAc/Hexane=l/l).
Methyl 2-(4-{3-[(hydrazinothioxomethyl)amino]phenoxy}phenyl)acetate was prepared using Procedure F from methyl 2-[4-(3-isothiocyanato-phenoxy)phenyl]acetate (l.lg; 3.6mmol) and hydrazine hydrate (0.35mL; 7.2mmol) in toluene (lOmL). Yield: 1.05 g (88%). 1H NMR: (300 MHz, DMSO-d6) 9.20 δ (IH, s); 7.68 5 (IH, s); 7.29 δ (5H, m); 6.98 δ (2H, d); 6.71 δ (IH, d); 3.67 δ (2H, s) 3.62 δ (3H, s).
Methyl 2-[4-(3-{[({(lE)-l-aza-2-[3,5-bis(phenylmethoxy)phenyl]vinyl}amino) thioxomethyl]amino}phenoxy)phenyl]acetate was prepared as in Example 2 from methyl 2-(4- {3-[(hydrazinothioxomethyl)amino] phenoxy} phenyl)acetate (331mg; lmmol) and 3,5 dibenzyloxy benzaldehyde (318mg; lmmol) in ethanol (5mL). Yield: 490mg (77%). Mass (APCI): (MH)+: 632.
Methyl 2-{4-[3-({5-[3 , 5-bis(phenylmethoxy)phenyl] -1,3 ,4-thiadiazol-2-yl} amino) phenoxy]phenyl} acetate was prepared using the procedure as in Example 2 from methyl 2-[4-(3- { [( {(1 E)- 1 -aza-2- [3 ,5 -bis(phenylmethoxy)phenyl]vinyl} amino)thioxomethyl]amino}phenoxy)phenyl]acetate (379mg; 0.6mmol) and Iron chloride (486mg; 1.8mmol) in Ethanol. Yield: 146mg (37%). Mass (APCI): (MH)+: 630.
The title compound was prepared as in Example 7 from methyl 2-{4-[3-({5-[3,5- bis(phenylmethoxy)phenyl]-l,3,4-thiadiazol-2-yl} amino) phenoxy]phenyl} acetate (lOOmg; 0.16mmol) and lithium hydroxide (24mg; lmmol). Yield: 33mg (34%). 1H NMR: (300 MHz, DMSO-d6) 12.30 δ (IH, b); 10.66 δ (IH, s); 7.38 δ (15H, m); 7.28 5 (4H, d); 6.82 δ (IH, s); 6.25 δ (IH, d) 5.18 δ (4H, s); 3.57 5 (2H, d). Mass: (MH)+: 616 (Calc); 616 (Obsd.). Example 53: N2-(3-chloro-4-bromophenyl)-5-(3-ethoxyphenyl)-l,3,4-thiadiazol-2-amine
3-chloro-4-bromophenyl isothiocyanate and 3-ethoxybenzhydrazide were combined as described in Example 1 to yield the title compound with an overall yield of 69%. 'HNMR (DMSO-de) δ 1.36 (t, 3H), 4.12 (q, 2H), 7.08 (m, IH), 7.43 (m, 4H), 7.72 (d, IH), 8.13 (d, IH).
13C NMR (DMSO-d6) δ 14.6, 63.3, 112.1, 112.7, 116.6, 117.8, 118.6, 119.4, 130.5, 131.2, 133.3, 134.0, 140.8, 158.5, 158.9, 163.4.
Example 54:
(3-nitrophenyl) [5-(3-nitrophenyl)(l,3,4-thiadiazol-2-yl)] amine
The title compound was prepared as described in Example 1 from 3- nifrobenzenecarbohydrazide (500mg) and 3-nifrobenzenisothiocyanate (500mg). The title compound had the following physical properties: mp 325-330°C (decomposition).
Example 55: (2-chloro-5-nitrophenyl)[5-(3-ethoxyphenyl)(l,3,4-thiadiazol-2-yl)]amine
The title compound was prepared as described in Example 1 from 2-chloro-5- nifrobenzenisothiocyanate (lOOmg) and 3-ethoxybenzenecarbohydrazide (90mg). The title compound had the following physical properties: mp 128-130°C.
Example 56: [5-(3-methoxyphenyl)(l,3,4-thiadiazol-2-yl)](3-nitrophenyl)amine The title compound was prepared as described in Example 1 from 3- nifrobenzenisothiocyanate (lOOmg) and 3-methoxybenzenecarbohydrazide (lOOmg). The title compound had the following physical properties: mp 206-208°C. Example 57: [5-(3-ethoxyphenyl)(l,3,4-thiadiazol-2-yl)](3-nitrophenyl)amine
The title compound was prepared as described in Example 1 from 3- nifrobenzenisothiocyanate (lOOmg) and 3-ethoxybenzenecarbohydrazide (lOOmg). The title compound had the following physical properties: mp 155-157°C.
Example 58: [5-(3-methylphenyl)(l,3,4-thiadiazol-2-yl)](3-nitrophenyl)amine
The title compound was prepared as described in Example 1 from 3- nifrobenzenisothiocyanate (lOOmg) and 3-methylbenzenecarbohydrazide (90mg). The title compound had the following physical properties: mp 219-221°C.
Example 59: [5-(3-nitrophenyl)(l,3,4-thiadiazol-2-yl)][3-(trifluoromethyl)-phenyl]amine The title compound was prepared as described in Example 1 from
3-(trifluoromethyl)benzenisothiocyanate (250mg) and 3-nifrobenzenecarbohydrazide (200mg). The title compound had the following physical properties: mp 266-268°C.
Example 60: (4-ethylphenyl) [5-(3-nitrophenyl)(l,3,4-thiadiazol-2-yl)] amine
The title compound was prepared as described in Example 1 from 3- ethylbenzenisothiocyanate (200mg) and 3-nifrobenzenecarbohydrazide (200mg). The title compound had the following physical properties: mp 208-210°C.
Example 61:
(3-methoxyphenyl)[5-(3-mtrophenyl)(l,3,4-thiadiazol-2-yl)]amine
The title compound was prepared as described in Example 1 from 3- methoxybenzenisothiocyanate (220mg) and 3-nifrobenzenecarbohydrazide (200mg). The title compound had the following physical properties: mp 207-209°C. Example 62: (4-nitrophenyl)[5-(3-nitrophenyl)(l,3,4-thiadiazoI-2-yl)]amine
The title compound was prepared as described in Example 1 from 4-nifrobenzenisothiocyanate (220mg) and 3-nifrobenzenecarbohydrazide (200mg). The title compound had the following physical properties: mp 327-329°C.
Example 63: (3-bromophenyl)[5-(3-methoxyphenyl)(l,3,4-thiadiazol-2-yl)]amine
The title compound was prepared as described in Example 1 from 3-bromobenzenisothiocyanate (320mg) and 3-methoxybenzenecarbohydrazide (250mg). The title compound had the following physical properties: LC-MS 364.6.
Example 64: (2,5-dibromophenyl)[5-(3-nitrophenyl)(l,3,4-thiadiazol-2-yl)]amine The title compound was prepared as described in Example 1 from 2,5- dibromobenzenisothiocyanate (300mg) and 3-nifrobenzenecarbohydrazide (190mg). The title compound had the following physical properties: LC-MS 457.4.
Example 65: (4-bromophenyl) [5-(3-nitrophenyl)(l,3,4-thiadiazol-2-yl)] amine
The title compound was prepared as described in Example 1 from 4- bromobenzenisothiocyanate (500mg) and 3-nifrobenzenecarbohydrazide (400mg). The title compound had the following physical properties: LC-MS 377.4.
Example 66:
(4-bromo-3-chlorophenyl)[5-(3-ethoxyphenyl)(l,3,4-thiadiazol-2-yl)]amine
The title compound was prepared as described in Example 1 from 4-bromo-3- chlorobenzenisothiocyanate (500mg) and 3-ethoxybenzenecarbohydrazide (300mg). The title compound had the following physical properties: mp 204-205°C; LC-MS 410.6. Example 67: (3-chloro-4-fluorophenyl)[5-(3-nitrophenyl)(l,3,4-thiadiazol-2-yl)]amine
The title compound was prepared as described in Example 1 from 3-chloro-4- fluorobenzenisothiocyanate (570mg) and 3-nifrobenzenecarbohydrazide (500mg). The title compound had the following physical properties : LC-MS 351.3.
Example 68: (3-chloro-4-fluorophenyl)[5-(3-methoxyphenyl)(l,3,4-thiadiazol-2-yl)]amine
The title compound was prepared as described in Example 1 from 3-chloro-4- fluorobenzenisothiocyanate (620mg) and 3-methoxybenzenecarbohydrazide (500mg). The title compound had the following physical properties: mp 185-187°C; LC-MS 336.7.
Example 69:
(4-bromo-3-chlorophenyl)[5-(3-methoxyphenyl)(l,3,4-thiadiazol-2- yl)] amine
The title compound was prepared as described in Example 1 from 4-bromo-3- chlorobenzenisothiocyanate (650mg) and 3-methoxybenzenecarbohydrazide (400mg). The title compound had the following physical properties: mp 215-217°C; LC-MS 398.1.
Example 70:
(3-chloro-4-fluorophenyl)[5-(3-ethoxyphenyl)(l,3,4-thiadiazol-2-yl)]amine
The title compound was prepared as described in Example 1 from 3-chloro-4- fluorobenzenisothiocyanate (260mg) and 3-ethoxybenzenecarbohydrazide (250mg). The title compound had the following physical properties: mp 170-172°C; LC-MS 350.5.
Example 71:
(4-bromo-3-methylphenyl) [5-(3-ethoxyphenyl)(l ,3,4-thiadiazol-2-yl)] amine
The title compound was prepared as described in Example 1 from 4-bromo-3- methylbenzenisothiocyanate (700mg) and 3-ethoxybenzenecarbohydrazide (500mg). The title compound had the following physical properties: mp 201-202°C; LC-MS 392.1. Example 72: (4-bromo-3-methylphenyl)[5-(3-methoxyphenyl)(l,3,4-thiadiazol-2-yl)]amine
The title compound was prepared as described in Example V from 4-bromo-3- methylbenzenisothiocyanate (760mg) and 3-methoxybenzenecarbohydrazide (500mg). The title compound had the following physical properties: mp 190-192°C; LC-MS 378.4.
Example 73: (4-bromo-3-methylphenyl)[5-(3-nitrophenyl)(l,3,4-thiadiazol-2-yl)]amine
The title compound was prepared as described in Example 1 from 4-bromo-3- methylbenzemsothiocyanate (690mg) and 3-nifrobenzenecarbohydrazide (500mg). The title compound had the following physical properties: LC-MS 391.4.
Example 74: (3-bromophenyl)[5-(3-ethoxyphenyl)(l,3,4-thiadiazol-2-yl)]amine The title compound was prepared as described in Example 1 from 3- bromobenzenisothiocyanate (650mg) and 3-ethoxybenzenecarbohydrazide (500mg). The title compound had the following physical properties: mp 195-197°C; LC-MS 376.5.
Example 75: Methyl 3-{[5-(3-nitrophenyl)-l,3,4-thiadiazol-2-yl]ammo}benzoate
The title compound was prepared as described in Example 1 from methyl 3- isothiocyanatobenzoate (500mg) and 3-nitoobenzenecarbohydrazide (500mg). The title compound had the following physical properties: LC-MS 357.5.
Example 76:
(2,3-dichlorophenyl)[5-(3-nitrophenyl)(l,3,4-thiadiazol-2-yl)]amine
The title compound was prepared as described in Example 1 from 2,3- dichlorobenzenisothiocyanate (620mg) and 3-nifrobenzenecarbohydrazide (500mg). The title compound had the following physical properties: mp 240-242°C; LC-MS 367.3. Example 77: (3,4-dibromophenyl)[5-(3,5-dimethoxyphenyl)(l,3,4-thiadiazol-2-yl)]amine
The title compound was prepared as described in Example 1 from 3,4- dibromobenzenisothiocyanate (280mg) and 3,5-dimethoxybenzenecarbohydrazide (220mg). The title compound had the following physical properties: mp 240-242°C; LC-MS 426.1.
Example 78: [5-(3-ethoxyphenyl)(l,3,4-thiadiazol-2-yl)](3-nitrophenyl)amine.
The title compound was prepared as described in Example 1 from 3- nifrobenzenisothiocyanate (4.0g) and 3-ethoxybenzenecarbohydrazide (4.1g). The title compound had the following physical properties: mp 183-185°C.
Example 79: (5-benzo[3,4-c]l,2,5-oxadiazol-5-yl(l,3,4-thiadiazol-2-yl))(2,3-dichlorophenyl)amine The title compound was prepared as described in Example 1 from 3-methyl-4- bromobenzenisothiocyanate (80mg) andbenzo[c]l,2,5-oxadiazole-5-carbohydrazide (53mg). The title compound had the following physical properties: mp 229-231°C.
Example 80: (3-bromophenyl)[5-(3-nitrophenyl)(l,3,4-thiadiazol-2-yl)]amine
The title compound was prepared as described in Example 1 from 3- bromobenzenisothiocyanate (1.3g) and 3-nifrobenzenecarbohydrazide (l.Og). The title compound had the following physical properties: mp 273-275°C; LC-MS 376.88.
Example 81:
[5-({2-[(4,5-dichloroimidazolyl)methyl]phenoxy}methyl)(l,3,4-thiadiazol-2-yl)](4-bromo-3- chlorophenyl)amine
Following the procedure described in Example 1, the title compound was prepared from 4-bromo-3-chlorobenzenisothiocyanate (430mg) and 2-{2-[(4,5-dichloroimidazolylthio)methyl] phenoxy} acetohydrazide (500mg). The title compound had the following physical properties: mp 183-185°C. Example 82:
[(4-methylphenyl)sulfonyl](4-{[5-(3-nitrophenyl)(l,3,4-thiadiazol-2-yl)]amino}phenyl) amine
Following the procedure described in Example 10 (with sulfonyl chloride in place of acyl chloride), the title compound was prepared from (4-{[5-(3-nifrophenyl)(l,3,4-thiadiazol-2- yl)]amino}phenyl)amine (lOOmg) and 4-toluenesulfonyl chloride (96mg). The title compound had the following physical properties: mp 255-257°C.
Example 83: (4-{[5-(3-ethoxyphenyl)(l,3,4-thiadiazol-2-yl)]amino}phenyl)-(phenylsulfonyl)amine
As described in Example 10 (with sulfonyl chloride in place of acyl chloride), the title compound was prepared from (4-{[5-(3-ethoxyphenyl)(l,3,4-thiadiazol-2-yl)]amino}phenyl) amine (lOOmg) and benzenesulfonyl chloride (lOOmg). The title compound had the following physical properties: mp 216-218°C.
Example 84:
[(4-{ [5-(3-Nitrophenyl)-l ,3,4-thiadiazol-2-yl] amine}phenyl)sulf onyl] pip eridine
The reactions described in Example 1 were repeated using 3-nifrobenzenecarbohydrazide (362mg; 2.0mmol) and 4-(piperidylsulfonyl) benzenisothiocyanate (565mg; 2.0mmol) to yield (3 -nitrophenyl)-N- [( { [4-(piperidylsulfonyl)phenyl] amino} thioxomethyl)amino] carboxamide (910mg, 98%) in the first step. In the second step, (3-nifrophenyl)-N-[({[4- (piperidylsulfonyl)phenyl]amino}thioxomethyl)amino]carboxamide (800mg; 1.7mmol) and sulfuric acid (2.0mL) were used to yield the title compound (751mg; 98%) with the following physical properties: mp 266-267°C; Mass (M+l)+ 446 (Calc); 446 (Obsd.). (A&A)
Example 85: (4-Bromo-3-chlorophenyl)[5-(3-nitrophenyl)(l,3,4-thiadiazol-2-yl)amine
The reactions described in Example 1 were repeated using 3-nifrobenzenecarbohydrazide (362mg; 2.0mmol) and 4-bromo-3-chlorobenzenisothiocyanate (497mg; 2.0mmol) to yield N- ({[(4-bromo-3-chlorophenyl)amino]thioxo-methyl}amino)(3-nifrophenyl)carboxamide (810mg; 94%) in the first step. In the second step, N-({[(4-bromo-3- chlorophenyl)amino]thioxomethyl}amino)(3-nifrophenyl)carboxamide (750mg; 1.7mmol) and sulfuric acid (2.0mL) were used to yield the title compound (698mg; 97%) with the following physical properties: mp 330-331°C; Mass (M+l)+ 413 (Calc); 413 (Obsd.). (A&A)
Example 86: [5-(3-Nitrophenyl)(l,3,4-thiadiazol-2-yl) (2,3,4,5-tetrachlorophenyl)amine
The reactions described in Example 1 were repeated using 3-nifrobenzenecarbohydrazide (362mg; 2.0mmol) and 2,3,4,5-tetrachlorobenzenisothiocyanate (546mg; 2.0mmol) to yield (3- nifrophenyl)-N-({[(2,3,4,5-tefrachlorophenyl)amino] thioxomethyl} amino) carboxamide (690mg; 76%) in the first step. In the second step, (3-nifrophenyl)-N-({[(2,3,4,5- tefrachlorophenyl)amino]thioxomethyl} amino) carboxamide (550mg; 1.2mmol) and sulfuric acid (2.0mL) were used to yield the title compound (516mg; 98%) with the following physical properties: p 250-251°C; Mass (M+l)+ 437 (Calc); 437 (Obsd.). (A&A)
Example 87: (3-Chloro-4-methylphenyl)[5-(3-nitrophenyl)(l,3,4-thiadiazol-2-yl)amine
The reactions described in Example 1 were repeated using 3-nifrobenzenecarbohydrazide (362mg; 2.0mmol) and 3-chloro-4-methylbenzenisothiocyanate (367mg; 2.0mmol) to yield N- ({[(3-chloro-4-methylphenyl)amino]thioxomethyl}amino)-(3-niteophenyl)carboxamide (700mg; 96%) in the first step. In the second step, N-({[(3-chloro-4-methylphenyl)amino]thioxomethyl} amino)(3-nifrophenyl)carboxamide (550mg; 1.5mmol) and sulfuric acid (2.0mL) were used to yield the title compound (486mg; 93%) with the following physical properties: mp 289-290°C; Mass (M)+ 347 (Calc); 347 (Obsd.); Elemental analysis C 51.95, H 3.20, N 16.16, S 9.25 (Calc); C52.12, H 3.16, N 16.16, S 9.42 (Obsd.). (NuMega) Example 88: (4-Methylthiophenyl)[5-(3-nitrophenyl)(l,3,4-thiadiazol-2-yl)amine
The reactions described in Example 1 were repeated using 3-nifrobenzenecarbohydrazide (362mg; 2.0mmol) and 4-methylthiobenzenisothiocyanate (362mg; 2.0mmol) to yield N-({[(4- methylthiophenyl)amino]thioxomethyl}amino)(3-nifrophenyl)carboxamide (710 mg; 98%) in the first step. In the second step, N-({[(4-methylthiophenyl)amino]thioxomethyl}amino)(3- nifrophenyl)carboxamide (600mg; 1.7mmol) and sulfuric acid (2.0mL) were used to yield the title compound (528mg; 93%) with the following physical properties: mp 247-248°C; Mass (M+l)+ 345 (Calc); 345 (Obsd.). (NuMega)
Example 89:
[4-(Methylethyl)phenyl] [5-(3-nitrophenyl)(l,3,4-thiadiazol-2-yl)amine
The reactions described in Example 1 were repeated using 3-nifrobenzenecarbohydrazide (362mg; 2.0mmol) and 4-(methylethyl)benzenisothiocyanate (354mg; 2.0mmol) to yield N- ({[(4-(methylethyl)phenyl)amino]thioxomethyl}amino)-(3-nifrophenyl)carboxamide (680mg; 94%) in the first step. In the second step, N-({[(4-(methylethyl)phenyl)amino]thioxomethyl} amino)-(3-nifrophenyl)carboxamide (600mg; 1.7mmol) and sulfuric acid (2.0mL) were used to yield the title compound (516mg; 90%) with the following physical properties: mp 243-244°C; Mass (M+l)+ 341 (Calc); 341 (Obsd.); (M+23)+ 363 (Calc); 363 (Obsd.). (NuMega)
Example 90:
(4-Butylphenyl) [5-(3-nitrophenyl)(l,3,4-thiadiazol-2-yl)amine
The reactions described in Example 1 were repeated using 3-nifrobenzenecarbohydrazide (362mg; 2.0mmol) and 4-butylbenzenisothiocyanate (383mg; 2.0mmol) to yield N-({[(4- butylphenyl)amino]thioxomethyl}amino)(3-niteophenyl)carboxamide (680mg; 92%) in the first step. In the second step, N-({[(4-butylphenyl)amino]thioxomethyl}amino)(3- nifrophenyl)carboxamide (500mg; 1.3mmol) and sulfuric acid (2.0mL) were used to yield the title compound (428mg; 90%) with the following physical properties: mp 198-199°C; Mass (M+l)+ 355 (Calc); 355 (Obsd.). (A&A) Example 91: (4-Decylphenyl)[5-(3-nitrophenyl)(l,3,4-thiadiazol-2-yl)amine
The reactions described in Example 1 were repeated using 3-nifrobenzenecarbohydrazide (154mg; O.δmmol) and 4-decylbenzenisothiocyanate (237mg; 0.8 mmol) to yieldN-({[(4- decylphenyl)amino]thioxomethyl}amino)-(3-nifrophenyl)carboxamide (340 mg; 81%) in the first step. In the second step, N-({[(4-decylphenyl)ammo]thioxomethyl}amino)-(3- nifrophenyl)carboxamide (300mg; 0.7mmol) and sulfuric acid (2.0mL) were used to yield the title compound (264mg; 92%) with the following physical properties: mp 169-171°C; Mass (M+l)+ 440 (Calc); 440 (Obsd.). (A&A)
Example 92:
[5-(3-Nitrophenyl)(l,3,4-thiadiazol-2-yl) [4-(4-nitrophenoxy)phenyl] amine
The reactions described in Example 1 were repeated using 3-nifrobenzenecarbohydrazide (362mg; 2.0mmol) and 4-(4-nifrophenoxy)benzenisothiocyanate (545mg; 2.0mmol) to yield (3- nifrophenyl)-N-[({[4-(4-nitrophenoxy)ρhenyl]amino}thioxomethyl)amino]carboxamide (890mg; 98%) in the first step. In the second step, (3-nifrophenyl)-N-[({[4-(4- nitrophenoxy)phenyl]amino}thioxomethyl)amino]carboxamide (500mg; 1. lmmol) and sulfuric acid (2.0mL) were used to yield the title compound (480mg; 100%) with the following physical properties: mp 285-286°C; Mass (M+l)+ 436 (Calc); 436 (Obsd.). (A&A)
Example 93: [(4-{[5-(3-Methoxyphenyl)-l,3,4-thiadiazol-2-yl]amine}phenyl)sulfonyl]piperidine
The reactions described in Example 1 were repeated using 3- methoxybenzenecarbohydrazide (332mg; 2.0mmol) and 4-(piperidylsulfonyl) benzenisothiocyanate (565mg; 2.0mmol) to yield (3-methoxyphenyl)-N-[({[4-
(piperidylsulfonyl)phenyl]amino}thioxomethyl)amino]carboxamide (775mg; 86%) in the first step. In the second step, (3-methoxyphenyl)-N-[({[4-
(piperidylsulfonyl)phenyl]amino}thioxomethyl)amino]carboxamide (500mg; 1. lmmol) and sulfuric acid (2.0mL) were used to yield the title compound (751mg; 98%) with the following physical properties: mp 205-206°C; Mass (M+l)+ 432 (Calc); 432 (Obsd.). (A&A) Example 94: [(4-{[5-(3-Methylphenyl)-l,3,4-thiadiazol-2-yl]amine}phenyl)sulfonyl]piperidine
The reactions described in Example 1 were repeated using 3-nifrobenzenecarbohydrazide (300mg; 2.0mmol) and 4-(piperidylsulfonyl) benzenisothiocyanate (565mg; 2.0mmol) to yield (3-methylphenyl)-N-[({[4-(piperidylsulfonyl)phenyl]amino}thioxomethyl)amino]carboxamide (757mg; 88%) in the first step. In the second step, (3-methylphenyl)-N-[({[4- (piperidylsulfonyl)phenyl]amino}thioxomethyl)amino]carboxamide (500mg; 1.2mmol) and sulfuric acid (2.0mL) were used to yield the title compound (751mg; 98%) with the following physical properties: mp 213-214°C; Mass (M+l)+ 415 (Calc); 415 (Obsd.). (A&A)
Example 95: (5-Chloro-2,4-dimethoxyphenyl)[5-(3-nitrophenyl)(l,3,4-thiadiazol-2-yl)] amine
The reactions described in Example 1 were repeated using 3-nifrobenzenecarbohydrazide (362mg; 2.0mmol) and 5-chloro-2,4-dimethoxybenzenisothiocyanate (459mg; 2.0mmol) to yield N-({[(5-chloro-2,4-dimethoxyphenyl)amino]thioxomethyl}amino)(3-nitrophenyl)carboxamide , (796mg; 97%) in the first step. In the second step, N-({[(5-chloro-2,4- dimethoxyphenyl)amino]thioxomethyl}amino)(3-nifrophenyl)carboxamide (550mg; 1.3mmol) and sulfuric acid (2.0mL) were used to yield the title compound (470mg; 89%) with the following physical properties: mp 218-219°C; Mass (M)+ 393 (Calc); 393 (Obsd,). (A&A)
Example 96: (3-Chloro-4-methylphenyl){5-[3-(phenylmethoxy)phenyl](l,3,4-thiadiazol-2-yl)} amine
As described in Procedure D, [(3-chloro-4-methylphenyl)amino]hydrazinomethane-l- thione (3.38g, 78%) was prepared from 3-chloro-4-methylbenzenisothiocyanate (3.67g; 20mmol) and hydrazine monohydrate (1.50g; 30mmol).
The reactions described in Example 2 were repeated using [(3-chloro-4- methylphenyl)amino]hydrazinomethane-l -thione (216mg; Ommol) and 3- (phenylmethoxy)benzaldehyde (212mg; Ommol) to yield ({l-aza-2-[3- (phenylmethoxy)phenyl]vinyl}amino)[(3-chloro-4-methylphenyl)amino]methane-l-thione (320mg; 78%) in the first step. In the second step, ({l-aza-2-[3-
(phenylmethoxy)phenyl] vinyl} amino) [(3 -chloro-4-methylphenyl)amino]methane- 1 -thione (205mg; 0.5mmol) and iron (III) chloride hexahydrate (405mg; 1.5mmol) were used to yield the title compound (80mg, 39%) with the following physical properties: mp 211-212°C; Mass (M)+ 408 (Calc); 408 (Obsd.). (A&A)
Example 97: (3-Chloro-4-methylphenyl)[5-(4-morpholin-4-yl-3-nitrophenyl)(l,3,4-thiadiazol-2-yl)]amine
The reactions described in Example 2 were repeated using [(3-chloro-4- methylphenyl)amino]hydrazinomethane-l -thione (216mg; Ommol) and 4-morpholin-4-yl-3- nifrobenzaldehyde (236mg; l.Ommol) to yield {[l-aza-2-(4-moφholin-4-yl-3- nifrophenyl)vinyl]amino}[(3-chloro-4-methylphenyl)amino]methane-l-thione (330mg, 77%) in the first step. In the second step, {[l-aza-2-(4-morpholin-4-yl-3-nifrophenyl)vinyl]amino}[(3- chloro-4-methylphenyl)amino]methane-l -thione (217mg; 0.5mmol) and iron (III) chloride hexahydrate (405mg; 1.5mmol) were used to yield the title compound (83mg, 38%) with the following physical properties: mp 268-269°C; Mass (M)+ 432 (Calc); 432 (Obsd.). (A&A)
Example 98: 2-(3-{5-[(3-Chloro-4-methylphenyl)amino]-l,3,4-thiadiazol-2-yl}phenoxy)ethan-l-oI
The reactions described in Example 2 were repeated using [(3-chloro-4- methylphenyl)amino]hydrazinomethane-l -thione (216mg; Ommol) and 3-(2- hydroxyethoxy)benzaldehyde (166mg; Ommol) to yield 2-{3-[2-aza-2-({[(3-chloro-4- methylphenyl)amino]thioxomethyl}amino)vinyl]phenoxy}ethan-l-ol (145mg, 40%) in the first step. In the second step, 2-{3-[2-aza-2-({[(3-chloro-4-methylphenyl)amino]thioxomethyl} amino)vinyl]phenoxy}ethan-l-ol (104mg; 0.3mmol) and iron (III) chloride hexahydrate (243mg; 0.9mmol) were used to yield the title compound (42mg, 23%) with the following physical properties: mp 193-194°C; Mass (M+l)+ 363 (Calc); 363 (Obsd.). (A&A)
Example 99: (3-Chloro-4-methylphenyl){5-[4-(trifluoromethylthio)phenyl](l,3,4-thiadiazol-2-yl)} amine
The reactions described in Example 2 were repeated using [(3-chloro-4- methylphenyl)amino]hydrazinomethane- 1 -thione (216mg; 1. Ommol) and 4-
(trifluoromethylthio)benzaldehyde (206mg; Ommol) to yield ({l-aza-2-[4-
(trifluoromethylthio)phenyl] vinyl} amino) [(3 -chloro-4-methylphenyl)amino]methane- 1 -thione
(268mg, 66%) in the first step. In the second step, ({l-aza-2-[4-
(trifluoromethylthio)phenyl] vinyl} amino) [(3 -chloro-4-methylphenyl)amino]methane- 1 -thione (202mg; 0.5mmol) and iron (III) chloride hexahydrate (405mg; 1.5mmol) were used to yield the title compound (89mg, 44%) with the following physical properties: mp 215-216°C; Mass (M)+
402 (Calc); 402 (Obsd.). (A&A)
Example 100: [(4-{[5-(4-Bromo-3-chlorophenyl)-l,3,4-thiadiazol-2-yl]amine}phenyl)sulfonyl]piperidine
The reactions described in Example 1 were repeated using l-bromo-2-chlorobenzene-4- carbohydrazide (250mg; Ommol) and 4-(piperidylsulfonyl) benzenisothiocyanate (282mg; Ommol) to yield (4-bromo-3-chlorophenyl)-N-[({[4-(piperidylsulfonyl)phenyl]amino} thioxomethyl)amino]carboxamide (511mg, 96%) in Hie first step. In the second step, (4-bromo- 3-chlorophenyl)-N-[({[4-(piperidylsulfonyl)phenyl]amino}thioxomethyl)amino]carboxamide (800mg; 1.7mmol) and sulfuric acid (2.0mL) were used to yield the title compound (394mg; 90%) with the following physical properties: mp 262-263°C; Mass (M+l)+ 515 (Calc); 515 (Obsd.). (A&A)
Example 101: [(4-{[5-(3-Bromo-4-chlorophenyl)-l,3,4-thiadiazol-2-yl]amine}phenyl)sulfonyl]piperidine
The reactions described in Example 1 were repeated using 2-bromo-l-chlorobenzene-4- carbohydrazide (250mg; LOmmol) and 4-(piperidylsulfonyl) benzenisothiocyanate (282mg; 1. Ommol) to yield (3 -bromo-4-chlorophenyl)-N- [( { [4-
(piperidylsulfonyl)phenyl]amino}thioxomethyl)amino]carboxamide (510mg; 96%) in the first step. In the second step, (3-bromo-4-chlorophenyl)-N-[({[4-(piperidylsulfonyl)phenyl]amino} thioxomethyl)amino]carboxamide (450mg; 0.8mmol) and sulfuric acid (2.0mL) were used to yield the title compound (412mg; 95%) with the following physical properties: mp 246-247°C; Mass (M+l)+ 515 (Calc); 515 (Obsd.). (A&A)
Example 102: (3-Chloro-4-methylphenyl){5-[3-(trifluoromethoxy)phenyl](l,3,4-thiadiazol-2-yl)}amme
The reactions described in Example 2 were repeated using [(3-chloro-4- methylphenyl)amino]hydrazinomethane-l -thione (216mg; Ommol) and 3- (trifluoromethoxy)benzaldehyde (190mg; Ommol) to yield ({l-aza-2-[3-
(trifluoromethoxy)phenyl] vinyl} amino) [(3 -chloro-4-methylphenyl)amino]methane- 1 -thione (262mg; 68%) in the first step. In the second step, ({l-aza-2-[3-
(trifluoromethoxy)phenyl]vinyl} amino) [(3 -chloro-4-methylphenyl)amino]methane- 1 -thione (194mg; 0.5mmol) and iron (III) chloride hexahydrate (405mg; 1.5mmol) were used to yield the title compound (46mg; 32%) with the following physical properties: mp 180-181°C; Mass (M)+ 386 (Calc); 386 (Obsd.). (A&A)
Example 103:
(5-{3-[4-(tert-Butyl)phenoxy]phenyl}(l,3,4-thiadiazol-2-yl))(3-chloro-4-methylphenyl) amine
The reactions described in Example 2 were repeated using [(3-chloro-4- methylphenyl)amino]hydrazinomethane-l -thione (216mg; Ommol) and 3-[4-(tert- butyl)phenoxy]benzaldehyde (254mg; Ommol) to yield [(l-aza-2-{3-[4-(tert- butyl)phenoxy]phenyl}vinyl)amino][(3-chloro-4-methylphenyl)amino]methane-l-thione (333mg; 74%) in the first step. In the second step, [(l-aza-2-{3-[4-(tert- butyl)phenoxy]phenyl}vinyl)ammo][(3-chloro-4-methylphenyl)amino]methane-l-thione (226mg; 0.5mmol) and iron (III) chloride hexahydrate (405mg; 1.5mmol) were used to yield the title compound (50mg, 22%) with the following physical properties: mp 187-189°C; Mass (M) 450 (Calc); 450 (Obsd.). (A&A)
Example 104: (3,4-Dichlorophenyl){5-[4-methoxy-3-(phenylmethoxy)phenyl](l,3,4-thiadiazol-2-yl)}amine
The reactions described in Example 2 were repeated using the product from Procedure D (236mg; Ommol) and 4-methoxy-3-(phenylmethoxy)benzaldehyde (242mg; Ommol) to yield ({l-aza-2-[4-methoxy-3-(phenylmethoxy)phenyl]vinyl}amino)[(3,4-dichlorophenyl)amino] methane- 1 -thione (439mg; 95%) in the first step. In the second step, ({l-aza-2-[4-methoxy-3- (phenylmethoxy)phenyl]vinyl}amino)[(3,4-dichlorophenyl)amino]methane-l-thione (322mg; 0.7mmol) and iron (III) chloride hexahydrate (568mg; 2. lmmol) were used to yield the title compound (127mg; 40%) with the following physical properties: mp 223-224°C; Mass (M+l)+ 459 (Calc); 459 (Obsd.). (A&A)
Example 105: (3,4-Dichlorophenyl){5-[4-(difluoromethoxy)phenyl](l,3,4-thiadiazol-2-yl)} amine
The reactions described in Example 2 were repeated using the product from Procedure D (236mg; Ommol) and 4-(difluoromethoxy)benzaldehyde (172mg; Ommol) to yield ({l-aza-2-
[4-(difluoromethoxy)phenyl] vinyl} amino) [(3 -chloro-4-methylphenyl)amino]methane- 1 -thione
(332mg, 85%) in the first step. In the second step, ({l-aza-2-[4-
(difluoromethoxy)phenyl] vinyl} amino) [(3 -chloro-4-methylphenyl)amino]methane- 1 -thione
(234mg; O.δmmol) and iron (III) chloride hexahydrate (486mg; 1.8mmol) were used to yield the title compound (134mg; 58%) with the following physical properties: mp 265-266°C; Mass (M)+
388 (Calc); 388 (Obsd.). (A&A)
Example 106: (3,4-Dichlorophenyl)[5-(4-butoxyphenyl)(l,3,4-thiadiazol-2-yl)]amine The reactions described in Example 2 were repeated using the product from Procedure D
(236mg; Ommol) and 4-butoxybenzaldehyde (178mg; Ommol) to yield {[l-aza-2-(3- butoxyphenyl)vinyl]amino} [(3 ,4-dichlorophenyl)amino]methane-l -thione (303mg; 76%) in the first step. In the second step, {[l-aza-2-(3-butoxyphenyl)vinyl]amino}[(3,4- dichlorophenyl)amino]methane-l -thione (238mg; 0.6mmol) and iron (III) chloride hexahydrate (486mg; 1.8mmol) were used to yield the title compound (112mg; 47%) with the following physical properties: mp 233-235°C; Mass (M)+ 394 (Calc); 394 (Obsd.). Example 107:
2-(4-{5-[(3,4-Dichlorophenyl)amino](l,3,4-thiadiazol-2-yl)}phenoxy)-l-(4- methylpiperidyl)ethan-l-one
The reactions described in Example 2 were repeated using the product from Procedure D (2.36g; lO.Ommol) and 2-(3-formylphenoxy)acetic acid (1.80g; lO.Ommol) to yield 2-{3-[2-aza-
2-({ [(3 ,4-dichlorophenyl)amino]thioxomethyl}amino)vinyl]phenoxy} acetic acid (4.05g; 95%) in the first step. In the second step, 2-{3-[2-aza-2-({[(3,4- dichlorophenyl)amino]thioxomethyl}amino)vinyl]phenoxy} acetic acid (3.38g; 7.9mmol) and iron (III) chloride hexahydrate (6.43g; 25.0mmol) were used to yield ethyl 2-(3-{5-[(3,4- dichlorophenyl)amino]-l,3,4-thiadiazol-2-yl}phenoxy)acetate (2.16g; 64%).
A solution of 4-methylpiperidine (1.98g; 20mmol) and ethyl 2-(3-{5-[(3,4- dichlorophenyl)amino]-l,3,4-thiadiazol-2-yl}phenoxy)acetate (420mg; lmmol) in ethanol
(lOmL) was refluxed for 24 hours. After cooling, a white solid was provided (280mg, 59%): mp
219-220°C; Mass (M)+ 477 (Calc); 477 (Obsd.).
Example 108:
(5-{3-[4-(tert-Butyl)phenoxy]phenyl}(l,3,4-thiadiazol-2-yl))indan-2-ylamine
As described in Procedure D, hydrazino(indan-2-ylammo)methane-l -thione (2.07g;
100%) was prepared from indan-2-isothiocyanate (1.75g; lO.Ommol) and hydrazine monohydrate (750mg; 15.0mmol).
The reactions described in Example 2 were repeated using of hydrazino(indan-2- ylamino)methane-l -thione (415mg; 2.0mmol) and 3-[4-(tert-butyl)phenoxy]benzaldehyde
(509mg; 2.0mmol) to yield [(l-aza-2-{3-[4-(tert-butyl)phenoxy]phenyl}vinyl)amino](indan-2- ylamino)methane-l -thione (491mg; 55%) in the first step. In the second step, [(l-aza-2-{3-[4- (tert-butyl)phenoxy]phenyl}vinyl)amino](indan-2-ylamino)methane-l-thione (444mg; LOmmol) and iron (III) chloride hexahydrate (81 lmg; 3.0mmol) were used to yield the title compound
(109mg; 25%) with the following physical properties: p 132-133°C; Mass (M)+ 442 (Calc);
442 (Obsd.). Example 109:
(5-{3-[4-(tert-Butyl)phenoxy]phenyl}(l,3,4-thiadiazol-2-yl))(3,3,5- trimethylcyclohexyl)amine
As described in Procedure D, hydrazino[(3,3,5-trimethylcyclohexyl)amino]methane-l- thione (1.16g; 98%) was prepared from 3,3,5-trimethylcyclohexanisothiocyanate (l.Olg; 5.5mmol) and hydrazine monohydrate (400mg; 8.0mmol).
The reactions described in Example 2 were repeated using hydrazino[(3,3,5- trimethylcyclohexyl)amino]methane-l -thione (43 lmg; 2.0mmol) and 3-[4-(tert- butyl)phenoxy]benzaldehyde (509mg; 2. Ommol) to yield [(l-aza-2-{3-[4-(tert- butyl)phenoxy]phenyl}vinyl)amino][(3,3,5-trimethylcyclohexyl)amino]methane-l-thione (484mg; 54%) in the first step. In the second step, [(l-aza-2-{3-[4-(tert- butyl)phenoxy]phenyl}vmyl)amino][(3,3,5-trimethylcyclohexyl)amino]methane-l-thione (452mg; 1.Ommol) and iron (III) chloride hexahydrate (81 lmg; 3. Ommol) were used to yield the title compound (240mg, 53%) with the following physical properties: mp 166-167°C; Mass (M) 450 (Calc); 450 (Obsd.).
Example 110: (5-{3-[4-(tert-Butyl)phenoxy]phenyl}(l,3,4-thiadiazol-2-yl))(methylhexyI)amine
As described in Procedure D, hydrazino[(methylhexyl)amino]methane-l -thione (1.81g; 96%>) was prepared from heptan-2-isothiocyanate (1.57g; lO.Ommol) and of hydrazine monohydrate (750mg; 15.0mmol).
The reactions described in Example 2 were repeated using hydrazino[(methylhexyl)amino]methane-l-thione (379mg; 2. Ommol) and 3-[4-(tert- butyl)phenoxy]benzaldehyde (509mg; 2.0mmol) to yield [(l-aza-2-{3-[4-(tert- butyl)phenoxy]phenyl}vinyl)amino][(methylhexyl)amino]methane-l-thione (320mg, 78%) in the first step. In the second step, [(l-aza-2-{3-[4-(tert- butyl)phenoxy]phenyl}vinyl)amino][(methylhexyl)amino]methane-l -thione (425mg; 1.Ommol) and iron (III) chloride hexahydrate (81 lmg; 3. Ommol) were used to yield the title compound (21 lmg; 50%) with the following physical properties: mp 115-116°C; Mass (M)+ 424 (Calc); 424 (Obsd.). Example 111:
(5-{3-[3-(Trifluoromethyl)phenoxy]phenyl}(l,3,4-thiadiazol-2-yl))(3,355- trimethylcyclohexyl)amine
The reactions described in Example 2 were repeated using hydrazino[(3,3,5- trimethylcyclohexyl)amino]methane-l -thione (43 lmg; 2.0mmol) and 3-[3-
(trifluoromethyl)phenoxy]benzaldehyde (532mg; 2. Ommol) to yield [(l-aza-2-{3-[3- (trifluoromethyl)phenoxy]phenyl} vinyl)amino] [(3 ,3 ,5-trimethylcyclohexyl)amino]methane- 1 - thione (420mg; 45%) in the first step. In the second step, [(l-aza-2-{3-[3- (trifluoromethyl)phenoxy]phenyl} vinyl)amino] [(3 ,3, 5-trimethylcyclohexyl)amino]methane- 1 - thione (400mg; 0.9mmol) and iron (III) chloride hexahydrate (700mg; 2.6mmol) were used to yield the title compound (121mg; 30%) with the following physical properties: mp 101-102°C; Mass (M)+ 462 (Calc); 462 (Obsd.).
Example 112: 2-[4-(Phenylmethoxy)phenyl]-N-(5-{3-[3-(trifluoromethyl)phenoxy]phenyl}(l,3,4- thiadiazol-2-yl))acetamide
The reactions described in Example 10 were repeated using the product from Example 23 (202mg; 0.6mmol), 2-[4-(phenylmethoxy)phenyl]acetyl chloride (313mg; 1.2mmol) and dimethyl-4-pyridylamine (244mg; 2. Ommol) to yield the title compound (107mg; 32%) with the following physical properties: mp 194-195°C; Mass (M)+ 562 (Calc); 562 (Obsd.).
Example 113: Naphthyl-N-(5-{3-[3-(trifluoromethyl)phenoxy]phenyl}(l,3,4-thiadiazol-2-yl))carboxamide
The reactions described in Example 10 were repeated using the product from Example 23 (202mg; O.δmmol), naphthalene-2-carbonyl chloride (229mg; 1.2mmol) and dimethyl-4- pyridylamine (244mg; 2. Ommol) to yield the title compound (24 lmg; 82%) with the following physical properties: mp 236-238°C; Mass (M+l)+ 492 (Calc); 492 (Obsd.).
Example 114:
2-[(3-{5-[(3,4-Dichlorophenyl)amino](l,3,4-thiadiazol-2-yl)}phenyl)[3- (trifluoromethyl)phenyl] methoxy] acetic acid
The reactions described in Example 7 were repeated using ethyl 2-[(3-{5-[(3,4- dichlorophenyl)amino](l,3,4-thiadiazol-2-yl)}phenyl)[3-
(trifluoromethyl)phenyl]methoxy]acetate (210mg; 0.4mmol), lithium hydroxide (72mg; 3mmol), MeOH/H20 (3:1) (5mL) and THF (3mL) to yield the title compound (55mg; 28%) with the following physical properties: mp 89-91°C; Mass (M)+ 554 (Calc); 554 (Obsd.).
Example 115:
2-[4-(tert-Butyl)phenoxy]-N-(5-{3-[3-(trifluoromethyl)phenoxy]phenyl}(l,3,4-thiadiazol-2- yl))acetamide
The reactions described in Example 10 were repeated using the product from Example 23 (202mg; 0.6mmol), 2-[4-(tert-butyl)phenoxy]acetyl chloride (181mg; 0.8mmol) and dimethyl-4- pyridylamine (244mg; 2.0mmol) to yield the title compound (1 lOmg; 35%) with the following physical properties: mp 179-180°C; Mass (M)+ 528 (Calc); 528 (Obsd.).
Example 116:
[2-(4-Methoxyphenoxy)-5-nitrophenyl]-N-(5-{3-[3-(trifluoromethyl)phenoxy]phenyl}(l,3,4- thiadiazol-2-yl))carboxamide
The reactions described in Example 10 were repeated using the product from Example 23 (202mg; 0.6mmol), 2-(4-methoxyphenoxy)-5-nifrobenzoyl chloride (246mg; 0.8mmol) and dimethyl-4-pyridylamine (244mg; 2.0mmol) to yield the title compound (15mg; 4%) with the following physical properties: mp 130-132°C; Mass (M)+ 609 (Calc); 609 (Obsd.).
Example 117:
[5-(3,5-Dichlorophenoxy)(2-furyl)]-N-(5-{3-[3-(trifluoromethyl)phenoxy]phenyl}(l,3,4- thiadiazol-2-yl))carboxamide
The reactions described in Example 10 were repeated using the product from Example 23 (202mg; 0.6mmol), 5-(3,5-dichlorophenoxy)furan-2-carbonyl chloride (233mg; 0.8mmol) and dimethyl-4-pyridylamine (244mg; 2.0mmol) to yield the title compound (30mg; 8%) with the following physical properties: mp 205-207°C; Mass (M)+ 592 (Calc); 592 (Obsd.). Example 118:
(3-Nitrophenyl)-N-(5-{3-[3-(trifluoromethyl)phenoxy]phenyl}(l,3,4-thiadiazoI-2- yl))carboxamide The reactions described in Example 10 were repeated using the product from Example 23
(202mg; O.όmmol), 3-nifrobenzoyl chloride (148mg; O.δmmol) and dimethyl-4-pyridylamine (244mg; 2.0mmol) to yield the title compound (72mg; 25%) with the following physical properties: mp 200-202°C; Mass (M+l)+ 487 (Calc); 487 (Obsd.).
Example 119-120:
3-{2-[aza(4-bromo-3-chlorophenyI)methyIene]-3-benzyl(l,3,4-thiadiazoIin-5-yl)}-l- phenoxybenzene and
(4-bromo-3-chlorophenyl)benzyl[5-(3-phenoxyphenyl)(l,3,4-thiadiazol-2-yl)]amine The reaction described in Example 8 was repeated using (4-bromo-3-chlorophenyl)[5-(3- phenoxyphenyl)(l,3,4-thiadiazol-2-yl)]amine (126mg; 0.27mmol), potassium tert-butoxide
(0.27mL; 0.27mmol) and benzyl bromide (0.039mL; 0.33mmol) to yield 3-{2-[aza(4-bromo-3- chlorophenyl)methylene]-3-benzyl(l,3,4-thiadiazolin-5-yl)}-l-phenoxybenzene (21mg; 19%) with the following physical properties: Rf: 0.56 (hexanes / ethyl acetate, 2/1); MS (M)+: 547, 549, 551.
1H NMR (300 MHz, dι-CDCl3): δ 7.53 (IH, d), 7.45 (2H, d), 7.38-7.30 (8H, m), 7.18-7.11 (2H, m), 7.02-6.70 (3H, m), 6.85 (IH, dd), 5.31 (2H, s), and
(4-bromo-3-chlorophenyl)benzyl[5-(3-phenoxyphenyl)(l,3,4-thiadiazol-2-yl)]amine (44mg;
30%) with the following physical properties: Rf: 0.45 (hexanes / ethyl acetate, 2/1); MS (M)+: 547, 549, 551;
1H NMR (300 MHz, dι-CDCl3): δ 7.59 (IH, d), 7.46-7.44 (3H, m), 7.37-7.28 (8H, m), 7.15-7.01
(5H, m), 5.20 (2H, s).
Example 121: 2-{5-[(4-bromo-3-chlorophenyl)amino]-l,3,4-thiadiazol-2-yl}-3-hydroquinazolin-4-one
The reactions described in Example 1 were repeated using 4-oxo-3-hydroquinazoline-2- carbohydrazide (lOOmg; 0.49mmol) and 4-bromo-3-chlorobenzenisothiocyanate (122mg; 0.49mmol) to yield N-({[(4-bromo-3-chlorophenyl)amino] thioxomethyl}amino)(4-oxo(3- hydroquinazolin-2-yl))carboxamide in the first step. In the second step, all the crude product and sulfuric acid (0.4mL) were used to yield the title compound (85mg; 40%) with the following physical properties: mp 348-349°C; MS (M)+: 433, 435, 437.
Example 122:
(5-benzo[3,4-c]l,2,5-oxadiazol-5-yl(l,3,4-thiadiazol-2-yl))(4-bromo-3-chlorophenyl) amine
The reactions described in Example 1 were repeated using benzo[c]l,2,5-oxadiazole-5- carbohydrazide (150mg; 0.84mmol) and 4-bromo-3-chlorobenzenisothiocyanate (209mg; 0.49mmol) to yield benzo[3,4-c]l,2,5-oxadiazol-5-yl-N-({[(4-bromo-3- chlorophenyl)amino]thioxomethyl}amino)carboxamide in the first step. In the second step, all the crude product and sulfuric acid (0.5mL) were used to yield the title compound (272mg; 79%) with the following physical properties: mp 326-327°C; Anal. Calcd for C14H7BrClN5OS: C, 41.15; H, 1.73; N, 17.14; S, 7.85. Found: C, 41.28; H, 1.62; N, 16.93; S, 8.01.
Example 123: ethyl 4-{[5-(4-phenoxyphenyl)-l,3,4-thiadiazol-2-yl]amino}benzoate
The reactions described in Example 1 were repeated using l-phenoxybenzene-4- carbohydrazide (500mg; 2.2 mmol) and ethyl 4-isothiocyanatobenzoate (454mg; 2.2mmol) to yield ethyl 4-[({[(4-phenoxyphenyl)carbonylamino]amino}thioxomethyl)amino]benzoate in the first step. In the second step, all the crude product and sulfuric acid (0.5mL) were used to yield the title compound (589mg; 64%) with the following physical properties: mp 206-207°C; MS (M+H)+: 418.
Example 124:
(3,4-dichlorophenyl)[5-(3-{[4-(tert-butyl)phenyl]methoxy}phenyl)(l,3,4-thiadiazol-2- yl)] { [4-(tert-butyl)phenyl] methyl} amine
The reaction described in Example 8 was repeated using 3-{5-[(3,4- dichlorophenyl)amino]-l,3,4-thiadiazol-2-yl}phenol (200mg; 0.59mmol), potassium tert- butoxide (1.18mL; l.lδmmol) and l-(tert-butyl)-4-(bromomethyl)benzene (O.l lmL; 0.59mmol) to yield the title compound (168mg; 45%) with the following physical properties: 1H NMR (300 MHz, dι-CDCl3): δ 7.50-7.18 (14H, m), 7.04-7.00 (IH, m), 5.19 (2H, s), 5.06 (2H, s), 1.33 (9H, s), 1.29 (9H, s).
Example 125:
5-{5-[(3,4-dichlorophenyl)amino](l,3,4-thiadiazol-2-yl)}-3-[3-(trifluoromethyl)phenoxy] phenol ,
• The reactions described in Procedure B were followed using methyl 3,5- dihydroxybenzoate (5.00g; 29.7mmol), l-bromo-3-(trifluoromethyl)benzene (6.2mL;
44.5mmol), potassium carbonate (8.22g; 59.5mmol), copper(II) oxide (4.73g; 59.5mmol)and pyridine (30mL) to yield methyl 5-hydroxy-3-[3-(trifluoromethyl)phenoxy]benzoate (1.22g; 13%) as white solid. 1H NMR (300 MHz, dι-CDCl3): δ 7.49-7.37 (3H, m), 7.26-7.17 (3H, m), 6.74 (IH, s), 6.10 (IH, br s), 3.90 (3H, s).
A solution of methyl 5-hydroxy-3-[3-(frifluoromethyl)phenoxy]benzoate (1.22g; 3.9mmol) and hydrazine monohydrate (0.38mL; 7.8mmol) in dry ethanol (4.5mL) under nifrogen was refluxed for 30 hours. After cooling to RT, the solvent was removed by rotovapor. The residue was wash by water then hexanes, dried by vacuum to yield 5-hydroxy-3-[3- (trifluoromethyl)phenoxy]benzenecarbohydrazide (980mg; 80%) as a light yellow solid. The reactions described in Example 1 were repeated using 5-hydroxy-3-[3- (frifluoromethyl)phenoxy]benzenecarbohydrazide (500mg; 1.6mmol) and 3,4- dichlorobenzenisothiocyanate (327mg; l.όmmol) to yield N-({ [(3,4- dichlorophenyl)ammo]thioxomethyl}amino){3-[3-(trifluoromethyl)phenoxy]phenyl} carboxamide in the first step. In the second step, all the crude product and sulfuric acid (0.8mL) were used to yield the title compound (712mg; 89%) with the following physical properties: mp 193-194°C; MS (M)+: 497, 499. Example 126: (3,4-dichlorophenyl){5-[3-(3-nitrophenoxy)phenyl](l,3,4-thiadiazol-2-yl)}amine
The reactions described in Procedure B were followed using (3-hydroxyphenyl) formaldehyde (5.00g; 40.9mmol), l-bromo-3 -nitrobenzene (9.925g; 49. lmmol), potassium carbonate (11.318g; 81.9mmol), copper(II) oxide (6.513g; 81.9mmol) and pyridine (50mL) to yield [3-(3-nifrophenoxy)phenyl]formaldehyde (2.49g; 25%) as light yellow solid. 1HNMR (300 MHz, dι-CDCl3): δ 10.01 (IH, s), 8.01 (IH, dd), 7.83 (IH, t), 7.73 (IH, d), 7.63- 7.52 (3H, m), 7.39-7.33 (2H, m). The reactions described in Example 2 were repeated using [3-(3- nifrophenoxy)phenyl]formaldehyde (2.240g; 9.2mmol) and the product from Procedure D (2.177g; 9.2mmol) to yield ({(lE)-l-aza-2-[3-(3-mfrophenoxy)phenyl]vinyl}amino)[(3,4- dichlorophenyl)amino]methane-l -thione in the first step. In the second step, all the crude product and iron(III) chloride hexahydrate (7.47g; 27.6mmol) were used to yield the title compound (3.71g; 88%) with the following physical properties: mp 210.5-211.5°C; MS (M)+: 458, 460.
Example 127: 2-[3-(3-{5-[(3,4-dichlorophenyl)amino]-l,3,4-thiadiazol-2-yl}phenoxy)phenyl]acetic acid The reactions described in Procedure B were followed using (3- bromophenyl)formaldehyde (2.95g; 15.96mmol), methyl 2-(3-hydroxyphenyl)acetate (2.56g;
15.96mmol), potassium carbonate (4.41g; 31.93mmol), copper(II) oxide (2.54g; 31.93mmol) and pyridine (20mL) to yield methyl 2-[3-(3-carbonylphenoxy)phenyl]acetate (532mg; 12%) as a colorless oil. 1H NMR (300 MHz, dι-CDCl3): δ 9.96 (IH, s), 7.61 (IH, d), 7.53-7.47 (2H, m), 7.35-7.26 (2H, m), 7.08 (IH, d), 6.99 (IH, s), 6.94 (IH, d), 3.70 (3H, s), 3.62 (2H, s).
The reactions described in Example 2 were repeated using methyl 2-[3-(3- carbonylphenoxy)phenyl]acetate (532mg; 1.97mmol) and the product from Procedure D
(465mg; 1.97mmol) to yield methyl 2-(3-{3-[(lE)-2-aza-2-({[(3,4- dichlorophenyl)amino]thioxomethyl}amino)vinyl]phenoxy}phenyl)acetate in the first step. In the second step, all the crude product and iron(III) chloride hexahydrate (1.597g; 5.9mmol) were used to yield methyl 2-[3-(3-{5-[(3,4-dichlorophenyl)amino]-l,3,4-thiadiazol-2- yl}phenoxy)phenyl] acetate (49 lmg; 51%).
The reaction described in Example 7 was repeated using methyl 2-[3-(3-{5-[(3,4- dichlorophenyl)amino]-l,3,4-thiadiazol-2-yl}phenoxy)phenyl]acetate (140mg; 0.29mmol) and lithium hydroxide (20mL; 0.25 ) to yield the title compound (123mg; 91%) with the following physical properties: mp 183-184°C; MS (M)+: 471 , 473.
Example 128: 4-(3-{5-[(3,4-dichlorophenyl)amino]-l,3,4-thiadiazol-2-yl}phenoxy)phenol The reactions described in Procedure B were followed using 4-hydroxyphenyl benzoate
(3.00g; 14. Ommol), (3-bromophenyl)formaldehyde (3.3mL; 28.0mmol), potassium carbonate (3.87g; 28.0mmol), copper(II) oxide (2.23g; 28.0mmol) and pyridine (15mL) to yield 4-(3- carbonylphenoxy)phenyl benzoate (305mg; 9%) and [3-(4-hydroxyphenoxy)phenyl] formaldehyde (417mg; 14%). The reactions described in Example 2 were repeated using [3-(4-hydroxyphenoxy) phenyl]formaldehyde (306mg; 1.4mmol) and the product from Procedure D (337mg; 1.4mmol) to yield 4- {3 - [( 1 E)-2-aza-2-( { [(3 ,4-dichlorophenyl)amino]thioxomethyl} amino)vinyl] phenoxy}phenol in the first step. In the second step, all the crude product and iron (III) chloride hexahydrate (1.159g; 4.3mmol) were used to yield the title compound (332mg; 55%) with the following physical properties: mp 224-225.5°C; MS (M)+: 429, 431.
Example 129:
(3,4-dichlorophenyl) [5-(3-{ [3-(trifluoromethoxy)phenyl] methoxy}phenyl)(l,3,4-thiadiazol-
2-yl)] amine To a solution of 3-{5-[(3,4-dichlorophenyl)amino]-l,3,4-thiadiazol-2-yl}phenol (150mg;
0.44mmol) in dry DMF (5mL) was added a solution of potassium tert-butoxide (0.44mL, IM, 0.44mmol) in THF at RT under an argon atmosphere. After 5 minutes, [3- (bromomethyl)phenoxy]trifluoromethane (0.086mL; 0.53mmol) was injected, and the solution was stirred overnight. The DMF was evaporated (rotovap) under vacuum. The crude residue was purified by flash chromatography (ethyl acetate / hexanes, 1 : 10 to 1 :2) to yield the title compound (138mg; 61%) with the following physical properties: mp 166-167°C; MS (M)+: 511, 513. Example 130: (4-bromo-3-chlorophenyl)[5-(4-ethoxyphenyl)(l,3,4-thiadiazol-2-yl)]amine
The reactions described in Example 1 were repeated using 4- ethoxybenzenecarbohydrazide (145mg; 0.80mmol) and 4-bromo-3-chlorobenzenisothiocyanate (200mg; 0.80mmol) to yield N-({[(4-bromo-3-chlorophenyl)amino]thioxomethyl}amino)(4- ethoxyphenyl)carboxamide (314mg; 92%) in the first step. In the second step, all the crude product and sulfuric acid (0.2mL) were used to yield the title compound (205mg; 68%) with the following physical properties: mp 225-226°C; !H NMR (300 MHz, d6-DMSO): δ 10.78 (IH, s), 8.13 (IH, d), 7.78 (2H, d), 7.71 (IH, d), 7.43 (IH, dd), 7.06 (2H, d), 4.10 (2H, q), 1.35 (3H, t).
Example 131-132: (3-bromophenyl)[5-(3-nitrophenyl)(l,3,4-thiadiazol-2-yl)]benzylamine and
2-[aza(3-bromophenyl)methylene]-5-(3-nitrophenyl)-3-benzyl-l,3,4-thiadiazoline
The reaction described in Example 8 was repeated using (3-bromophenyl)[5-(3- niteophenyl)(l,3,4-thiadiazol-2-yl)]amine (150mg; 0.40mmol), potassium tert-butoxide (0.40mL; 0.40mmol) and benzyl bromide (0.057mL; 0.47mmol) to yield 2-[aza(3- bromophenyl)methylene]-5-(3-nifrophenyl)-3-benzyl-l,3,4-thiadiazoline (46mg; 24%) with the following physical properties: Rf: 0.50 (hexanes / ethyl acetate, 2/1); mp 133-134°C; 'HNMR (300 MHz, d CDCl3): δ 8.49 (IH, s), 8.25 (IH, d), 7.93 (lH,d), 7.60 (IH, t), 7.51 (2H, d), 7.41-7.33 (3H, m), 7.26-7.23 (3H, m), 7.06-7.03 (IH, m), 5.40 (2H,s); and (3-bromophenyl)[5-(3-nifrophenyl)(l,3,4-thiadiazol-2-yl)]benzylamine (136mg; 73%) with the following physical properties: Rf: 0.35 (hexanes / ethyl acetate, 2/1); MS (M)+: 466, 468;
1H NMR (300 MHz, dι-CDCl3): δ 8.53 (IH, s), 8.24 (IH, d), 8.18 (IH, d), 7.60 (IH, t), 7.51-7.47 (2H, m), 7.34-7.23 (7H,'m), 5.26 (2H, s).
Example 133: [5-(3,4-dimethoxyphenyl)(l,3,4-thiadiazol-2-yl)](4-bromo-3-chlorophenyl)amine
The reactions described in Example 1 were repeated using l,2-dimethoxybenzene-4- carbohydrazide (158mg; 0.80mmol) and 4-bromo-3-chlorobenzenisothiocyanate (200mg; 0.80mmol) to yield (3 ,4-dimethoxyphenyl)-N-( { [(4-bromo-3 - chlorophenyl)amino]thioxomethyl}amino)carboxamide (330mg; 93%) in the first step. In the second step, all the crude product and sulfuric acid (0.3mL) were used to yield the title compound (218mg; 70%) with the following physical properties: mp 251.5-252.5°C; *H NMR (300 MHz, d6-DMSO): δ 10.81 (IH, s), 8.14 (IH, d), 7.72 (IH, d), 7.45-7.35 (3H, m), 7.07 (IH, d).
Example 134: 4-{5-[(4-bromo-3-chlorophenyl)amino]-l,3,4-thiadiazol-2-yl}benzene-l,2-diol
The reactions described in Example 1 were repeated using 2H-benzo[d]l,3-dioxolane-5- carbohydrazide (145mg; 0.80mmol) and 4-bromo-3-chlorobenzenisothiocyanate (200mg;
0.80mmol) to yield 2H-benzo[3,4-d]l,3-dioxolan-5-yl-N-({[(4-bromo-3- chlorophenyl)amino]thioxomethyl}amino)carboxamide (302mg; 88%) in the first step with the following physical properties:
'H NMR (300 MHz, di-CDCl3): δ 10.43 (IH, s), 9.95 (IH, s), 9.87 (IH, s), 7.83 (IH, s), 7.71 (IH, d), 7.54 (IH, d), 7.48-7.46 (2H, m), 7.04 (IH, d), 6.12 (2H, s).
In the second step, all the crude product and sulfuric acid (0.4mL) were used to yield the title compound (190mg; 68%) with the following physical properties: mp 220°C decomposed; H
NMR (300 MHz d6-DMSO): δ 10.73 (IH, s), 9.56 (IH, s), 9.42 (IH, s), 8.13 (IH, d), 7.71 (IH, d), 7.41 (IH, dd), 7.30 (IH, d), 7.11 (IH, dd), 6.83 (IH, d).
Example 135: (4-bromo-3-chlorophenyl)[5-(3-phenoxyphenyl)(l,3,4-thiadiazol-2-yl)]amine
The reactions described in Example 1 were repeated using l-phenoxybenzene-3- carbohydrazide (184mg; 0.80mmol) and 4-bromo-3-chlorobenzenisothiocyanate (200mg; 0.80mmol) to yield N-({[(4-bromo-3-chlorophenyl)amino]thioxomethyl}amino)(3- phenoxyphenyl)carboxamide (365mg; 95%) of in the first step. In the second step, all the crude product and sulfuric acid (0.4mL) were used to yield the title compound (286mg; 81%) with the following physical properties: mp 216-217°C; MS (M)+: 457, 459, 461.
Example 136:
(4-{5-[(4-bromo-3-chlorophenyl)amino](l,3,4-thiadiazol-2-yl)}phenyl)diethylamine
The reactions described in Example 1 were repeated using 4-(diethylamino) benzenecarbohydrazide (167mg; 0.80mmol) and 4-bromo-3-chlorobenzenisothiocyanate
(200mg; 0.80mmol) to yield [4-(diethylamino)phenyl]-N-({[(4-bromo-3-chlorophenyl) amino]thioxomethyl}amino)carboxamide (319mg; 88%) in the first step. In the second step, all the crude product and sulfuric acid (0.4mL) were used to yield the title compound (226mg; 74%) with the following physical properties: mp 232-233°C;
!H NMR (300 MHz, d6-DMSO): δ 10.68 (IH, s), 8.13 (IH, d), 7.70 (IH, d), 7.63 (2H, d), 7.40
(IH, dd), 6.74 (2H, d), 3.40 (4H, q), 1.12 (6H, t).
Example 137:
(4-bromo-3-chlorophenyl)[5-(3-methylphenyl)(l,3,4-thiadiazol-2-yl)]amine
The reactions described in Example 1 were repeated using l-methylbenzene-3- carbohydrazide (167mg; 0.80mmol) and 4-bromo-3-chlorobenzenisothiocyanate (121mg; 0.80mmol) to yield N-({[(4-bromo-3-chlorophenyl)amino]thioxomethyl}amino)(3- methylphenyl)carboxamide (306mg; 93%) in the first step. In the second step, all the crude product and sulfuric acid (0.3mL) were used to yield the title compound (230mg; 79%) with the following physical properties: mp 230-231°C; lR NMR (300 MHz, d6-DMSO): δ 10.87 (IH, s), 8.14 (IH, s), 7.74-7.66 (3H, m), 7.46-7.38 (2H, m), 7.33 (IH, d), 2.39 (3H, s). Example 138: (naphthylmethyl)[5-(3-nitrophenyl)(l,3,4-thiadiazol-2-yl)]amine
The reactions described in Example 1 were repeated using l-nifrobenzene-3- carbohydrazide (245mg; 1.35mmol) and naphthylmethanisothiocyanate (270mg; 1.35mmol) to yield N-({[(naphthylmethyl)amino]thioxomethyl}amino)(3-nifrophenyl)carboxamide (482mg; 94%) in the first step. In the second step, all the crude product and sulfuric acid (0.5mL) were used to yield the title compound (244mg; 53%) with the following physical properties: mp 150- 151°C;
1H NMR (300 MHz, d6-DMSO): δ 8.72 (IH, t), 8.51 (IH, s), 8.27 (IH, d), 8.18 (IH, d), 8.14 (IH, d), 7.99 (IH, d), 7.91 (IH, d), 7.77 (IH, t), 7.64-7.48 (4H, m), 5.05 (2H, d).
Example 139: (3,4-dichlorophenyl)[5-(4-phenylphenyl)(l,3,4-thiadiazol-2-yl)]amine
The reactions described in Example 1 were repeated using l-phenylbenzene-4- carbohydrazide (200mg; 0.94mmol) and 3,4-dichlorobenzenisothiocyanaτe (192mg; 0.94mmol) to yield N-({[(3,4-dichlorophenyl)amino]thioxomethyl}amino)(4-phenylphenyl)carboxamide (360mg; 92%) in the first step. In the second step, all the crude product and sulfuric acid (0.4mL) were used to yield the title compound (283mg; 82%) with the following physical properties: mp 305.5-306.5°C; *H NMR (300 MHz, d6-DMSO): δ 10.92 (IH, s), 8.16 (IH, d), 7.97 (2H, d), 7.84 (2H, d), 7.74 (2H, d), 7.62 (IH, d), 7.54-7.49 (3H, m), 7.45-7.42 (IH, m).
Example 140: (4-{5-[(3,4-dichlorophenyl)amino](l,3,4-thiadiazol-2-yl)}phenyl)dimethylamine The reactions described in Example 1 were repeated using 4-(dimethylamino) benzenecarbohydrazide (200mg; 1. lmmol) and 3,4-dichlorobenzenisothiocyanate (228mg; 1.1 mmol) to yield [4-(dimethylamino)phenyl]-N-({[(3,4-dichlorophenyl)amino]thioxomethyl} amino)carboxamide (404mg; 94%) in the first step. In the second step, all the crude product and sulfuric acid (0.4mL) were used to yield the title compound (368mg; 96%) with the following physical properties: mp 298.5-299.5°C;
'HNMR (300 MHz, de-DMSO): δ 10.70 (IH, s), 8.13 (IH, s), 7.66 (2H, d), 7.58 (IH, d), 7.48 (IH, d), 6.79 (2H, d), 2.99 (6H, s). Example 141: (3,4-dichlorophenyl)[5-(4-methylthiophenyl)(l,3,4-thiadiazol-2-yl)]amine
The reactions described in Example 1 were repeated using l-methylthiobenzene-4- carbohydrazide (200mg; 1.1 mmol) and 3,4-dichlorobenzenisothiocyanate (224mg; 1. lmmol) to yield N-({[(3,4-dichlorophenyl)amino]thioxomethyl}amino)(4-methylthiophenyl)carboxamide (358mg; 84%) in the first step. In the second step, all the crude product and sulfuric acid (0.4mL) were used to yield the title compound (25 lmg; 74%) with the following physical properties: mp 247.5-248.5°C; JH NMR (300 MHz, d6-DMSO): δ 10.86 (IH, s), 8.13 (IH, d), 7.80 (2H, d), 7.60 (IH, d), 7.49 (IH, dd), 7.38 (2H, d), 2.54 (3H, s).
Example 142: methyl 3-({2- [aza(3,4-dichlor ophenyl)methylene] -5-(3-ethoxyphenyl)-l ,3,4-thiadiazolin-3- yl}methyI)benzoate
The reactions described in Example 1 were repeated using l-ethoxybenzene-3- carbohydrazide (l.OOOg; 5.6mmol) and 3,4-dichlorobenzenisothiocyanate (1.133g; 5.6mmol) to yield N-({[(3,4-dichlorophenyl)amino]thioxomethyl}amino)(3-ethoxyphenyl)carboxamide (1.922g; 90%) in the first step. In the second step, all the crude product and sulfuric acid (2.0mL) were used to yield the title compound (1.738g; 95%) with the following physical properties:
1H NMR (300 MHz, d6-DMSO): δ 10.88 (IH, s), 8.15 (IH, d), 7.61 (IH, d), 7.51 (IH, dd), 7.44- 7.39 (3H, m), 7.10-7.07 (IH, m), 4.11 (2H, q), 1.37 (3H, t).
Example 143-144: methyl 3-({2-[aza(3,4-dichlorophenyl)methylene]-5-(3-ethoxyphenyl)-l,3,4-thiadiazolin-3- yl}methyl)benzoate and methyl 3-({(3,4-dichlorophenyl) [5-(3-ethoxyphenyl)(l,3,4-thiadiazol-2- yl)]amino}methyl)benzoate
The reaction described in Example 8 was repeated using (3,4-dichlorophenyl)[5-(3- ethoxyphenyl)(l,3,4-thiadiazol-2-yl)]amine (120mg; 0.33mmol), potassium tert-butoxide (33mL;
0.33mmol) and methyl 3-(bromomethyl)benzoate (90mg; 0.39mmol) to yield methyl 3-({2- [aza(3,4-dichlorophenyl)methylene]-5-(3-ethoxyphenyl)-l,3,4-thiadiazolin-3- yl}methyl)benzoate (24mg; 14%) with the following physical properties: Rf: 0.55 (hexanes / ethyl acetate, 2/1); mp 87-88°C; MS (M)+: 513, 515; and methyl 3-({(3,4-dichlorophenyl)[5-(3- ethoxyphenyl)(l,3,4-thiadiazol-2-yl)]ammo}methyl)benzoate (128mg; 75%) with the following physical properties: Rf: 0.34 (hexanes / ethyl acetate, 2/1); MS (M)+: 513, 515.
Example 145:
(3,4-dichlorophenyl)[5-(3-ethoxyphenyl)(l,3,4-thiadiazol-2-yl)][(4- phenylphenyl)methyl]amineethyl)benzoate
The reaction described in Example 8 was repeated using (3,4-dichlorophenyl)[5-(3- ethoxyphenyl)(l,3,4-thiadiazol-2-yl)]amine (120mg; 0.33mmol), potassium tert-butoxide
(0.33mL; 0.33mmol) and 4-(bromomethyl)-l-phenylbenzene (97mg; 0.39mmol) to yield the title compound (132mg; 75%) with the following physical properties: MS (M+H)+: 532, 534;
!H NMR (300 MHz, dι-CDCl3): δ 7.58-7.26 (14H, m), 7.21 (IH, dd), 6.96-6.91 (IH, m), 5.26
(2H, s), 4.07 (2H, q), 1.42 (3H, t).
Example 146: l-({2-[aza(3,4-dichlorophenyl)methylene]-5-(3-ethoxyphenyl)(l,3,4-thiadiazolin-3- yl)}methyl)-3-methoxybenzene
The reaction described in Example 8 was repeated using (3,4-dichlorophenyl)[5-(3- ethoxyphenyl)(l,3,4-thiadiazol-2-yl)]amine (120mg; 0.33mmol), potassium tert-butoxide (0.33mL; 0.33mmol) and 3 -(bromomethyl)-l -methoxybenzene (79mg; 0.39mmol) to yield 1- ({2-[aza(3,4-dichlorophenyl)methylene]-5-(3-ethoxyphenyl)(l,3,4-thiadiazolin-3-yl)}methyl)-3- methoxybenzene (2 lmg; 13%) with the following physical properties: Rf: 0.54 (hexanes / ethyl acetate, 2/1); mp 89-90°C; MS (M)+: 485, 487; and (3,4-dichlorophenyl)[5-(3- ethoxyphenyl)(l,3,4-thiadiazol-2-yl)][(3-methoxyphenyl)methyl]amine (108mg; 67%) with the following physical properties: Rf: 0.38 (hexanes / ethyl acetate, 2/1); MS (M)+: 485, 487.
Example 147:
(3,4-dichlorophenyl)[5-(3-ethoxyphenyl)(l,3,4-thiadiazol-2-yl)][(3-nitrophenyl)methyl] amine
The reaction described in Example 8 was repeated using (3,4-dichlorophenyl)[5-(3- ethoxyphenyl)(l,3,4-thiadiazol-2-yl)]amine (120mg; 0.33mmol), potassium tert-butoxide (0.33mL; 0.33mmol) and 3 -(bromomethyl)-l -nitrobenzene (85mg; 0.39mmol) to yield 3-{2- [aza(3,4-dichlorophenyl)methylene]-3-[(3-nifrophenyl)methyl](l,3,4-thiadiazolin-5-yl)}-l- ethoxybenzene (30mg; 18%) with the following physical properties: Rf: 0.53 (hexanes / ethyl acetate, 2/1); mp 114-115°C; MS (M)+: 500, 502; and (3,4-dichlorophenyl)[5-(3- ethoxyphenyl)(l,3,4-thiadiazol-2-yl)][(3-nifrophenyl)methyl]amine (98mg; 59%) with the following physical properties: Rf: 0.30 (hexanes / ethyl acetate, 2/1); MS (M)+: 500, 502; 1H NMR (300 MHz, dι-CDCl3): δ 8.18 (IH, s), 8.16 (IH, d), 7.78 (IH, d), 7.55-7.49 (3H, m), 7.38 (IH, s), 7.32-7.19 (3H, m), 6.95 (IH, d), 5.33 (2H, s), 4.07 (2H, q), 1.42 (3H, t).
Example 148-149:
3-{2-[aza(3,4-dichlorophenyl)methylene]-3-(2-naphthylmethyl)(l,3,4-thiadiazolin-5-yl)}-l- ethoxybenzene and (3,4-dichlorophenyl)[5-(3-ethoxyphenyl)(l,3,4-thiadiazol-2-yl)](2-naphthylmethyl)amine
The reaction described in Example 8 was repeated, but using of (3,4-dichlorophenyl)[5- (3-ethoxyphenyl)(l,3,4-thiadiazol-2-yl)]amine (120mg; 0.33mmol), potassium tert-butoxide (0.33mL; 0.33mmol) and 2-(bromomethyl)naphthalene (87mg; 0.39 mmol) to yield 3-{2- [aza(3,4-dichlorophenyl)methylene]-3-(2-naphthylmethyl)(l,3,4-thiadiazolin-5-yl)}-l- ethoxybenzene (23mg; 14%) with the following physical properties: Rf: 0.52 (hexanes / ethyl acetate, 2/1); mp 74-75°C; MS (M)+: 505, 507; and (3,4-dichlorophenyl)[5-(3- ethoxyphenyl)(l,3,4-thiadiazol-2-yl)](2-naphthylmethyl)amine (HOmg; 66%) with the following physical properties: Rf: 0.43 (hexanes / ethyl acetate, 2/1); mp 43-44°C; MS (M)+: 505, 507.
Example 150:
(3,4-dichlorophenyl){5-[3-(4-methoxyphenoxy)phenyl](l,3,4-thiadiazol-2-yl)}amine
The reactions described in Example 2 were repeated, but using [3-(4- methoxyphenoxy)phenyl]formaldehyde (193mg; 0.85mmol) and the product from Procedure D (200mg; 0.85mmol) to yield ({(lE)-l-aza-2-[3-(4-methoxyphenoxy)phenyl]vinyl}amino)[(3,4- dichlorophenyl)amino]methane-l -thione (326mg; 86%) in the first step. In the second step, all the crude product and iron (III) chloride hexahydrate (593mg; 2.20mmol) were used to yield the title compound (158mg; 45%) with the following physical properties: mp 198-199°C; MS (M)+: 443, 445.
Example 151:
(3,4-dichlorophenyl){5-[3-(4-methylphenoxy)phenyl](l,3,4-thiadiazol-2-yl)}amine
The reactions described in Example 2 were repeated using [3-(4-methylphenoxy)phenyl] formaldehyde (180mg; 0.85mmol) and the product from Procedure D (200mg; 0.85mmol) to yield ({(lE)-l-aza-2-[3-(4-methylphenoxy)phenyl]vinyl}amino)[(3,4-dichlorophenyl)amino] methane- 1 -thione (322mg; 88%) in the first step. In the second step, all the crude product and of iron (HI) chloride hexahydrate (607mg; 2.25mmol) were used to yield the title compound (166mg; 52%) with the following physical properties: mp 210-211°C; MS (M)+: 427, 429. Example 152: (3,4-dichlorophenyl){5-[3-(3,5-dichlorophenoxy)phenyl](l,3,4-thiadiazol-2-yl)}amine
The reactions described in Example 2 were repeated using [3-(3,5-dichlorophenoxy) phenyl]formaldehyde (226mg; 0.85mmol) and the product from Procedure D (200mg; 0.85mmol) to yield ({(lE)-l-aza-2-[3-(3,5-dichlorophenoxy)phenyl]vinyl}amino)[(3,4- dichlorophenyl)amino]methane-l -thione (366mg; 89%) in the first step. In the second step, all the crude product and iron (III) chloride hexahydrate (612mg; 2.26mmol) were used to yield the title compound (192mg; 53%) with the following physical properties: mp 242-243°C; MS (M)+: 481, 483, 485.
Example 153: (3,4-dichlorophenyl){5-[3-(3,4-dichlorophenoxy)phenyl](l,3,4-thiadiazol-2-yl)}amine
The reactions described in Example 2 were repeated using [3 -(3 ,4- dichlorophenoxy)phenyl]formaldehyde (226mg; 0.85mmol) and the product from Procedure D (200mg; 0.85mmol) to yield ({(lE)-l-aza-2-[3-(3,4-dichlorophenoxy)phenyl]vinyl}amino)[(3,4- dichlorophenyl)amino]methane-l -thione (292mg; 71%) in the first step. In the second step, all the crude product and iron (III) chloride hexahydrate (488mg; l.δlmmol) were used to yield the title compound (20mg; 7%) with the following physical properties: mp 189-190°C; MS (M)+: 481, 483, 485.
Example 154:
(3,4-dichlorophenyl)(5-{3-[3-(trifluoromethyl)phenoxy]phenyl}(l,3,4-thiadiazol-2- yl))amine The reactions described in Example 2 were repeated using {3-[3-
(trifluoromethyl)phenoxy]phenyl} formaldehyde (226mg; 0.85mmol) and the product from Procedure D (200mg; 0.85mmol) to yield [((lE)-l-aza-2-{3-[3-
(trifluoromethyl)phenoxy]phenyl} vinyl)amino] [(3 ,4-dichlorophenyl)amino]methane- 1 -thione (2δ2mg; 69%) in the first step. In the second step, all the crude product and iron (III) chloride hexahydrate (472mg; 1.75mmol) were used to yield the title compound (156mg; 56%) with the following physical properties: mp 212-213°C; MS (M)+: 481, 483. Example 155: (5-(2H-benzo[d]l,3-dioxolan-5-yl)(l,3,4-thiadiazol-2-yl))(3,4-dichlorophenyl)amine
The reactions described in Example 2 were repeated using 2H-benzo[3,4-d]l,3-dioxolan- 5-ylformaldehyde (127mg; 0.85mmol) and the product from Procedure D (200mg; 0.85mmol) to yield [(( 1 E)-2-(2H-benzo[3 ,4-d] 1 ,3-dioxolan-5-yl)-l -azavinyl)amino] [(3 ,4-dichlorophenyl) amino]methane-l -thione (274mg; 88%) in the first step. In the second step, all the crude product and iron (III) chloride hexahydrate (604mg; 2.23mmol) were used to yield the title compound (120mg; 50%) with the following physical properties: mp 271-272°C; H NMR (300 MHz, d6-DMSO): δ 10.82 (IH, s), 8.13 (IH, d), 7.59 (IH, d), 7.49 (IH, dd), 7.44' (IH, s), 7.36 (IH, d), 7.05 (IH, d), 6.13 (2H, s).
Example 156:
Methyl 4-{[(3,4-dichlorophenyl)(5-{3-[3-(trifluoromethyl)phenoxy]phenyl}(l,3,4-thiadiazol-
2-yl))amino]methyl}benzoate As described in Example 8, the title compound was prepared from (3,4- dichlorophenyl)(5-{3-[3-(trifluoromethyl)-phenoxy]phenyl}(l,3,4-thiadiazol-2-yl))amine (300mg) and methyl-(4-(bromomethyl)benzoate (210mg). The title compound had the following physical properties: MS 629.96.
Example 157:
4-{[(3,4-dichlorophenyl)(5-{3-[3-(trifluoromethyl)phenoxy]phenyl}-(l,3,4-thiadiazol-2- yl))amino]methyl}benzoic acid
As described in Example 7, the title compound was prepared from methyl 4-{[(3,4- dichlorophenyl)(5-{3-[3-(trifluoromethyl)phenoxy]phenyl}(l,3,4-thiadiazol-2- yl))amino]methyl}benzoate (50mg) and sodium hydroxide (0.8mL; 2.5M). The title compound had the following physical properties: mp 114-116°C (from 4/1 Hexanes/Ethyl Acetate), MS 615.93. Example 158: (3,4-dichlorophenyl)(5-{3-[3-(oxymethyl)phenoxy]phenyl}(l,3,4-thiadiazol-2-yl))amine
The reaction described in Procedure B was repeated using 3-hydroxybenzyl alcohol (1.5g) and 3-bromobenzaldehyde (2.7g). In the second step, using a procedure similar to that described in Example 2, {3-[3-(hydroxymethyl)phenoxy]phenyl} formaldehyde (500mg), semicarbazide (400mg) and FeCl36 H2O (120mg) in ethanol (lOmL) were used to yield the title compound with the following physical properties: mp 128-130°C, MS 443.90.
Example 159: [(4-methylphenyl)sulfonyl](4-{[5-(3-nitrophenyl)(l,3,4-thiadiazol-2-yl)]amino} phenyl)amine
As described in Example 1, (4-aminophenyl)[5-(3-nifrophenyl)(l,3,4-thiadiazol-2- yl)]amine was prepared from (tert-butoxy)-N-(4-isothiocyanatophenyl)carboxamide (200mg) and N-amino(3-nifrophenyl)-carboxamide (130mg). The Boc protecting group is lost during the cyclization reaction.
As described in Example 10 (with sulfonyl chloride in place of acyl chloride), the title compound was prepared from (4-{[5-(3-nifrophenyl)(l,3,4-thiadiazol-2-yl)]amino}phenyl)amine (lOOmg) and 4-toluenesulfonyl chloride (96mg). The title compound had the following physical properties: mp 255-257°C.
Example 160: (3,4-dichlorophenyl){5-[3,5-bis(phenylmethoxy)phenyl](l,3,4-thiadiazol-2-yl)} amine
As described in Example 2, the title compound was prepared from [3,5- bis(phenylmethoxy)phenyl]formaldehyde (400mg) and [(3,4-dichloro- phenyl)amino]hydrazinomethane-l -thione (290mg). The title compound had the following physical properties: mp 212-214°C; LC-MS: 533.99.
Example 161: 3-{5-[(3-bromophenyl)amino]-l,3,4-thiadiazol-2-yl}benzoic acid
As described in Example 2, the title compound was prepared from 3-carbonylbenzoic acid (70mg) and [(3 -bromophenyl)amino]hydrazinomethane-l -thione (lOOmg). The title compound had the following physical properties: mp 270-272°C.
Example 162: (5-benzo[c]l,2,5-oxadiazol-5-yl(l,3,4-thiadiazol-2-yl))(3,4-dichlorophenyl)amine
As described in Example 1, the title compound was prepared from 3,4- dichlorobenzenisothiocyanate (120mg) and N-aminobenzo[3,4-c]l,2,5-oxadiazol-5- ylcafboxamide (88mg). The title compound had the following physical properties: mp 315- 317°C; LC-MS 364.1.
Example 163: [(3-phenylmethoxy)phenyl](5-{3-[3-trifluoromethyl)phenoxy]-phenyl}(l,3,4-thiadiazol-2- yl)} amine
As described in Example 2, the title compound was prepared from {3-[3- (trifluoromethyl)phenoxy]phenyl} formaldehyde (490mg) and [({3-phenylmethoxy} phenyl)amino]hydrazinomethane-l -thione (500mg). The title compound had the following physical properties: mp 150-152°C; LC-MS: 520.02.
Example 164:
3-{3-[5-(3,4-Dichloro-phenylimino)-4-methyl-4,5-dihydro-[l,3,4]thiadiazol-2-yl]-phenoxy}- benzoic acid 3-{3-[5-(3,4-Dichloro-phenylimino)-4-methyl-4,5-dihydro-[l,3,4]thiadiazol-2-yl]- phenoxy} -benzoic acid methyl ester: The title compound was prepared using the procedure described in Example δ from 3-{3-[5-(3,4-Dichloro-phenylamino)-[l,3,4]thiadiazol-2-yl]- phenoxy} -benzoic acid methyl ester (0.32mmols, 150mg), potassium tert-butoxide (0.32mL, 1 M, 0.32mmol) and methyl iodide (3.2mmol, 0.2mL). Yield: 54 mg (35%). !H NMR (300 MHz, d6-DMSO): δ 7.78-7.07 (11 H, m), 3.84 (3 H, s), 3.69 (3 H, s).
The title compound was prepared using the procedure described in Example 7 from 3-{3- [5-(3,4-Dichloro-phenylimino)-4-methyl-4,5-dihydro-[l,3,4]thiadiazol-2-yl]-phenoxy}-benzoic acid methyl ester (0.03mmols, 16mg) and LiOH (0.03mmol, 7.8mg). Yield: 12mg (85%). mp
193-196°C.
1H NMR (300 MHz, dι-CDCl3): 5 7.89 (1 H, d), 7.70 (1 H, s), 7.50-7.21 (7 H, m), 7.07 (1 H, d),
6.95 (1 H, d), 3.78 (3 H, s).
Example 165:
4-{N'-[l-(3-{5-[3-(3-Trifluoromethyl-phenoxy)-phenyl]-[l,3,4]thiadiazol-2-ylamino}- phenyl)-ethylidene]-hydrazino}-benzoic acid
N-({[(3-acetylphenyl)amino]thioxomethyl}amino){3-[3(trifluoromethyl)phenoxy] phenyl}carboxamide: The title compound was prepared using the procedure described in
Example 1 from 3-(3-Trifluoromethyl-phenoxy)-benzoic acid hydrazide (lmmol, 300mg) and 1-
(3-Isothiocyanato-phenyl)-ethanone (lmmol, 180mg). l-(3-{5-[3-(3-Trifluoromethyl-phenoxy)-phenyl]-[l,3,4]thiadiazol-2-ylamino}-phenyl)- ethanone was prepared using the procedure described in Example 1 from N-({[(3- ' acetylphenyl)amino]thioxomethyl}amino){3-[3(trifluoromethyl)phenoxy] phenyl}carboxamide and sulfuric acid (0.4mL). Yield: 158mg (35% from first step), mp 130-133°C.
1H NMR (300 MHz, d^CDCls): δ 9.67 (1 H, s), 8.09 (1 H, s), 7.75-7.20 (10 H, m), 7.10 (1 H, d),
2.65 (3 H, s).
A solution of l-(3-{5-[3-(3-Trifluoromethyl-phenoxy)-phenyl]-[l,3,4]thiadiazol-2- ylamino}-phenyl)-ethanone (0.18mmol, 80mg) and 4-Hydrazino-benzoic acid (0.18mmol,
27mg) in dry ethanol (5mL) under nifrogen refluxed overnight. After cooling to room temperature, the mixture was filtered and the solid washed by ethanol, IN HCl (aqueous), water and hexanes to give the title compound as a light brown solid (60mg, 57%); mp 277.5-279°C.
LCMS (M+H) 589.9; (M-H) 588.0.
Example 166:
4-({[5-(3-phenoxyphenyl)-l,3,4-thiadiazol-2-yl]amino}methyl)benzoic acid
A solution of the product from Procedure D (3-phenoxybenzaldehyde) (lg, 5.04mmol) and methyl 4-(isocyanate)benzoate (1.04g, 5.04mmol) in dry Ethanol (25mL) under Argon was refluxed for two hours. After cooling to room temperature, the mixture was filtered and the solid washed by ethanol. The solid was suspended in dry ethanol (20mL) and iron (III) chloride hexahydrate (5.7mmol, 1.54g) was added. The reaction mixture was refluxed for two more hours, then cooled to room temperature. The solid was collected by filter and washed by ethanol, then crystallized from ethyl acetate/hexane yielded 1.36g (65%) of methyl 4-({[5-(3- phenoxyphenyl)-l ,3,4-thiadiazol-2-yl]amino}methyl)benzoate.
A solution of methyl 4-({[5-(3-phenoxyphenyl)-l,3,4-thiadiazol-2- yl]amino}methyl)benzoate (1.36g, 3.26mmol) and LiOH (1.96g, 3.5mmol) in lOmL of a mixture of H2O/MeOH/THF (6:2:2) was stirred at room temperature for two hours. The solvent was removed and the residue was purified using flash chromatography on silica gel. Eluting with chloroform/methanol (91:10) provide a white solid (1.16g, 85%) of 4-({[5-(3-phenoxyphenyl)- 1 ,3 ,4-thiadiazol-2-yl]amino}methyl)benzoic acid.
MS (SSQ 7000): M+ = 404. Column: Betasil C18 5μm 50x3mm Solvent A: Water + 0.01% AcOH; Solvent B: CA + 0.1% AcOH M.P: 192-195°C
Example 167:
N- [4-({(3,4-dichlor ophenyl) [5-(3-phenoxyphenyl) (l,3,4-thiadiazol-2-yl)]amino}methyl)phenyl]methanecarboxylic acid.
Following the procedure described in Example 8, the methyl ester of the title compound was prepared from 0.17g of (3,4-dichlorophenyl)[5-(3-phenoxyphenyl)(l,3,4-thiadiazol-2- yl)]amine and 0.1 lg of methyl {N-[4-(bromomethyl)phenyl]carbamoyl}-formate.
This ester was subjected to the procedure described in Example 7, yielding the title compound from 0.1 lg of methyl {N-[4-({(3,4-dichlorophenyl)[5-(3-phenoxyphenyl)(l,3,4- thiadiazol-2-yl)]amino}methyl)phenyl]carbamoyl} formate and 2.0mL of 2.5M lithium hydroxide, with the following physical properties: mp 198-200°C (from 2/1 Hexanes/Ethyl Acetate), LC-MS 589.
Example 168: 4-({(3,4-dichlorophenyl)[4-(4-phenylphenyl)(l,3-thiazol-2-yl)]amino}methyl)benzoic acid.
Following the procedure described in Example 8, the methyl ester of the title compound was prepared from 0.40g of (3,4-dichlorophenyl)[4-(4-phenylρhenyl)(l,3-thiazol-2-yl)]amine and 0.23g of methyl-(4-(bromomethyl)benzoate. This ester was subjected to the procedure described in Example 7, yielding the title compound from 0.30g of methyl 4-({(3,4-dichlorophenyl)[4-(4-phenylphenyl)(l,3-thiazol-2- yl)]amino}methyl)benzoate and 2.0mL of 2.5 M lithium hydroxide, with the following physical properties: mp 202-204°C (from 4/1 Hexanes/Ethyl Acetate), LC-MS 529.
Example 169:
N-(3-{[(3,4-dichlorophenyl)(5-{3-[3(trifluoromethyl)phenoxy]phenyl}-(l,3,4-thiadiazol-2- yl))amino] methyl}phenyl)methanecarboxylic acid
Following the procedure described in Example 8, the methyl ester of the title compound was prepared from 0.3g of (3,4-dichlorophenyl)(5-{3-[3-(trifluoromethyl)- phenoxy]phenyl}(l,3,4-thiadiazol-2-yl))amine and 0.2g of methyl {N-[4- (bromomethyl)phenyl]carbamoyl} formate.
This ester was subjected to the procedure described in Example 7, yielding the title compound from 0.1 lg of methyl[N-(4-{[(3,4-dichlorophenyl)(5-{3-[3- (trifluoromethyl)phenoxy]phenyl}(l,3,4-thiadiazol-2- yl))amino]methyl}phenyl)carbamoyl]formate and 0.2mL 2.5M lithium hydroxide, with the following physical properties: mp 172-174°C (from 4/1 Hexanes/Ethyl Acetate), MS 659.4 [M+].
Example 170:
2-{4-[(2-[aza(3,4-dichlorophenyl)methylene]-5-{3-[3-(trifluoromethyl)phenoxy]phenyl}- l,3,4-thiadiazolin-3-yl)methyl]phenyl} acetic acid.
Following the procedure described in Example 8, the methyl ester of the title compound was prepared from 0.30g of (3,4-dichlorophenyl)(5-{3-[3-(frifluoromethyl)- phenoxy]phenyl}(l,3,4-thiadiazol-2-yl))amine and 0.l5g of methyl-(4-(bromomethyl)benzoate. This ester was subjected to the procedure described in Example 7, yielding the title compound from 0.013g of methyl 2-(4-{[(3,4-dichlorophenyl)(5-{3-[3- (trifluoromethyl)phenoxy]phenyl}(l,3,4-thiadiazol-2-yl))amino]methyl}phenyl)acetate and 0.04mL of 2.5M lithium hydroxide, with the following physical properties: mp 136-138°C (from 4/1 Hexanes/Ethyl Acetate), MS 630.5 [M+]. Example 171:
4-{5-[3-3-{5-[(3,4-dichlorophenyl)amino]-l,3,4-thiadiazol-2-yl}phenoxy) phenyl]-l,2,3,4- tetrazoyl}butanoic acid
3-(3-{5-[3,4-dichlorophenylammo]-l,3,4-thiadiazol-2-yl}phenoxy) benzenecarbonitrile, 3.2mmol, was dissolved in dry DMF. Sodium azide, 9.5mmol, and ammonium chloride, 9.5mmol, were added and the mixture was stirred at 115°C for 24 hours. The mixture was cooled to room temperature and recharged with 5mmol of sodium azide/ammonium chloride and heated at 115°C for 6 hours. The mixture was then cooled to room temperature and applied directly to silica gel chromatography, hexane/acetone (4/1) to yield 1.2g of pure (3,4- Dichlorophenyl)-(5-{3-[3-(2H-tertazol-5-yl)-phenoxy]-phenyl}-[l,3,4]thiadiazol-2-yl)-amine (78%). •
(3,4-Dichlorophenyl)-(5-{3-[3-(2H-tertazol-5-yl)-phenoxy]-phenyl}-[l,3,4]thiadiazol-2- yl)-amine, 0.09mmol, was dissolved in ~ ImL acetone/DMF (1/1). Triethylamine, 0.12mmol, and 4-Iodo-methyl butyrate, 0. lmmol, were added and heated to 80°Celsius for two hours. The residue was applied directly to silica gel chromatography. The pure product was hydrolyzed in lithium hydroxide/THF/Methanol (2/1/1). The solution was then neutralized with IM HCl (aq). The crude product was collected by filtration, washing several times with water, followed by hexane, then dried en vacuo. The product was recrystallized from ethanol/water to give 25mg (48%) of the title compound, with the following physical properties: mp 137-142°C (decomposition); MS (A&A Labs); m/z 568.2/570.2 [M+H].
Example 172:
4-({(lE)-l-aza-2-[3-(3-{5-[(3,4-dichlorophenyl)amino] (l,3,4-thiadiazol-2- yl)}phenoxy)phenyl]vinyl}amino)benzoic acid 3-(3-[l,3] dioxalan-2-yl-phenoxy) benzaldehyde, 16.6mmol, and [(3,4- dichloropheny)amino] hydrazinomethane-1 -thione, 16.6mmol, were combined in ethanol and heated to reflux for two hours. The solution was cooled to room temperature and the precipitate was collected by filfration, and washed with hexane (3x). The white solid was slurried in ethanol and 3eq of Fe(III)Cl3 was added. The slurry was refluxed for two hours, cooled and the crude product collected by filtration. The crude product was washed (3x) with water followed by hexane. The product was recrystallized from hot ethanol water to give 3.2g of the title compound. Yield 39%(isolated). This product was subjected to 0. IM HCl in methanol at room temperature for 18 hours to reveal the aldehyde, 3-{3-[5-(3,4-dichloro-phenylamino)-[l,3,4]thiadiazol-2-yl]-phenoxy}- benzaldehyde, which was purified on silica gel; hexane/ethyl acetate (1/1), followed by recrystalization to give 1.7g of product (60%).
3-{3-[5-(3,4-dichloro-phenylamino)-[l,3,4]thiadiazol-2-yl]-phenoxy}-benzaldehyde 0.38mmol, and 4-carboxy-phenyl hydrazine were combined in ethanol and heated at reflux for 4 hours. Upon cooling the product precipitated and was washed with water and hexane to give 75mg (34%) of analytically pure title compound, with the following physical properties: mp 259- 262°C. MS (A&A Labs); m/z 576.5 [M+H].
Example 173:
(6Z)-7-[3-(3-{5-[3,4-dichlorophenyl)amino](l,3,4-thiadiazol-2- yl)}phenoxy)phenyl]heptanoic acid
[6-(Ethoxycarbonyl)hexyl]triphenylphosphonium bromide, 35mmol, in 75mL THF at 0°C under an Argon atmosphere was treated with 34mmol of Na HMDS (2.5M in THF) and stirred for 30 minutes at room temperature. The mixture was then cooled to 0°C and 3-(3-[l,3] dioxalan-2-yl-phenoxy) benzaldehyde, 3.5mmol in lOmL THF was added via syringe. The ice bath was removed and the reaction was stirred at room temperature for one hour. The reaction was then diluted with ether and 250mL of saturated ammonium chloride was added. The aqueous layer was exfracted with ether (3x) and the combined organic fraction was washed with brine, dried with MgS04, and the solvent removed on a rotovap. The crude compound was purified by silica gel chromatography (hexane/ethyl acetate) to give 1.2g of product (~9/l) cis/frans. The acetal was hydrolyzed with IN HCl / THF (1/9) at room temp for 12 hours. The product was purified by silica gel chromatography to yield 765mg of the cis isomer; 7-[3-(3- Formyl-phenoxy)-phenyl]-hept-6-enoic acid ethyl ester (yield: 63 %, from 3-(3-[l,3] dioxalan-2- yl-phenoxy) benzaldehyde).
7-[3-(3-Formyl-phenoxy)-phenyl]-hept-6-enoic acid ethyl ester. 0.85mmol, and [(3,4- dichloropheny)amino] hydrazinomethane-1 -thione, 0.85mmol, were combined as described in Example 2, followed by hydrolysis with 0.25M LiOH in THF to give 200mg of the title compound, yield: 43%, which was recrystallized from ethanol/water, with the following physical properties: mp 142-145°C. MS m/z 540.3 [M+H]. Selected compounds of the invention are evaluated for biological activity as inhibitors of tyrosine phosphatase as described previously, and the results are presented in Figure 1.
In addition, selected compounds of the present invention, identified by example or compound number, have been evaluated for biological activity as inhibitors of other tyrosine phosphatases as described previously, and the results are as follows:
Compound PTP-IB TC-PTP PTP-β CD-45 ICso (μM) ICso (μM) ICso (μM) ICso (μM)
Example 16 12 30,30 >100 30
Example 135 6 20, 12 >100 20
Example 66 7 20, 30 >100 25
Example 80 7 14, 8 >100 80
Example 14 5 12 24 10
Example 7 12 15 31 17
Example 172 0.8 1.6 30 14
Example 168 1
Example 169 1
Example 171 2
Compound 187 1 1 5 5
Compound 188 10
Compound 190 5
Compound 198 4
All patents and patent applications cited in this specification are hereby incorporated by reference as if they had been specifically and individually indicated to be incorporated by reference.

Claims

Claims:
1. A method of inhibiting protein tyrosine phosphatase activity which comprises administering to a mammal an effective amount of a compound having the formula:
R1 R2
(I)
R3 or a pharmaceutically acceptable salt thereof, wherein: Rl, R2, and R3 are each independently selected from
H, hydroxyl, alkoxy, alkylthio, nifro, amino or amido (each unsubstituted or substituted with alkyl, amino, cycloheteroalkyl, cycloalkyl fluoro, aryl, heteroaryl, cycloheteroalkyl, alkylthio, arylthio, cyano, OR', OC=OR", C=O-OR'", or C=O- NR""R""); small alkyl (C1-C10) (unsubstituted or substituted with alkyl, amino, cycloheteroalkyl, cycloalkyl fluoro, aryl, heteroaryl, cycloheteroalkyl, alkylthio,
P=O(OR")2, CH2P=0(OR")2, CF2P=0(OR")2, NHCOCOOR", CH(COOR")2, arylthio, cyano, OR", OC=OR", C=0-OR'", or C=0-NR""R""); phenyl and mono and disubstituted (at positions 3 and 4) phenyl (wherein the phenyl ring is independently substituted with alkyl, trifluoromethyl, mono and di halogen atoms, alkylthio, alkoxy, nitro, cyano, morphilino, cyclohexyl, phenyl, phenolic, dioxymethylene, nifro, acetylamino, OR', P=O(OR")2, CH2P=0(OR") , CF2P=0(OR")2, NHCOCOOR", CH(COOR")2 ); heteroaryl, cycloheteroalkyl and cycloheteroalkyl (each unsubstituted or substituted with alkyl, halogen, alkylthio, alkoxy, or nitro, OR', P=0(OR")2, CH2P=0(OR")2, CF2P=O(OR")2, NHCOCOOR", CH(COOR")2, ); cycloalkyl (C3-C10) (unsubstituted or substituted with alkyl, fluoro, aryl, heteroaryl, cycloheteroalkyl, cycloheteroalkyl alkylthio, arylthio, cyano, P=O(OR")2,
CH2P=O(OR")2, CF2P=O(OR")2, NHCOCOOR", CH(COOR")2, OR', OC=OR', C=O- OR", or C=0-NR'"R""); alkenyl (C1-C10) (unsubstituted or substituted with alkyl, fluoro, aryl, heteroaryl, cycloheteroalkyl, cycloheteroalkyl, alkylthio, arylthio, cyano, P=0(OR")2,
CH2P=0(OR")2, CF2P=O(OR")2, NHCOCOOR", CH(COOR")2, OR', OC=OR', COOR", or C=0-NR'"R""); alkadienyl (C1-C10) (unsubstituted or substituted with alkyl, fluoro, aryl, heteroaryl, cycloheteroalkyl, cycloheteroalkyl, alkylthio, arylthio, cyano, P=0(OR' ')2,
CH2P=0(OR")2, CF2P=O(OR")2, NHCOCOOR", CH(COOR")2, OR', -OC=OR5, - C=0-OR", C=0-NR"'R""); cycloalkenyl (C4-C10), unsubstituted or substituted with alkyl, fluoro, aryl, heteroaryl, cycloheteroalkyl, cycloheteroalkyl, alkylthio, arylthio, cyano, P=O(OR")2, CH2P=O(OR")2, CF2P=0(OR")2, NHCOCOOR", CH(COOR")2, OR', -OC=OR', - C=O-OR", C=0-NR"'R""; bicycloalkyl (C5-C12), unsubstituted or substituted with alkyl, fluoro, aryl, heteroaryl, cycloheteroalkyl, cycloheteroalkyl, alkylthio, arylthio, cyano, P=O(OR")2, CH2P=O(OR")2, CF2P=0(OR")2, NHCOCOOR", CH(COOR")2, OR', -OC=OR', - C=O-OR", C=0-NR"'R""; tricycloalkyl (C8-C14) , unsubstituted or substituted with alkyl, fluoro, aryl, heteroaryl, cycloheteroalkyl, cycloheteroalkyl, alkylthio, arylthio, cyano, P=O(OR")2, CH2P=0(OR")2, CF2P=0(OR")2, NHCOCOOR", CH(COOR")2, OR', -OC=OR', - COOR", C=0-NR"'R""; where
Each R' is independently: hydrogen; alkyl (C1-C10), unsubstituted or substituted with alkyl, keto, fluoro, alkoxy, alkylthio, aryl, heteroaryl, cycloheteroalkyl, cycloheteroalkyl, cyano, aryloxy, cycloalkyl, COOR", P=O(OR")2, CH2P=O(OR")2, CF2P=O(OR")2, NHCOCOOR", CH(COOR")2; aryl, unsubstituted or substituted with alkyl, keto, fluoro, alkoxy, alkylthio, cyano, aryloxy, COOR", P=0(OR")2, CH2P=0(OR")2, CF2P=0(OR")2, NHCOCOOR", CH(COOR")2; heteroaryl, cycloheteroalkyl, cycloheteroalkyl, unsubstituted or substituted with alkyl, keto, fluoro, alkoxy, alkylthio, cyano, aryloxy, COOR", P=O(OR")2, CH2P=0(OR")2, CF2P=0(OR")2, NHCOCOOR", CH(COOR")2; cycloalkyl, unsubstituted or substituted with alkyl, keto, fluoro, alkoxy, alkylthio, aryl, heteroaryl, cycloheteroalkyl, cycloheteroalkyl, cyano, COOR", P=O(OR")2, CH2P=0(OR")2, CF2P=0(OR")2, NHCOCOOR", CH(COOR")2;
Each R" is independently hydrogen, alkyl (C1-C10), unsubstituted or substituted with alkyl, keto, fluoro, alkoxy, alkylthio, aryl, heteroaryl, cycloheteroalkyl, cycloheteroalkyl; aryl, unsubstituted or substituted with alkyl, keto, fluoro, alkoxy, alkylthio; heteroaryl, cycloheteroalkyl, unsubstituted or substituted with alkyl, keto, fluoro, alkoxy, alkylthio; cycloalkyl, unsubstituted or substituted with alkyl, keto, fluoro, alkoxy, alkylthio, aryl, heteroaryl, cycloheteroalkyl;
Each R'" is independently alkyl (C1-C10), unsubstituted or substituted with alkyl, keto, fluoro, alkoxy, alkylthio, aryl, heteroaryl, cycloheteroalkyl, COOR' ', P=0(OR' ')2,
CH2P=0(OR")2, CF2P=0(OR")2, NHCOCOOR", CH(COOR")2; aryl, unsubstituted or substituted with alkyl, keto, fluoro, alkoxy, alkylthio; heteroaryl, cycloheteroalkyl, unsubstituted or substituted with alkyl, keto, fluoro, alkoxy, alkylthio, COOR", P=O(OR")2, CH2P=O(OR")2, CF2P=O(OR")2, NHCOCOOR", CH(COOR")2; cycloalkyl, unsubstituted or substituted with alkyl, keto, fluoro, alkoxy, alkylthio, aryl, heteroaryl, cycloheteroalkyl, COOR' ' , P=O(OR' ')2,
CH2P=O(OR")2, CF2P=O(OR")2, NHCOCOOR", CH(COOR")2; and
Each R"" is independently alkyl (C1-C10), unsubstituted or substituted with alkyl, keto, fluoro, alkoxy, alkylthio, aryl, heteroaryl, cycloheteroalkyl, COOR", P=O(OR")2, CH2P=O(OR")2, CF2P=O(OR")2, NHCOCOOR", CH(COOR")2; aryl, unsubstituted or substituted with alkyl, keto, fluoro, alkoxy, alkylthio, COOR", P=O(OR")2, CH2P=O(OR")2, CF2P=O(OR")2,
NHCOCOOR", CH(COOR")2; heteroaryl, cycloheteroalkyl, unsubstituted or substituted with alkyl, keto, fluoro, alkoxy, alkylthio, COOR", P=O(OR")2, CH2P=0(OR")2, CF2P=0(OR")2, NHCOCOOR", CH(COOR")2; and cycloalkyl, unsubstituted or substituted with alkyl, keto, fluoro, alkoxy, alkylthio, aryl, heteroaryl, cycloheteroalky, COOR", P=0(OR")2, CH2P=O(OR")2, CF2P=O(OR")2, NHCOCOOR", CH(COOR")2; and wherein each of Rl, R2 and R3 are linked to their respective core atoms through C, N, O or S of the substiuent group, provided that if R2 is to be linked through O or S, then the core atom S is oxidized.
2. A method as recited in claim 1 wherein Rl and R2 are taken together with the core unit to which they are attached (formula I) to form a heterocyclic group having formula (II) as follows:
R5
R5
R1 , R2 = N = (i.e. A (H)
R3
wherein R5 is an amino group with two substituents, where one substituent is arylcarbonyl, arylmethylcarbonyl, arylsulfonyl, aryldimethyloxycarbonyl, or aryloxymethylcarbonyl, [where the aryl group is phenyl, benzox[c]l,2,5-oxadiazol-5-yl, 1-furyl, 2-furyl 1 -naphthyl or 2-naphthyl, unsubstituted or substituted with one or more of the following or their combinations: perfluoroalkyl (C1-C4), alkyl (C1-C4), nifro, alkoxycarbonyl (C1-C4), carboxyl, carboxyalkyl(Cl-C4), CF2P=O(OH)2, NHCOCOOH, phenoxy (unsubstituted or substituted with alkoxy (C1-C4), CF2P=O(OH)2, NHCOCOOH, COOH, and/or halogen), or phenylalkoxy (C1-C4)], hydrogen, CF2P=0(OH)2, NHCOCOOH, or a phenyl group [unsubstituted or with one or more of the following substituents or combinations: hydroxy, halogen, nifro, CF2P=O(OH)2, NHCOCOOH, carboxy, carboxyalkyl(Cl-C4), carboxyalkylthio (C1-C6), phenyl, alkyl (C1-C10) or alkoxy (C1-C10) (unsubstituted or substituted withNRlR2, COOH, cycloheteroalkyl), perfluoroalkyl (C1-C4), alkoxycarbonyl (C1-C4), alkylthio (C1-C4), phenylalkoxy (C1-C4), phenylsulfonylamino (each unsubstituted or substituted on phenyl with alkyl (C 1 -C4)), phenoxy (unsubstituted or substituted on phenyl with nifro, perfluoroalkyl (C1-C4), carboxymethyl, carboxy, CF2P=O(OH)2, NHCOCOOH, alkoxycarbonylmethyl (C1-C4)), carboxyalkyl(Cl-C4), phenylalkylthio (C1-C4, unsubstituted or substituted on phenyl with alkoxy (C1-C4), and/or phenyl), aminosulfonyl, alkylaminosulfonyl (C1-C4), dialkylammosulfonyl (C1-C4 where the two alkyls unsubstituted or form a heteroalicyclic ring)]; and the second substituent on the amino group forming R5 is hydrogen, alkyl (C1-C10) or alkoxy (C1-C10) (each unsubstituted or substituted with NR1R2, COOH, CF2P=O(OH)2, NHCOCOOH, cycloheteroalkyl), naphthylalkyl (C1-C4), phenylalkyl (C1-C4, with the phenyl group unsubstituted or substituted with phenyl, alkyl (C1-C4), halo, amino, amido, keto, CF2P=0(OH)2, NHCOCOOH, alkyl (C1-C10) or alkoxy (C1-C10) (unsubstituted or substituted with NR1R2, COOH, cycloheteroalkyl), nifro, carboxy, perfluoroalkylthio (C1-C4), halogen, CF2P=O(OH)2, NHCOCOOH, 1,2,3-thiadiazolyl, and/or alkoxy carbonyl (C1-C4)), alkyl (Cl- C10), cycloalkyl (C4-C8, unsubstituted or substituted with alkyl (C1-C4)), or indanyl (unsubstituted or substituted with alkyl (C1-C4)).
3. A method as recited in claim 2 wherein R3 is
(1) a phenyl group unsubstituted or substituted with one to three of the following and their combinations: halogen, hydroxy, aryloxy, nifro, carboxylic acid, CF2P=0(OH)2, NHCOCOOH, alkyl (C 1 -C 10) or alkoxy (C 1 -C 10) (unsubstituted or substituted with NRl R2, COOH, cycloheteroalkyl), alkylthio (C1-C4), 2'-hydroxyethoxy, alkoxycarbonylmethoxy (Cl- C4), dialkylamino (C1-C4 where the two alkyls can form a heteroalicyclic ring), 2- (dialkylamino)-2-oxoethoxy (C1-C7 where the two alkyls can form a heteroalicyclic ring), difluoromethoxy, perfluoroalkyl (C1-C4), perfluoroalkylthio (C1-C4), perfluoroalkoxy (C1-C4), 2-carboxyvinyl, alkanoyl (C1-C5), alkoxycarbonyl (C1-C4), alkanoylamino (C1-C8), benzoylamino (unsubstituted or substituted with one or more perfluoroalkyl group (Cl- C4)anά7or CF2P=O(OH)2, NHCOCOOH,), aryl, aryloxy, arylcarbonyl, arylmethoxy, arylmethyl in which the methyl group is substituted with hydroxyl, 0(CH2)nCOOH (n=l-5), S(CH2)nCOOH (n=l-5), (4-carboxy)benzyloxy, (3-carboxybenzyloxy), or the group =N-O-CH2R in which R is carboxyl, alkoxycarbonyl (C1-C4), hydrogen, or phenyl (unsubstituted or substituted with one or more halogens), or the group =N-NHAr in which Ar is a phenyl (unsubstituted or substituted with one or more alkyl groups (C1-C4), and/or a carboxyl group, and/or
Figure imgf000115_0001
NHCOCOOH), or the group-Y-(CH2)n-Z, where Y is O or S, n is 1, 2, or 3, and Z is hydrogen, methyl, branched alkyl (C3-C5), cycloalkyl (C3-C6), phenyl (unsubstituted or substituted with one or more of the following: halogen, frifluoroalkyl, carboxy, alkoxycarbonyl (C1-C4), CF2P=0(OH)2, NHCOCOOH, or carboxyl; or
(2) a pyridylthio group unsubstituted or substituted with one or more halogen and/or one or more nifro groups, methylenedioxyphenyl, benzo[3,4-c]l,2,5-oxadiazol-5-yl, 4-oxo-3- hydroquinazolin-2-yl, or a group having formula (III) as follows:
Figure imgf000116_0001
in which the imidazole ring is unsubstituted or substituted with one or more halogens.
4. A method as recited in Claim 1 wherein Rl and R2 are taken together with the core unit to which they are attached (formula I) to form a heterocyclic group having formula (IV) as follows:
Figure imgf000116_0002
wherein R6 and R7 are each independently as defined for Rl, R2 and R3.
5. A method as recited in Claim 1 wherein Rl and R2 are linked through an aromatic ring, and taken together with the N=CR3-S unit to which they are attached, form a tricyclic heterocyclic group having formula (V) as follows:
Figure imgf000116_0003
Where R9, RIO and Rl 1 are each independently as defined for Rl, R2 and R3.
6. A method as recited in Claim 1 wherein Rl and R2, taken together with the N=CR3-S unit to which they are attached, form a heterocyclic group having formula (VI) as follows:
Figure imgf000117_0001
Wherein R12 and R13 are each independently as defined for Rl, R2 and R3.
7. A method as recited in Claim 1 wherein Rl and R3, taken together with the N=C-
SR2 unit to which they are attached, form a heterocyclic group having formula (VII) as follows:
Figure imgf000117_0002
Wherein Rl 4 and Rl 5 are each independently as defined for Rl , R2 and R3.
8. A method as recited in Claim 1 wherein Rl and R3, taken together with the N=C- SR2 unit to which they are attached, form a bicylic heterocyclic group having formula (VIII) as follows:
Figure imgf000117_0003
Wherein R18 and R19 are each independently as defined for Rl, R2 and R3.
9. A method as recited in Claim 1 wherein Rl, R2 and R3, taken together with the N=C-S unit to which they are attached, form a bicyclic heterocyclic group having formula (IX) as follows:
)
Figure imgf000118_0001
Wherein R20, R21 and R22 are each independently as defined for Rl, R2 and R3.
10. A method as recited in Claim 1 wherein Rl, R2 and R3, taken together with the N=C-S unit to which they are attached, form a bicyclic heterocyclic group having formula (X) as follows:
Figure imgf000118_0002
Where R23 and R24 are each independently as defined for Rl, R2 and R3.
11. A pharmaceutical composition which comprises an effective amount of a compound having the formula:
Figure imgf000119_0001
or a pharmaceutically acceptable salt thereof, wherein:
Rl, R2, and R3 are each independently selected from
H, hydroxyl, alkoxy, alkylthio, nifro, amino or amido (each unsubstituted or substituted with alkyl, amino, cycloheteroalkyl, cycloalkyl fluoro, aryl, heteroaryl, cycloheteroalkyl, alkylthio, arylthio, cyano, OR', OC=OR", C=0-OR'", or C=0- NR""R""); small alkyl (C1-C10) (unsubstituted or substituted with alkyl, amino, cycloheteroalkyl, cycloalkyl fluoro, aryl, heteroaryl, cycloheteroalkyl, alkylthio,
P=O(OR")2, CH2P=0(OR")2, CF2P=0(OR")2, NHCOCOOR", CH(COOR")2, arylthio, cyano, OR", OC=OR", C=O-OR'", or C=0-NR""R""); phenyl and mono and disubstituted (at positions 3 and 4) phenyl (wherein the phenyl ring is independently substituted with alkyl, trifluoromethyl, mono and di halogen atoms, alkylthio, alkoxy, nitro, cyano, morphilino, cyclohexyl, phenyl, phenolic, dioxymethylene, nifro, acetylamino, OR', P=O(OR")2, CH2P=0(OR")2, CF2P=0(OR")2, NHCOCOOR", CH(COOR")2 ); heteroaryl, cycloheteroalkyl and cycloheteroalkyl (each unsubstituted or substituted with alkyl, halogen, alkylthio, alkoxy, or nifro, OR', P=O(OR")2, CH2P=0(OR")2, CF2P=0(OR")2, NHCOCOOR", CH(COOR")2, ); cycloalkyl (C3-C10) (unsubstituted or substituted with alkyl, fluoro, aryl, heteroaryl, cycloheteroalkyl, cycloheteroalkyl alkylthio, arylthio, cyano, P=O(OR")2,
CH2P=O(OR")2, CF2P=0(OR")2, NHCOCOOR", CH(COOR")2, OR', OC=OR', COOR", or C=0-NR'"R""); alkenyl (C1-C10) (unsubstituted or substituted with alkyl, fluoro, aryl, heteroaryl, cycloheteroalkyl, cycloheteroalkyl, alkylthio, arylthio, cyano, P=0(OR")2,
CH2PO(OR")2, CF2P (OR")2. NHCOCOOR", CH(COOR")2, OR', OCOR', COOR", or CO-NR"'R""); alkadienyl (C1-C10) (unsubstituted or substituted with alkyl, fluoro, aryl, heteroaryl, cycloheteroalkyl, cycloheteroalkyl, alkylthio, arylthio, cyano, P (OR")2,
CH2P=0(OR")2, CF2P (OR")2, NHCOCOOR", CH(COOR")2, OR', -OC R5, - CO-OR", C -NR"'R""); cycloalkenyl (C4-C10), unsubstituted or substituted with alkyl, fluoro, aryl, heteroaryl, cycloheteroalkyl, cycloheteroalkyl, alkylthio, arylthio, cyano, P=O(OR")2, CH2P (OR")2, CF2P=O(OR")2, NHCOCOOR", CH(COOR")2, OR', -OCOR', - CO-OR", CO-NR'"R' bicycloalkyl (C5-C12), unsubstituted or substituted with alkyl, fluoro, aryl, heteroaryl, cycloheteroalkyl, cycloheteroalkyl, alkylthio, arylthio, cyano, P=O(OR")2, CH2PO(OR")2, CF2P=0(OR")2, NHCOCOOR", CH(COOR")2, OR', -OCOR', - CO-OR", CO-NR'"R' fricycloalkyl (C8-C14) , unsubstituted or substituted with alkyl, fluoro, aryl, heteroaryl, cycloheteroalkyl, cycloheteroalkyl, alkylthio, arylthio, cyano, P=O(OR")2, CH2PO(OR")2, CF2P (OR")2, NHCOCOOR", CH(COOR")2, OR', -OCOR', - CO-OR", CO-NR"'R""; where
Each R' is independently: hydrogen; alkyl (C1-C10), unsubstituted or substituted with alkyl, keto, fluoro, alkoxy, alkylthio, aryl, heteroaryl, cycloheteroalkyl, cycloheteroalkyl, cyano, aryloxy, cycloalkyl, COOR", PO(OR")2, CH2PO(OR")2, CF2P=O(OR")2, NHCOCOOR", CH(COOR")2; aryl, unsubstituted or substituted with alkyl, keto, fluoro, alkoxy, alkylthio, cyano, aryloxy, COOR", P=0(OR")2, CH2PO(OR")2, CF2PO(OR")2, NHCOCOOR", CH(COOR")2; heteroaryl, cycloheteroalkyl, cycloheteroalkyl, unsubstituted or substituted with alkyl, keto, fluoro, alkoxy, alkylthio, cyano, aryloxy, COOR", P (OR")2, CH2PO(OR")2, CF2P=0(OR")2, NHCOCOOR", CH(COOR")2; cycloalkyl, unsubstituted or substituted with alkyl, keto, fluoro, alkoxy, alkylthio, aryl, heteroaryl, cycloheteroalkyl, cycloheteroalkyl, cyano, COOR", PO(OR")2, CH2PO(OR")2, CF2P (OR")2, NHCOCOOR", CH(COOR")2;
Each R" is independently hydrogen, alkyl (C1-C10), unsubstituted or substituted with alkyl, keto, fluoro, alkoxy, alkylthio, aryl, heteroaryl, cycloheteroalkyl, cycloheteroalkyl; aryl, unsubstituted or substituted with alkyl, keto, fluoro, alkoxy, alkylthio; heteroaryl, cycloheteroalkyl, unsubstituted or substituted with alkyl, keto, fluoro, alkoxy, alkylthio; cycloalkyl, unsubstituted or substituted with alkyl, keto, fluoro, alkoxy, alkylthio, aryl, heteroaryl, cycloheteroalkyl;
Each R'" is independently alkyl (C1-C10), unsubstituted or substituted with alkyl, keto, fluoro, alkoxy, alkylthio, aryl, heteroaryl, cycloheteroalkyl, COOR' ' , P=0(OR' ')2,
CH2P (OR")2, CF2P=0(OR") , NHCOCOOR", CH(COOR")2; aryl, unsubstituted or substituted with alkyl, keto, fluoro, alkoxy, alkylthio; heteroaryl, cycloheteroalkyl, unsubstituted or substituted with alkyl, keto, fluoro, alkoxy, alkylthio, COOR", PO(OR")2, CH2PO(OR")2, CF2P (OR")2, NHCOCOOR", CH(COOR")2; cycloalkyl, unsubstituted or substituted with alkyl, keto, fluoro, alkoxy, alkylthio, aryl, heteroaryl, cycloheteroalkyl, COOR' ' , P (OR' ')2,
CH2P (OR")2, CF2P=0(OR")2, NHCOCOOR", CH(COOR")2; and
Each R"" is independently alkyl (C1-C10), unsubstituted or substituted with alkyl, keto, fluoro, alkoxy, alkylthio, aryl, heteroaryl, cycloheteroalkyl, COOR", P=0(OR")2, CH2P=0(0R")2, CF2P=0(OR")2, NHCOCOOR", CH(COOR")2; aryl, unsubstituted or substituted with alkyl, keto, fluoro, alkoxy, alkylthio, COOR", PO(OR")2, CH2PO(OR")2, CF2PO(OR")2,
NHCOCOOR", CH(COOR")2; heteroaryl, cycloheteroalkyl, unsubstituted or substituted with alkyl, keto, fluoro, alkoxy, alkylthio, COOR", PO(OR")2, CH2P=O(OR")2, CF2P=0(OR")2, NHCOCOOR", CH(COOR")2; and cycloalkyl, unsubstituted or substituted with alkyl, keto, fluoro, alkoxy, alkylthio, aryl, heteroaryl, cycloheteroalky, COOR", PO(OR")2, CH2PO(OR")2, CF2PO(OR")2, NHCOCOOR", CH(COOR")2;
and wherein each of Rl, R2 and R3 are linked to their respective core atoms through C, N, O or S of the substiuent group, provided that if R2 is to be linked through O or S, then the core atom S is oxidized.
12. A pharmaceutical composition as recited in claim 11 wherein Rl and R2 are taken together with the core unit to which they are attached (formula I) to form a heterocyclic group having formula (II) as follows:
R5
R5
R1 , R2 = N=\ (i.e. I -\ lM" ^ Sb ) ) (π) •(
R3
wherein R5 is an amino group with two substituents, where one substituent is arylcarbonyl, arylmethylcarbonyl, arylsulfonyl, aryldimethyloxycarbonyl, or aryloxymethylcarbonyl, [where the aryl group is phenyl, benzox[c]l,2,5-oxadiazol-5-yl, 1-ftιryl, 2-furyl 1 -naphthyl or 2-naphthyl, unsubstituted or substituted with one or more of the following or their combinations: perfluoroalkyl (C1-C4), alkyl (C1-C4), nifro, alkoxycarbonyl (C1-C4), carboxyl, carboxyalkyl(Cl-C4), CF2PO(OH)2, NHCOCOOH, phenoxy (unsubstituted or substituted with alkoxy (C1-C4), CF2P=0(OH)2, NHCOCOOH, COOH, and/or halogen), or phenylalkoxy (C1-C4)], hydrogen, CF2PO(OH) , NHCOCOOH, or a phenyl group [unsubstituted or with one or more of the following substituents or combinations: hydroxy, halogen, nifro, CF2PO(OH)2, NHCOCOOH, carboxy, carboxyalkyl(Cl-C4), carboxyalkylthio (C1-C6), phenyl, alkyl (C1-C10) or alkoxy (C1-C10) (unsubstituted or substituted with NR1R2, COOH, cycloheteroalkyl), perfluoroalkyl (C1-C4), alkoxycarbonyl (C1-C4), alkylthio (C1-C4), phenylalkoxy (C1-C4), phenylsulfonylamino (each unsubstituted or substituted on phenyl with alkyl (C1-C4)), phenoxy (unsubstituted or substituted on phenyl with nifro, perfluoroalkyl (C1-C4), carboxymethyl, carboxy, CF2PO(OH)2, NHCOCOOH, alkoxycarbonylmethyl (C 1 -C4)), carboxyalkyl(C 1 -C4), phenylalkylthio (C 1 -C4, unsubstituted or substituted on phenyl with alkoxy (C1-C4), and/or phenyl), aminosulfonyl, alkylaminosulfonyl (C1-C4), dialkylaminosulfonyl (C1-C4 where the two alkyls unsubstituted or form a heteroalicyclic ring)]; and the second substituent on the amino group forming R5 is hydrogen, alkyl (C1-C10) or alkoxy (C1-C10) (each unsubstituted or substituted with NR1R2, COOH, CF2PO(OH)2, NHCOCOOH, cycloheteroalkyl), naphthylalkyl (C1-C4), phenylalkyl (C1-C4, with the phenyl group unsubstituted or substituted with phenyl, alkyl (C1-C4), halo, amino, amido, keto, CF2PO(0H)2, NHCOCOOH, alkyl (C1-C10) or alkoxy (C1-C10) (unsubstituted or substituted with NRl R2, COOH, cycloheteroalkyl), nitro, carboxy, perfluoroalkylthio (C1-C4), halogen, CF2P=O(OH)2, NHCOCOOH, 1,2,3-thiadiazolyl, and/or alkoxy carbonyl (C1-C4)), alkyl (Cl- C10), cycloalkyl (C4-C8, unsubstituted or substituted with alkyl (C1-C4)), or indanyl (unsubstituted or substituted with alkyl (C1-C4)).
13. A pharmaceutical composition as recited in claim 12 wherein R3 is
(1) a phenyl group unsubstituted or substituted with one to three of the following and their combinations: halogen, hydroxy, aryloxy, nifro, carboxylic acid, CF2PO(OH)2, NHCOCOOH, alkyl (C 1 -C 10) or alkoxy (C 1 -C 10) (unsubstituted or substituted with NRl R2, COOH, cycloheteroalkyl), alkylthio (C1-C4), 2'-hydroxyethoxy, alkoxycarbonylmethoxy (Cl- C4), dialkylamino (C1-C4 where the two alkyls can form a heteroalicyclic ring), 2- (dialkylamino)-2-oxoethoxy (C1-C7 where the two alkyls can form a heteroalicyclic ring), difluoromethoxy, perfluoroalkyl (C1-C4), perfluoroalkylthio (C1-C4), perfluoroalkoxy (C1-C4), 2-carboxyvinyl, alkanoyl (C1-C5), alkoxycarbonyl (C1-C4), alkanoylamino (C1-C8), benzoylamino (unsubstituted or substituted with one or more perfluoroalkyl group (Cl- C4)and/or CF2P=0(OH)2, NHCOCOOH,), aryl, aryloxy, arylcarbonyl, arylmethoxy, arylmethyl in which the methyl group is substituted with hydroxyl, 0(CH2)nCOOH (n=l-5), S(CH2)nCOOH (n=l-5), (4-carboxy)benzyloxy, (3-carboxybenzyloxy), or the group =N-0-CH2R in which R is carboxyl, alkoxycarbonyl (C1-C4), hydrogen, or phenyl (unsubstituted or substituted with one or more halogens), or the group =N-NHArin which Ar is a phenyl (unsubstituted or substituted with one or more alkyl groups (C1-C4), and/or a carboxyl group, and/or CF2P=0(0H)2, NHCOCOOH), or the group-Y-(CH2)n-Z, where Y is O or S, n is 1, 2, or 3, and Z is hydrogen, methyl, branched alkyl (C3-C5), cycloalkyl (C3-C6), phenyl (unsubstituted or substituted with one or more of the following: halogen, trifluoroalkyl, carboxy, alkoxycarbonyl (C1-C4), CF2P=0(OH)2, NHCOCOOH, or carboxyl; or
(2) a pyridylthio group either unsubstituted or substituted with one or more halogen and/or one or more nifro groups, methylenedioxyphenyl, benzo[3,4-c]l,2,5-oxadiazol-5-yl, 4- oxo-3 -hydroquinazolin-2-yl, or a group having formula (III) as follows:
Figure imgf000124_0001
in which the imidazole ring is unsubstituted or substituted with one or more halogens.
14. A pharmaceutical composition as recited in Claim 11 wherein Rl and R2 are taken together with the core unit to which they are attached (formula I) to form a heterocyclic group having formula (IV) as follows:
Figure imgf000124_0002
wherein R6 and R7 are each independently as defined for Rl, R2 and R3.
15. A pharmaceutical composition as recited in Claim 11 wherein Rl and R2 are linked through an aromatic ring, and taken together with the NOR3-S unit to which they are attached, form a tricyclic heterocyclic group having formula (V) as follows:
Figure imgf000124_0003
Where R9, RIO and Rl 1 are each independently as defined for Rl, R2 and R3.
16. A pharmaceutical composition as recited in Claim 11 wherein Rl and R2, taken together with the N=CR3-S unit to which they are attached, form a heterocyclic group having formula (VI) as follows:
Figure imgf000125_0001
Wherein R12 and R13 are each independently as defined for Rl, R2 and R3.
17. A pharmaceutical composition as recited in Claim 11 wherein Rl and R3, taken together with the N=C-SR2 unit to which they are attached, form a heterocyclic group having formula (VII) as follows:
Figure imgf000125_0002
Wherein R14 and R15 are each independently as defined for Rl, R2 and R3.
18. A pharmaceutical composition as recited in Claim 11 wherein Rl and R3, taken together with the NO-SR2 unit to which they are attached, form a bicylic heterocyclic group having formula (VIII) as follows:
Figure imgf000125_0003
Wherein R18 and R19 are each independently as defined for Rl, R2 and R3.
19. A pharmaceutical composition as recited in Claim 11 wherein Rl, R2 and R3, taken together with the N=C-S unit to which they are attached, form a bicyclic heterocyclic group having formula (IX) as follows:
R1 , R2, R3=
Figure imgf000126_0001
Wherein R20, R21 and R22 are each independently as defined for Rl, R2 and R3.
20. A pharmaceutical composition as recited in Claim 11 wherein Rl, R2 and R3, taken together with the N=C-S unit to which they are attached, form a bicyclic heterocyclic group having formula (X) as follows:
)
Figure imgf000126_0002
Wliere R23 and R24 are each independently as defined for Rl, R2 and R3.
structureNameTable
Figure imgf000127_0001
StructureNameTable
Figure imgf000128_0001
*ju υ uici .αinc i αuic
Figure imgf000129_0001
Figure imgf000130_0001
StructureNameTable
Figure imgf000131_0001
StructureNameTable
r--
©
© _n H U α.
©
© O
Figure imgf000132_0001
StructureNameTable
Figure imgf000133_0001
StructureNameTable
Figure imgf000134_0001
StructureNameTable
©
Molecular Structure
© Molecular Name *1
_5 υ q (3-{5-[(3-bromophenyl)amino](l,3,4-thiadiazol-2-yl)}phenyl)(naphthylsulfonyl)amine
3-{2-[aza(3,4-dichlorophenyl)methylene]-3-methyl(l,3,4-thiadiazolin-5-yl)}-l-[3-(trifIuoromethyl)phenoxy]benzene
6
(3,4-dichlorophenyl)methyl(5-{3-[3-(trifluoromethyl)phenoxy]phenyl}(l,3,4-thiadiazoI-2-yl))amine
3-methoxy-l-[6-(4-phenylphenyl)imidazolot2,l-b]l,3,4-thiadiazolin-2-yl]benzene c^"
.-O- l-{6-[3-(2,4-dichlorophenyl)isoxazol-5-yl]imidazolot2,l-b]l,3,4-thiadiazolin-2-yl}-3-methoxybenzeπe
2-(3-nitrophenyl)-6-(4-phenylphenyl)imidazolo[2,l-rj]l,3,4-thiadiazoline
>" 6-(2H,3H,4H-benzotb]l,4-dioxepan-7-yl)-2-(3-nitrophenyl)imidazolo[2,l-b]l,3,4-thiadiazoline
r
© O {3-[(4-methoxyphenyl)methylthio]phenyl}[5-(3-nitrophenyl)(l,3,4-thiadiazol-2-yl)]amine
StructureNameTable
Figure imgf000136_0001
struciurewdrnt: i duie
©
© _0 H U α.
0\
©
© O
Figure imgf000137_0001
StructureNameTable
Figure imgf000138_0001
StructureNameTable
©
© _n
H U α.
Figure imgf000139_0001
StructureNameTable
Figure imgf000140_0001
StructureNameTable
Figure imgf000141_0001
StructureNameTable
©
© _n
H U α.
o
Figure imgf000142_0001
StructureNameTable
r--
© m
©
S _
_5 o
0\ m
©_
© O
Figure imgf000143_0001
StructureNameTable
Figure imgf000144_0001
StructureName l able
Figure imgf000145_0001
StructureNameTable
Figure imgf000146_0001
StructureNameTable
Figure imgf000147_0001
StructureNameTable
Figure imgf000148_0001
StructureNameTable
Figure imgf000149_0001
StructureName i aoie
Figure imgf000150_0001
StructureNameTable
Figure imgf000151_0001
StructureNameTable
Figure imgf000152_0001
Figure imgf000152_0002
©
© _n
H U α.
0\
©
© O
Figure imgf000153_0001
Figure imgf000154_0002
Figure imgf000154_0001
o
Figure imgf000155_0001
Figure imgf000156_0001
Figure imgf000157_0001
Figure imgf000158_0001
Figure imgf000159_0001
Figure imgf000160_0002
Figure imgf000160_0001
© JJ
©
VI
S3 υ a.
Figure imgf000161_0001
©
© o
Figure imgf000162_0001
Figure imgf000163_0001
Figure imgf000163_0002
0\
©
© O
PCT/US2002/033076 2001-10-16 2002-10-16 Organosulfur inhibitors of tyrosine phosphatases WO2003032916A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2003535722A JP2005509616A (en) 2001-10-16 2002-10-16 Organic sulfur inhibitors for tyrosine phosphatase
EP02784123A EP1446110A2 (en) 2001-10-16 2002-10-16 Organosulfur inhibitors of tyrosine phosphatases
CA002463724A CA2463724A1 (en) 2001-10-16 2002-10-16 Organosulfur inhibitors of tyrosine phosphatases
US10/493,113 US20050065118A1 (en) 2001-10-16 2002-10-16 Organosulfur inhibitors of tyrosine phosphatases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32995701P 2001-10-16 2001-10-16
US60/329,957 2001-10-16

Publications (2)

Publication Number Publication Date
WO2003032916A2 true WO2003032916A2 (en) 2003-04-24
WO2003032916A3 WO2003032916A3 (en) 2004-03-04

Family

ID=23287734

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/033076 WO2003032916A2 (en) 2001-10-16 2002-10-16 Organosulfur inhibitors of tyrosine phosphatases

Country Status (5)

Country Link
US (1) US20050065118A1 (en)
EP (1) EP1446110A2 (en)
JP (1) JP2005509616A (en)
CA (1) CA2463724A1 (en)
WO (1) WO2003032916A2 (en)

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004034697A1 (en) * 2004-07-17 2006-02-09 Sanofi-Aventis Deutschland Gmbh Salicylthiazoles substituted with diphenylamine or diphenylamine derivatives, process for their preparation and their use
WO2006028970A1 (en) * 2004-09-02 2006-03-16 Cengent Therapeutics, Inc. Derivatives of thiazole and thiadiazole inhibitors of tyrosine phosphatases
WO2006064375A2 (en) * 2004-12-16 2006-06-22 Ab Science Aminoaryl substituted five-membered ring heterocyclic compounds for the treatment of diseases
US7141596B2 (en) 2003-10-08 2006-11-28 Incyte Corporation Inhibitors of proteins that bind phosphorylated molecules
JP2007504282A (en) * 2003-05-14 2007-03-01 トリーパインズ セラピューティクス， インコーポレイテッド Compounds and their use in the regulation of amyloid beta
US20080027050A1 (en) * 2004-04-30 2008-01-31 Takeda Pharmaceutical Company Limited Heterocyclic Amide Compound and Use Thereof as an Mmp-13 Inhibitor(Amended Ex Officio)
US7521473B2 (en) 2004-02-25 2009-04-21 Wyeth Inhibitors of protein tyrosine phosphatase 1B
WO2009103218A1 (en) * 2008-02-21 2009-08-27 上海恒瑞医药有限公司 Ethylidene hydrazine carboxamide derivatives, preparation process and pharmaceutical use thereof
WO2010012345A1 (en) * 2008-07-29 2010-02-04 Merck Patent Gmbh Imidazothiadiazoles derivatives
EP2305352A1 (en) 2004-04-02 2011-04-06 Merck Sharp & Dohme Corp. 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
WO2011069038A2 (en) 2009-12-03 2011-06-09 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US8030305B2 (en) 2005-12-21 2011-10-04 Janssen Pharmaceutica N.V. Triazolopyridazines as kinase modulators
WO2011119894A3 (en) * 2010-03-24 2012-02-23 Kinagen, Inc Heterocyclic compounds useful for kinase inhibition
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
WO2012121168A1 (en) * 2011-03-04 2012-09-13 国立大学法人京都大学 Kinase inhibitor
WO2013138352A1 (en) 2012-03-15 2013-09-19 Synergy Pharmaceuticals Inc. Formulations of guanylate cyclase c agonists and methods of use
WO2014142364A2 (en) 2013-03-15 2014-09-18 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
EP2810951A2 (en) 2008-06-04 2014-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2014197720A2 (en) 2013-06-05 2014-12-11 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase c, method of making and using same
EP2771069A4 (en) * 2011-10-27 2015-08-26 Mayo Foundation Inhibiting g protein coupled receptor 6 kinase polypeptides
EP2998314A1 (en) 2007-06-04 2016-03-23 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US9486433B2 (en) 2012-10-12 2016-11-08 Mochida Pharmaceuticals Co. Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
US9763957B2 (en) 2013-07-18 2017-09-19 Novartis Ag Autotaxin inhibitors
EP3241839A1 (en) 2008-07-16 2017-11-08 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US9902739B2 (en) 2014-04-21 2018-02-27 Mayo Foundation For Medical Education And Research Small molecule inhibitors of G protein coupled receptor 6 kinases polypeptides
US10441560B2 (en) 2013-03-15 2019-10-15 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
WO2020237131A1 (en) * 2019-05-23 2020-11-26 Dow Agrosciences Llc Fungicidal aryl amidines

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2005134659A (en) * 2003-04-09 2007-05-27 Джапан Тобакко Инк. (Jp) HETEROAROMATIC PENTACYCLIC COMPOUND AND ITS APPLICATION IN MEDICINE
EP1765332A2 (en) * 2004-06-17 2007-03-28 Cengent Therapeutics, Inc. Trisubstituted nitrogen modulators of tyrosine phosphatases
JP2008505916A (en) * 2004-07-09 2008-02-28 メタバシス・セラピューティクス・インコーポレイテッド Oxygen / nitrogen heterocycle inhibitors of tyrosine phosphatase
JP2008266295A (en) * 2007-01-29 2008-11-06 Santen Pharmaceut Co Ltd New thiadiazole derivative having kinase inhibitory activity
WO2009072002A2 (en) * 2007-09-14 2009-06-11 University Of Manitoba Bisphenols in cancer therapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5480874A (en) * 1993-02-15 1996-01-02 Otsuka Pharmaceutical Factory, Inc. Phosphonic diester derivatives

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) * 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4044126A (en) * 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
GB1429184A (en) * 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
USRE28819E (en) * 1972-12-08 1976-05-18 Syntex (U.S.A.) Inc. Dialkylated glycol compositions and medicament preparations containing same
HU184772B (en) * 1980-05-23 1984-10-29 Egyt Gyogyszervegyeszeti Gyar Process for preparing quinoxaline-1,4-dioxide derivatives
US4328245A (en) * 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4410545A (en) * 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4358603A (en) * 1981-04-16 1982-11-09 Syntex (U.S.A.) Inc. Acetal stabilized prostaglandin compositions
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5378803A (en) * 1987-12-11 1995-01-03 Sterling Winthrop Inc. Azole-fused peptides and processes for preparation thereof
US5033252A (en) * 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) * 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5585112A (en) * 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
IT1246382B (en) * 1990-04-17 1994-11-18 Eurand Int METHOD FOR THE TARGETED AND CONTROLLED DELIVERY OF DRUGS IN THE INTESTINE AND PARTICULARLY IN THE COLON
US5543390A (en) * 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US6010715A (en) * 1992-04-01 2000-01-04 Bertek, Inc. Transdermal patch incorporating a polymer film incorporated with an active agent
US5348969A (en) * 1992-04-03 1994-09-20 Bristol-Myers Squibb Company Diphenyloxazolyl-oxazoles as platelet aggregation inhibitors
US6024975A (en) * 1992-04-08 2000-02-15 Americare International Diagnostics, Inc. Method of transdermally administering high molecular weight drugs with a polymer skin enhancer
US5323907A (en) * 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
SG67935A1 (en) * 1992-12-16 1999-10-19 Basf Ag Novel peptides the preparation and use thereof
US6274552B1 (en) * 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
US5985307A (en) * 1993-04-14 1999-11-16 Emory University Device and method for non-occlusive localized drug delivery
US5523092A (en) * 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US6004534A (en) * 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
US5733882A (en) * 1994-01-17 1998-03-31 Smithkline Beecham Corporation Retroviral protease inhibitors
US5759542A (en) * 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5660854A (en) * 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US5983134A (en) * 1995-04-23 1999-11-09 Electromagnetic Bracing Systems Inc. Electrophoretic cuff apparatus drug delivery system
US6316652B1 (en) * 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
US6167301A (en) * 1995-08-29 2000-12-26 Flower; Ronald J. Iontophoretic drug delivery device having high-efficiency DC-to-DC energy conversion circuit
US6039975A (en) * 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
US5705145A (en) * 1996-08-21 1998-01-06 E-L Management Corp. Skin tanning compositions and method
US5985317A (en) * 1996-09-06 1999-11-16 Theratech, Inc. Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents
US6139865A (en) * 1996-10-01 2000-10-31 Eurand America, Inc. Taste-masked microcapsule compositions and methods of manufacture
US6131570A (en) * 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
US5860674A (en) * 1997-01-31 1999-01-19 Robert Bosch Corporation AOS fan modulation systems
US5860957A (en) * 1997-02-07 1999-01-19 Sarcos, Inc. Multipathway electronically-controlled drug delivery system
US6120751A (en) * 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6060082A (en) * 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US5948433A (en) * 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
US6048736A (en) * 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
US6174874B1 (en) * 1998-09-21 2001-01-16 Merck Frosst Canada & Co. Phosphonic acids derivatives as inhibitors of protein tyrosine phosphate 1B (PTP-1B)
US6271359B1 (en) * 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
US6256533B1 (en) * 1999-06-09 2001-07-03 The Procter & Gamble Company Apparatus and method for using an intracutaneous microneedle array
US6777433B2 (en) * 1999-12-22 2004-08-17 Merck Frosst Canada & Co. Protein tyrosine phosphatase 1B (PTP-1B) inhibitors containing two ortho-substituted aromatic phosphonates
US6261983B1 (en) * 2000-01-12 2001-07-17 Baker Refractories Magnesia spinel refractory brick
US6465444B2 (en) * 2000-03-22 2002-10-15 Merck Frosst Canada & Co. Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors
WO2002102813A1 (en) * 2001-06-20 2002-12-27 Merck Frosst Canada & Co. Aryldifluoromethylphosphonic acids for treatment of diabetes
US6784205B2 (en) * 2002-03-01 2004-08-31 Sunesis Pharmaceuticals, Inc. Compounds that modulate the activity of PTP-1B and TC-PTP
JP4611751B2 (en) * 2002-12-30 2011-01-12 バーテックス ファーマシューティカルズ インコーポレイテッド Sulfhydantoins as phosphate equivalents for use as phosphatase inhibitors for the treatment of cancer and autoimmune disorders
US20040167188A1 (en) * 2003-02-14 2004-08-26 Zhili Xin Protein-tyrosine phosphatase inhibitors and uses thereof
EP1765332A2 (en) * 2004-06-17 2007-03-28 Cengent Therapeutics, Inc. Trisubstituted nitrogen modulators of tyrosine phosphatases
JP2008505916A (en) * 2004-07-09 2008-02-28 メタバシス・セラピューティクス・インコーポレイテッド Oxygen / nitrogen heterocycle inhibitors of tyrosine phosphatase
WO2006028970A1 (en) * 2004-09-02 2006-03-16 Cengent Therapeutics, Inc. Derivatives of thiazole and thiadiazole inhibitors of tyrosine phosphatases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5480874A (en) * 1993-02-15 1996-01-02 Otsuka Pharmaceutical Factory, Inc. Phosphonic diester derivatives

Cited By (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4847868B2 (en) * 2003-05-14 2011-12-28 ニューロジェネティック ファーマシューティカルズ、 インコーポレイテッド Compounds and their use in the regulation of amyloid beta
US8119680B2 (en) 2003-05-14 2012-02-21 Neurogenetic Pharmaceuticals, Inc. α-Haloketone derivatives of imidazolyl-substituted aromatic compounds and compounds prepared therefrom
US8017629B2 (en) 2003-05-14 2011-09-13 Neurogenetic Pharmaceuticals, Inc. Compounds and uses thereof in modulating amyloid β
JP2007504282A (en) * 2003-05-14 2007-03-01 トリーパインズ セラピューティクス， インコーポレイテッド Compounds and their use in the regulation of amyloid beta
US7141596B2 (en) 2003-10-08 2006-11-28 Incyte Corporation Inhibitors of proteins that bind phosphorylated molecules
US7521473B2 (en) 2004-02-25 2009-04-21 Wyeth Inhibitors of protein tyrosine phosphatase 1B
EP2305352A1 (en) 2004-04-02 2011-04-06 Merck Sharp & Dohme Corp. 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
US20080027050A1 (en) * 2004-04-30 2008-01-31 Takeda Pharmaceutical Company Limited Heterocyclic Amide Compound and Use Thereof as an Mmp-13 Inhibitor(Amended Ex Officio)
US9212149B2 (en) * 2004-04-30 2015-12-15 Takeda Pharmaceutical Company Limited Substituted 2-amidoquinazol-4-ones as matrix metalloproteinase-13 inhibitors
US9475822B2 (en) 2004-04-30 2016-10-25 Takeda Pharmaceutical Company Limited Substituted 2- amidoquinazol-4-ones as matrix metalloproteinase-13 inhibitors
DE102004034697A1 (en) * 2004-07-17 2006-02-09 Sanofi-Aventis Deutschland Gmbh Salicylthiazoles substituted with diphenylamine or diphenylamine derivatives, process for their preparation and their use
WO2006028970A1 (en) * 2004-09-02 2006-03-16 Cengent Therapeutics, Inc. Derivatives of thiazole and thiadiazole inhibitors of tyrosine phosphatases
WO2006064375A2 (en) * 2004-12-16 2006-06-22 Ab Science Aminoaryl substituted five-membered ring heterocyclic compounds for the treatment of diseases
US8030305B2 (en) 2005-12-21 2011-10-04 Janssen Pharmaceutica N.V. Triazolopyridazines as kinase modulators
US8173654B2 (en) 2005-12-21 2012-05-08 Janssen Pharmaceutica N.V. Triazolopyridazine compounds
EP2998314A1 (en) 2007-06-04 2016-03-23 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CN101679242B (en) * 2008-02-21 2013-07-10 上海恒瑞医药有限公司 Ethylidene hydrazine carboxamide derivatives, preparation process and pharmaceutical use thereof
WO2009103218A1 (en) * 2008-02-21 2009-08-27 上海恒瑞医药有限公司 Ethylidene hydrazine carboxamide derivatives, preparation process and pharmaceutical use thereof
EP2810951A2 (en) 2008-06-04 2014-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP3241839A1 (en) 2008-07-16 2017-11-08 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US8389554B2 (en) 2008-07-29 2013-03-05 MERCK Patent Gesellschaft mit beschränkter Haftung Imidazothiadiazole derivatives
WO2010012345A1 (en) * 2008-07-29 2010-02-04 Merck Patent Gmbh Imidazothiadiazoles derivatives
WO2011069038A2 (en) 2009-12-03 2011-06-09 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2923706A1 (en) 2009-12-03 2015-09-30 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia
US8957216B2 (en) 2010-03-24 2015-02-17 Amitech Therapeutic Solutions, Inc. Heterocyclic compounds useful for kinase inhibition
KR101844088B1 (en) 2010-03-24 2018-03-30 아미텍 테러퓨틱 솔루션즈 인크 Heterocyclic compounds useful for kinase inhibition
WO2011119894A3 (en) * 2010-03-24 2012-02-23 Kinagen, Inc Heterocyclic compounds useful for kinase inhibition
US9212151B2 (en) 2010-03-24 2015-12-15 Amitech Therapeutic Solutions, Inc. Heterocyclic compounds useful for kinase inhibition
US10214513B2 (en) 2010-03-24 2019-02-26 Amitech Therapeutic Solutions, Inc. Heterocyclic compounds useful for kinase inhibition
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
WO2012121168A1 (en) * 2011-03-04 2012-09-13 国立大学法人京都大学 Kinase inhibitor
US10252984B2 (en) 2011-10-27 2019-04-09 Mayo Foundation For Medical Education And Research Inhibiting G protein coupled receptor 6 kinase polypeptides
EP2771069A4 (en) * 2011-10-27 2015-08-26 Mayo Foundation Inhibiting g protein coupled receptor 6 kinase polypeptides
WO2013138352A1 (en) 2012-03-15 2013-09-19 Synergy Pharmaceuticals Inc. Formulations of guanylate cyclase c agonists and methods of use
EP3708179A1 (en) 2012-03-15 2020-09-16 Bausch Health Ireland Limited Formulations of guanylate cyclase c agonists and methods of use
EP4309673A2 (en) 2012-03-15 2024-01-24 Bausch Health Ireland Limited Formulations of guanylate cyclase c agonists and methods of use
US9486433B2 (en) 2012-10-12 2016-11-08 Mochida Pharmaceuticals Co. Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
US10058528B2 (en) 2012-10-12 2018-08-28 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
US9889108B2 (en) 2013-03-15 2018-02-13 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
US10441560B2 (en) 2013-03-15 2019-10-15 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
WO2014142364A2 (en) 2013-03-15 2014-09-18 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
WO2014197720A2 (en) 2013-06-05 2014-12-11 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase c, method of making and using same
EP4424697A2 (en) 2013-06-05 2024-09-04 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase c, method of making and using same
US10183025B2 (en) 2013-07-18 2019-01-22 Novartis Ag Autotaxin inhibitors
US9763957B2 (en) 2013-07-18 2017-09-19 Novartis Ag Autotaxin inhibitors
US9902739B2 (en) 2014-04-21 2018-02-27 Mayo Foundation For Medical Education And Research Small molecule inhibitors of G protein coupled receptor 6 kinases polypeptides
WO2020237131A1 (en) * 2019-05-23 2020-11-26 Dow Agrosciences Llc Fungicidal aryl amidines
CN113613494A (en) * 2019-05-23 2021-11-05 科迪华农业科技有限责任公司 Fungicidal arylamidines

Also Published As

Publication number Publication date
WO2003032916A3 (en) 2004-03-04
JP2005509616A (en) 2005-04-14
CA2463724A1 (en) 2003-04-24
EP1446110A2 (en) 2004-08-18
US20050065118A1 (en) 2005-03-24

Similar Documents

Publication Publication Date Title
WO2003032916A2 (en) Organosulfur inhibitors of tyrosine phosphatases
JP4610900B2 (en) Phosphate transport inhibitor
EP1041982B1 (en) INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS
US5958910A (en) Use of N-(4-aryl-thiazol-2-yl)-sulfonamides
Arya et al. The chemistry and biological potential of azetidin-2-ones
EP1043995B9 (en) INHIBITION OF p38 KINASE ACTIVITY USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS
RU2449998C2 (en) Gsk-3 inhibitors
CN1997638B (en) 1,1&#39; - (1, 2-acetylenediyl) bis-benzene derivatives as PTP1-B inhibitors
US20070032521A1 (en) Use of c-kit inhibitors for treating type II diabetes
IL136737A (en) Symmetrical and unsymmetrical diphenyl ureas and pharmaceutical compositions comprising them
US20120046290A1 (en) Inhibition of p38 kinase activity using substituted heterocyclic ureas
EP1452530A1 (en) Azole compound and medicinal use thereof
AU2004231106A1 (en) N- (((((1,3-thiazol-2-yl) amino) carbonyl) phenyl) sulfonyl) phenylalanine derivatives and related compounds for the treatment of diabetes
KR20090023746A (en) Biaryloxymethylarene carboxylic acids
KR20010099634A (en) Telomerase inhibitors and methods of their use
FR2993563A1 (en) THIOPHENE DERIVATIVES USEFUL IN THE TREATMENT OF DIABETES
JP2003502367A (en) Indole compounds
US7547716B2 (en) Sulfonamide derivatives
JP2006525312A (en) Methods of using tyrosine kinase inhibitors to treat cerebral ischemia
US20060135483A1 (en) Oxygen/nitrogen heterocycle inhibitors of tyrosine phosphatases
AU2002347912A1 (en) Organosulfur inhibitors of tyrosine phosphatases
HU211166A9 (en) Tetrazoleacetic acid derivatives and use for aldose reductase inhibitory activity
JP2000500490A (en) 4-Hydroxycoumarin-3-carboxamide for the treatment of diabetes
JP2003231679A (en) Azole compound and pharmaceutical use thereof
KR920005434B1 (en) Thio ketene derivatives and their process for preparation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FR GB GR IE IT LU MC NL PT SE SK TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 10493113

Country of ref document: US

Ref document number: 2463724

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003535722

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002347912

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002784123

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002784123

Country of ref document: EP